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Using Nucleotide Analogs as Biochemical Probes to Evaluate the Mechanisms
Involved in Translesion Replication by a High Fidelity DNA Polymerase

ABSTRACT

ANVESH DASARI

Translesion DNA synthesis (TLS) allows DNA polymerases to incorporate nucleotides
opposite and beyond damaged DNA. This activity is an important risk factor for the
initiation and progression of genetic diseases including cancer. My study evaluates the
ability of a high-fidelity DNA polymerase to perform TLS with 8-oxo-guanine, a promutagenic DNA lesion formed by reactive oxygen species. Using modified purine and
non-natural indole analogs as biochemical probes, I have evaluated the influence of
desolvation, hydrogen bonding interactions, and shape complementarity towards
nucleotide binding and incorporation opposite the miscoding lesion 8-oxo-guanine by the
high fidelity gp43exo- DNA polymerase. In Chapter II, I used modified purine nucleotide
analogs to provide evidence that nucleobase desolvation and hydrogen bonding
interactions play a crucial role towards binding and incorporation opposite 8-oxoguanine. This was further confirmed by studies in Chapter III through kinetic
characterization using non-natural indole nucleotide analogs. Overall, I have
demonstrated that the binding affinity of the incoming dNTP is controlled by the overall
hydrophobicity of the nucleobase. However, the rate constant for the conformational
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change preceding chemistry is regulated by hydrogen-bonding interactions and play a
much larger role during the replication of miscoding lesions such as 8-oxo-G. Results
generated here for the replication of 8-oxo-guanine were compared to those published for
the replication of an abasic site, a non-instructional DNA lesion. With both lesions,
nucleobase hydrophobicity is a common feature that controls nucleotide binding whereas
the physical nature of the lesion, i.e., miscoding versus non-instructional, influences the
rate constant of the conformational change step that precedes phosphoryl transfer.
Collectively, these studies highlight the importance of nucleobase desolvation as a key
physical feature that can hinder or facilitate the misreplication of structurally diverse
DNA lesions. In Chapter IV, I have investigated the unique selectivity of a modified
purine analog to DNA polymerases with varied biological function. Active analysis
demonstrated that differential architecture of high and low fidelity DNA polymerases
plays a predominant role in the replication of damaged DNA. Therefore, this differential
utilization provides a unique opportunity to develop a chemical probe to monitor
translesion DNA synthesis in-vivo.
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CHAPTER I
INTRODUCTION

1.1 DNA replication is responsible for our survival
Deoxyribonucleic acid (DNA) is the repository of genetic information for all
organisms ranging from viruses and bacteria to eukaryotes. Accurate replication of this
macromolecule is important for the transfer of genetic material, cell growth and
proliferation. Specific sequences of the DNA molecule contain information required to
produce RNA, proteins, and crucial cellular material important for the functioning and
survival of cells. The DNA is made up of four chemical bases: guanine (G), adenine (A),
thymine (T), and cytosine (C). Each chemical base is connected to a pentose sugar and a
phosphate group, together called as the nucleotide. Each nucleotide forms a
phosphodiester bond with an adjacent nucleotide forming the phosphate-deoxyribose
backbone of double helical DNA. This allows the nucleobases to be projected inwards
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allowing them to form hydrogen bonds with the opposite strand, providing further
stability to the duplex structure of DNA. These hydrogen bonds are the central dogma of
DNA replication contributing to accurate polymerization of DNA. Since their discovery
by Watson and Crick in 1953, these patterns are often referred to as Watson-Crick base
pairing (1) (Figure 1.1).
A duplex DNA structure is double helical, antiparallel and bidirectional. That is,
DNA has a sense of directionality, with each single strand having a 5’ end and a 3’ end.
The single strands are coiled in an antiparallel manner, with the 5’ prime end of one
strand facing the 3’ prime end of another. This sense of directionality influences
replication of DNA because DNA polymerases can only synthesize DNA by
incorporating nucleotides to the 3’ end of a DNA strand. Structural studies have shown
that the hydrogen bonding interactions between the complimentary base pairs provides
stability to the DNA structure. Despite being considered the most prominent biophysical
force responsible for maintaining the structural conformity of DNA, other forces such as
π-stacking interactions, desolvation, and shape complementarity were also found to
provide stability to the structure of the nucleic acid (2).
1.2 Getting a grip on DNA polymerases
For the efficient and accurate replication of DNA, our cells harbor a complex
replicative machinery which consists of a conglomerate of proteins. One of these proteins
are the DNA polymerases that play a predominant role in selecting and incorporating the
correct nucleotide opposite the templating base partner (Figure 1.2). Due to their critical
role in genome duplication and protecting the cell from DNA damage, DNA polymerases
play a crucial role in our survival.

2

Figure 1.1 Structure of duplex DNA. The figure demonstrates a duplex DNA consisting
of two natural base pairs, guanine:cytosine and adenine:thymine. Guanine base pairs with
cytosine via three hydrogen bonds, whereas adenine pairs with thymine via two hydrogen
bonds.
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Figure 1.2 General scheme of DNA polymerization. Figure represented here
demonstrates a simple scheme of the DNA polymerization pathway. DNA polymerase
performs the replicative process in 5’à3’ direction by incorporating the correct
nucleotide triphosphate opposite their templating base partner promoting cell growth. (PP-P; triphosphate, T; Thymine, A; Adenine, G; Guanine, C; Cytosine)
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1.2.1 Structural descriptions
The overall structure of DNA polymerases resembles a “right hand” containing a
palm, fingers, and thumb subdomains (Figure. 1.3) (3-5). Of these domains, the palm is
the most closely conserved structural feature due to the presence of two conserved
carboxylic amino acids that function to coordinate metal ions required to help catalyze
the phosphoryl transfer reaction (6). The fingers domain plays an important role in
nucleotide selection by interacting with the incoming dNTP and the templating base. The
thumb domain plays dual roles, first by positioning duplex DNA for the incoming dNTP
and then by facilitating translocation of the polymerase to the next templating base. When
a polymerase binds to the DNA substrate, it adopts an “open” conformation. Upon
binding with the correct incoming dNTP, the fingers subdomain rotates so that the protein
achieves a “closed” conformation. In the closed conformation, residues of the fingers
subdomain help constrain the active site containing the incoming dNTP opposite the
templating base. Once the correct nucleotide snuggly fits in the active site in the closed
conformation, the 3′-oxygen atom of the primer terminus and the α-phosphate of the
incoming nucleotide become properly aligned to allow for efficient catalysis (7). DNA
polymerases display subtle differences in these structural features which have a large
impact on their biological function. For example, polymerases involved in chromosomal
replication tend to have long, extended fingers whereas polymerases that specifically
replicate DNA lesions tend to have shorter fingers (8). The difference in the size of the
fingers influences the fidelity and processivity of these enzymes. In fact, there is evidence
that specialized DNA polymerases need shorter fingers to accommodate structurally
diverse DNA lesions whereas longer fingers found on replicative DNA polymerase are

5

important for higher replication fidelity and increased processivity (9). This is best
illustrated in Figure 1.4.
Only the four correct Watson–Crick base pairs fit properly within the active site
of classical DNA polymerases in the closed conformation. Upon formation of the closed
conformation, the 3′-oxygen atom of the primer terminus and the α-phosphate of the
incoming nucleotide become properly aligned to allow for efficient catalysis. The
structures of classical DNA polymerases bound to incorrect dNTPs in the closed
conformation have been difficult to obtain, presumably due to the unstable nature of such
complexes. However, some structures approximating this complex have been determined
(Figure 1.4).
For the efficient and accurate replication of DNA, our cells harbor a complex
replicative machinery which consists of a conglomerate of proteins. Of these proteins, the
DNA polymerases play a predominant role in selecting and incorporating the correct
nucleotide opposite the templating base partner. This process of DNA polymerases
binding to the incoming nucleotide and incorporating opposite the templating strand is
called as the DNA polymerization pathway. As simple as it seems, DNA polymerization
involves a series of complex steps that aid in accurate replication of DNA. This intricate
process is highly regulated, consisting of a series of kinetic checkpoints to ensure correct
replication of DNA to make multiple copies. Therefore, DNA polymerases are
considered to be the workhorse of the replication process.
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Figure 1.3 Structure of a DNA polymerase. A traditional high fidelity prokaryotic
polymerase (PDB ID: 3NCI) consists of the fingers domain, the palm domain and the
thumb domain (7). Fingers play an important role in selecting and interacting with the
incoming dNTP, DNA template bearing palm domain catalyzes the phosphoryl transfer
reaction, and the thumb domain facilitates in positioning the DNA template to the
incoming dNTP and also in translocation of the polymerase to the next template.
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Figure 1.4 The X-ray crystallographic structures show the crucial structural
domains: fingers, palm and thumb domains. Crystal structures of high fidelity DNA
polymerase (bacteriophage RB69) in (1) Open (PDB ID: 3NC1) and (2) Closed
conformations (PDB ID: 3NC1), (3) Repair DNA polymerase, Pol β (PDB ID: 3UPQ),
and (4) Specialized DNA polymerase, Pol η (PDB ID: 403R).
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1.2.2 Classification of DNA polymerases
The human genome encodes 15 different DNA polymerases. These polymerases
are involved in varied replicative functions, ranging from chromosomal replication, repair
of damaged DNA, or bypass of DNA lesions via TLS (10,11). Hence, based on their
biological roles DNA polymerases have been classified into 3 categories, 1.) replicative
polymerases, 2.) repair polymerases, and 3.) specialized polymerases (Table 1.1).
Replicative DNA polymerases such as pol α, pol δ, pol ɛ are involved in
chromosomal replication during the S-phase of the cell cycle (12). Pol α is exclusively
involved in starting DNA synthesis de novo, and synthesis of Okazaki fragments on the
lagging strand (13). Pol δ and pol ɛ displaces pol α to perform normal DNA synthesis
(14,15). One prime reason for this switch is the 3’-5’ exonuclease proofreading activity
of pol δ and pol ɛ, absent in pol α (16). Their ability to remove incorrectly incorporated
nucleotides enhances the replicative fidelity of DNA. Another reason is their high
processivity, a prerequisite for rapid DNA replication for the synthesis of genome.
Telomerase is exclusively involved in chromosomal replication at telomeres, at the end of
chromosomes (17). Pol γ is involved in replication and repair of mitochondrial DNA
(18).
Repair DNA polymerase such as pol β, a 39 kDa single polypeptide is involved in
base excision repair and nucleotide excision repair in mammalian cells (19). Despite
having all four chains and being ~32% identical to pol β, pol λ is functionally different,
involved in non-homologous end joining (NHEJ), a mechanism for rejoining doublestrand DNA breaks (20). Pol µ is functionally analogous to pol pol λ involved in NHEJ
where it repairs and resynthesizes DNA strands with missing nucleotides (21). Finally,
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terminal deoxynucleotidyl transferase (TdT), closely related to pol µ adds random
deoxynucleotides to double-strand DNA breaks formed during V(D)J recombination to
promote immunological diversity during an immune response (22). This activity seems to
be important as overexpression in acute lymphoblastic leukemia correlates with poor
responses to many anticancer that induce DNA damage (23). Although pol δ and pol ɛ
play essential roles in nuclear DNA synthesis, they are also involved in re-synthesis of
large patches of DNA that has been previously excised during DNA repair (24).
The final group of DNA polymerases represent a unique class referred to as
“specialized” polymerases. Members of this family include pol η, pol ι, pol κ, pol θ, pol
φ, pol σ, pol ζ, and Rev1. These polymerases have the ability to efficiently replicate
various DNA lesions, hence are also referred to as “non-classical” since they do not
always obey Watson–Crick base pairing rules when replicating DNA lesions with altered
hydrogen bonding coding information. Also, these specialized DNA polymerases do not
possess proofreading capabilities as they lack the 5′ → 3′ exonuclease activity. Of the
aforementioned specialized DNA polymerases, pol η has been the most extensively
studied and understood polymerase, due to its ability to accurately replicate naturally
occurring mutagenic lesions like thymine dimer. When pol η encountered the crosslinked lesion, it efficiently incorporated the correct adenine (25). In fact, absence of pol η
in humans caused xeroderma pigmentosum, a cancer prone genetic disorder. In addition
to thymine dimer, pol η also efficiently replicated other cancer-related lesions (26).
Another specialized polymerase, pol ι replicates a wide variety of lesions like the minor
and major groove-adducted purines (27). Surprisingly, Rev1 does not follow the A-rule
of translesion DNA synthesis as it misinserts cytosine opposite non-templating DNA
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lesions such as abasic sites and a variety of DNA lesions that occur at G residues (28).
Pol κ selectively bypasses BP-dG (Benzopyrene), a frequently formed carcinogenic
agent, by inserting the correct cytosine. Further, pol κ can also extend beyond aberrant
base pairs that result from the ability of other specialized DNA polymerases such as pol ι
to incorporate nucleotides opposite DNA lesions (29,30). Similarly, pol ζ also works in
cohort with other specialized DNA polymerases to perform efficient TLS. This activity
has also been found to be essential for normal embryogenesis (31).
Human pol θ appears to play multiple roles in TLS and in somatic hypermutation
of immunoglobulin genes. Also, it is the only polymerase found to be involved in
microhomology-mediated end-joining, an alternative to NHEJ that is triggered in
response to ds-DNA breaks. Evidence to this activity has been found in mice deficient in
pol θ.
However, the polymerase’s activity has been found to be promiscuous, with low fidelity
and is also believed to be involved in dRP-lyase activity that is used during singlenucleotide BER (32,33). Evidence of this activity is found in mice defective in pol θ,
where elevated levels in radiation induced frequencies within circulating blood cells
demonstrates that this polymerase is also involved in processing DNA damage that leads
to the formation of DSBs (34). However, more research is required to clearly define their
roles in replication of DNA damage and disease.
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Table 1.1 Classification of DNA polymerases in humans

Name

Proposed Biological
Function(s)

Polymerase
Family
Designation

Replicative polymerases
Pol α
Pol δ
Pol ɛ

Priming of chromosomal DNA
replication
Chromosomal DNA
replication
Chromosomal DNA
replication

B
B
B

Telomerase

Replication of telomeric DNA

RT

Pol γ

Mitochondrial DNA
replication

A

Pol β

Base excision repair

X

Pol λ

Non-homologous end joining

X

Pol µ

Non-homologous end joining

X

TdT

Somatic hypermutation during
NHEJ

X

Pol θ

TLS, base excision repair

A

Pol ν

TLS, DNA repair

A

Pol η

TLS, somatic hypermutation,
recombination

Y

Pol ι

TLS, somatic hypermutation,
base excision repair

Y

Pol κ

TLS, NER

Y

REV1

TLS, somatic hypermutation

Y

Pol ζ

TLS, somatic hypermutation

B

DNA repair polymerases

Specialized DNA
polymerases
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1.3 The chemistry of DNA polymerization
The proposed chemical mechanism for DNA polymerization was through a
nucleophilic attack at the 3’-OH on the a-phosphate of the incoming nucleotide
triphosphate (Figure 1.5). The carboxylate residues (aspartate; D654 and D475) align the
metal ions (Mg2+; A and B) towards the incoming dNTP’s deoxyribose sugar to extract
the proton from the 3’-OH group. This creates an electron rich nucleophile that attacks
the a-phosphate forming a pentavalent transition state stabilized with the oxygen atoms
of the b and g phosphate groups (35). The pyrophosphate group is released through
coordination with another divalent metal ion. This two metal ion mechanism appears to
be universal for all DNA (and RNA) polymerases while performing the polymerization
reaction. This metal ion catalytic reaction allows us to perform polymerization assays,
since the metal ions can be chelated using either ethylene diamine tetra acetic acid
(EDTA) or hydrochloric acid (HCl). Other divalent metal ions such as Ca2+ and Mn2+
also can be used as a substitute for the reaction assays. Ca2+ only supports nucleotide
binding but not the chemistry serving as a useful probe to measure the nucleotide binding
step. Though Mn2+ assists the chemistry step, it has been found to increase the rate of
misincorporation thereby decreasing the fidelity. Hence, it is often used to produce
random mutations during PCR (36,37).
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Figure 1.5 Two metal ion mechanism in the DNA polymerization pathway. The Mg2+
metal ion (A) coordinates with the 3’hydroxyl group of the primer DNA. The phosphate
group of the incoming dNTP then forms a bridge between the metal ion A and B. This
allows the hydroxyl group of the primer to attack the phosphate group, thus forming a
new O–P bond.
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1.4 General mechanism of DNA polymerases
All DNA polymerases follow a universal pathway for the incorporation of
nucleotides opposite the templating base. This is called as the DNA polymerization
pathway (Figure 1.6) (38). First, the polymerase binds DNA prior to binding a nucleotide
(step 1). This is followed by the binding of the incoming dNTP to the enzyme:DNA
complex, the first point for generating high catalytic efficiency and fidelity (step 2). The
binding affinity for a nucleotide opposite its correct pairing partner is generally
designated as a Kd value (kinetic dissociation constant). The Kd value for binding a
correct nucleotide is ~10 µM. For incorrect nucleotide the binding affinity decreases by
greater than this, indicating that it serves as a crucial check point for maintaining
genomic fidelity during DNA synthesis. For post nucleotide binding, the E:DNA:dNTP
complex undergoes a conformational change (step 3) to assist the incoming dNTP into a
precise geometrical orientation for efficient phosphoryl transfer (step 4). This
conformational change step reflects an “induced-fit” mechanism that serves as a second
checkpoint against incorrect nucleotide misinsertion (36). This conformational change
step is marked by the rotation of the fingers subdomain to constrain the active site
containing the nascent base pair. Therefore, this step serves as evidence for the transition
of the polymerase from an “open” conformation to the “closed” conformation in the
ternary complex (37). The rate constant for the conformational change step decreases
drastically by several fold for high fidelity DNA polymerases misincorporating an
incorrect nucleotide opposite a templating DNA. This reduction allows the incorrect
nucleotide to dissociate rather than be incorporated (38). A third point of control is the
phosphoryl transfer step (step 4) whose rate constant is decreased substantially upon
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misaligning of an incorrect nucleotide. In fact, this step appears to be the rate-limiting for
nucleotide incorporation with certain DNA polymerases (39). The maximal rate constant
for polymerization (kpol) for the incorporation of a correct nucleotide opposite its correct
templating partner generally ranges from 20 to 200 sec−1 (40,41) and the overall catalytic
efficiency (kpol/Kd), for is high at 107 M-1s-1. The kpol/Kd values is lowered by several
orders of magnitude for mismatches such as the misincorporation of dGTP opposite A.
This reduction is caused by a synergistic decrease in rate constant coupled with binding
affinity, both of which play large roles in maintaining genomic fidelity. This leads to the
chemistry step where a nucleophilic attack of the 3′-OH group present on the primer on
the α-phosphate of the incoming dNTP is followed by the elimination of pyrophosphate.
Post-phosphoryl transfer, a second conformational change (step 5) occurs and is required
for pyrophosphate release (step 6). This process enables the DNA polymerase to
translocate along DNA to the next templating position. Following this translocation step,
the polymerase can either dissociate from the elongated primer (step 7) to initiate DNA
synthesis on another usable primer template or remain bound to the extended DNA to
continue primer elongation (step 8).
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Figure 1.6 Kinetic scheme describing the DNA polymerization pathway. Step 1
illustrates the binding of the polymerase (E) to the DNA where it recognizes the primer
template. Step 2 involves binding of the E:DNA complex to the correct nucleotide (N).
Step 3 defines the conformational change step in the E:DNA complex to arrange the
active site for incorporation of the incoming nucleotide opposite the templating base.
This allows the phosphorolysis transfer to occur where the incoming nucleotide is
attached covalently to the elongating primer (Step 4). Step 5 represents the second
conformational change step enabling the release of the pyrophosphate (ppi). This allows
the polymerases to either dissociate and bind to a new DNA (Step 7) or continues to
replicate on the same DNA template (Step 8).
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1.5 Exonuclease proofreading activity of DNA polymerases
High fidelity DNA polymerases involved in genomic replication include a last
line of defense, called the exonuclease proofreading domain. They act as a kinetic barrier
to prevent translesion DNA synthesis by the high fidelity replicative DNA polymerases.
The mechanism involved in successful excision of an incorrect nucleotide involves a
combination of contention along with cooperation between the polymerase’s and the
exonuclease proofreading domain’s active sites. This process is different from
pyrophosphorolysis and is complicated, as it includes several chemical and kinetic steps
(Figure 1.7). These are as follows: (i) following a misincorporation, the primer terminus
is translocated from the active site of the polymerase to the exonuclease domain’s active
site, (ii) the duplex DNA is unwound, separating the strands to several nucleotides prior
to the formed mispair, (iii) this enables the 3’-primer strand to be place in to the
exonuclease’s active site, (iv) the terminal nucleotide is removed by breaking the
phosphodiester bond using hydrolysis, (v) after the mismatched nucleotides opposite the
templating base are excised, the primer-template is transferred back to the polymerase’s
active site to resume normal DNA synthesis. This activity is important for
chemotherapeutic intervention as it represents a potential mechanism of drug resistance
by removing chain-terminating nucleotides from DNA. Occasionally, misinsertions
opposite damaged DNA (lesions) can evade the exonuclease activity and bypass the
lesion. In an effort to maintain the genomic stability, our cells employ several repair
pathways (base excision repair, nucleotide excision repair, mismatch repair) to repair the
damaged DNA (43). However, under undue stress these repair mechanisms may fail, and
escape repair. Such damaged are often bypassed by a special process called translesion
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Figure 1.7 Exonuclease proofreading plays an important role in maintaining
replicative fidelity. After misinsertion of thymine (T) opposite the templating guanine
(G), the misinserted site is translocated to the exonuclease site (step i). The duplex DNA
is unwound to several nucleotides beyond the mispair (step ii). This allows the primer
strand to dock in the exonuclease domain’s active site, as represented in step iii. Step iv
represents the removal of the incorrect thymine via hydrolysis of the phosphodiester
bond. Following the excision step, the primer is transferred back to the enzyme’s active
site (step v).
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DNA synthesis (TLS). TLS has reduced replicative fidelity and is only employed in dire
circumstances, such as blocking a replicative DNA polymerase at a lesion (44,45).

1.6 Biophysical factors influencing DNA polymerization beyond hydrogen bonding
interactions
DNA polymerase’s primary function is to form DNA base pairs from a single strand with
free nucleotides in the solution. A long standing perception was that these DNA
polymerases use hydrogen bonding interactions to guide the correct nucleotide opposite
the templating base, hence considered important for efficient and selective replication.
However, this perception in recent times has been contested, arguing that hydrogen
bonding alone does not dictate nucleotide incorporation but other forces such as shape
complementarity, desolvation, and base-stacking interactions also influence nucleotide
incorporation during the polymerization cycle. Thermal denaturation studies have shown
that the error for the insertion of a correct to an incorrect nucleotide (~1:102) is too low
for the error rate of 1Í106 for exonuclease deficient high fidelity DNA polymerases
(46,47). These free energy differences indicate that, in addition to hydrogen bonding
interactions there are other biophysical forces that influence nucleotide selectivity and
polymerization. Towards understanding this, synthetic nucleotides were used as probes to
investigate the molecular forces influencing the DNA polymerization pathway. Here, I
briefly discuss the role of other biophysical forces during DNA polymerization using
nucleotide analogs as chemical probes.
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1.6.1 Shape complementarity
Though hydrogen bonding interactions between the natural bases (A:T, T:A, G:C,
C:G) have been attributed to the high fidelity and specificity of replicative DNA
polymerases during genomic replication, shape of the incoming nucleotide was also
suggested to play a predominant role in the incorporation of nucleotides. This was first
addressed by Kool’s lab, where they demonstrated the ability of Klenow fragment
enzyme (Kf) to efficiently insert difluorotoluene (dF; a structural mimic of thymine),
opposite a templating adenine (Figure 1.8). Devoid of hydrogen bonding groups, dF is
expected to behave as a poor substrate for DNA polymerases. However, dFMP is inserted
only ~100-fold lower than dTMP opposite templating adenine (48). Though the Vmax
(maximal rate of polymerization) are nearly equal, the binding affinities (Km) of dFMP is
~44 fold lower when compared to dTMP, suggesting that these perturbations could be
caused by the lack of hydrogen bonding interactions (48). Though more studies are
required to unambiguously determine this conclusion, these studies demonstrate that
shape complementarity plays a critical role during DNA polymerization. Likewise, Kf
was also able to form non-natural base pair, dF:Z with an overall catalytic efficiency of
only ~200 fold lower when compared to dT:A base pair (Figure 1.8) (48). The nonnatural base pair (dF:Z) is completely devoid of any hydrogen bonding interactions. But,
its resemblance to a dT:A base pair allows the polymerase to undergo the conformational
change after the nucleotide binding step. This allows the chemistry step to follow,
efficiently resulting in the polymerization of a non-canonical base pair.
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Figure 1.8 Structural comparison of natural base pair adenine (A):Thymine (T)
with adenine (A):2,4 difluorotoluene (dF) and 4-methylbenzimidazole (Z): 2,4
difluorotoluene (dF). The nucleotide base pairs and their interglycosyl distances have
been generated using the molecular modelling program Chimera. These structures
demonstrate the identical interglycosyl distances between the base pairs A:T, Z:dF and
A:dF.
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1.6.2 Desolvation
DNA helix exists as a packed hydrophobic biopolymer in an aqueous biological
environment. Hence, it is obvious that prior to polymerization, the water molecules
surrounding the incoming nucleotide need to be stripped to form effective hydrogen
bonds with the templating base. However, the role of desolvation during DNA
polymerization, that is, how and when still remains elusive. Understanding the influence
of desolvation will enable us to determine their role in nucleotide incorporation and
fidelity.
One of the most elaborate studies in determining the role of desolvation evolved
from the Romesberg and Schultz lab. In an effort to expand the genetic alphabet they
developed a library of hydrophobic analogs devoid of hydrogen bonding groups to study
DNA polymerization. Of the many base pairs developed, non-natural base pair such as 7azaindole:isocarbostyril (Figure 1.9) is commonly referred to as the most successfully
developed non-hydrogen bonding base pair (49). The catalytic efficiency for the insertion
of isocarbostyril monophosphate opposite a templating 7-azaindole or vice versa is nearly
identical, making them highly favorable for a probable novel third base pair. Also,
incorporation of any of the natural nucleotides opposite either non-natural templating
base was highly unfavorable. However, the non-natural bases easily form self-base pairs
(7-azaindole:7-azaindole; isocarbostyril: isocarbostyril), thus reducing the enzyme’s
fidelity (50). Collectively, these data suggest that a hydrophobic nucleotide analog can
achieve better binding affinities by decreasing the entropic penalty during nucleotide
incorporation. However, the same feature decreases nucleotide selectivity due to their
ability to easily form self-pairs.
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Figure 1.9 Chemical Structure of an unnatural base pair, 7-azaindole: isocarbostyril
The structures illustrated have been generated using the molecular modelling program
Chimera. (for convenience only the nucleobases are shown).
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1.6.3 Base stacking interactions
Base stacking is a noncovalent interaction dependent on several complex
noncovalent forces. With respect to the DNA, these stacking interactions are
predominantly referred to the juxtaposition of the aromatic nucleobases face-to-face with
their π-stacking systems in direct contact. The aromatic nucleobases seem to be
unsymmetrically aligned (distance between two aromatic planes is 3.4 Å), energetically
favoring the preferred conformation of the DNA’s helical backbone. The stacking ability
is also influenced by the Van der Waals forces, electrostatic effects of interacting dipoles,
and solvation effects of a DNA base. Kool’s lab extensively studied the electrostatic
effects in DNA base stacking using non-natural analogs (51). Their studies demonstrated
that, nucleotide analogs with large aromatic surface areas stack more naturally than
natural bases. However, influence of Van der Waals forces is not yet determined. Single
nucleotide insertion studies at the end of a duplex DNA where no hydrogen bonding is
present, purines were found to stack more strongly than pyrimidines preferably due to
their larger aromatic surface areas and greater polarizability. Abasic site, a non-coding
lesion served as an excellent model to study the influence of base stacking interactions.
Most polymerases selectively inserted adenine opposite the abasic site, followed by
guanine and pyrimidines. However, non-natural nucleotides with larger aromatic surface
areas like dPTP were inserted with catalytic efficiencies higher than adenine by three
orders of magnitude opposite abasic sites (Figure 1.10) (52). This is in congruence with
the extensive studies performed in the Berdis and Lee laboratories using 5’-substituted
indole analogs. Their enhanced base stacking interactions enabled them to be inserted
with incredibly fast rates of incorporation opposite the non-templating lesion (53,54).
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Figure 1.10 Non-natural nucleotide Pyrene triphosphate (dPTP) paired opposite an
abasic site. The chemical structures represented have been generated using Chimera.
(For clarity only the deoxyribose sugar bound to the nucleobase (dP) are shown).
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1.7 Role of active site architecture in nucleotide selectivity
The ability of high and low fidelity DNA polymerases to insert a correct/incorrect
nucleotide with varying efficiencies indicates that differential active site architecture play
a crucial role in nucleotide selectivity. Replicative DNA polymerases involved in normal
DNA replication were found to have incredibly high catalytic efficiencies for the
insertion of a correct nucleotide. This was followed by the repair DNA polymerases and
specialized DNA polymerases (55). These observations are consistent with their
biological function because replicative DNA polymerases are expected to perform
genomic replication with high efficiency. Unlike the replicative polymerases, the repair
and specialized DNA polymerase’s limited role in genomic maintenance suggests the role
of active site architecture in nucleotide selection in DNA polymerization. With respect to
the active site tightness, this suggests that the DNA polymerases with lower fidelity have
larger active sites when compared to the tighter active sites of high fidelity ones such as
the replicative DNA polymerases (55).
The concept of active site tightness is usually defined by the ability of the
enzyme:DNA to flexibly move and adapt to larger nucleotide analogs and also by the
closeness of amino acid residues by the wall adjoining the DNA template. The evidence
for the active site tightness in polymerase fidelity has been tested by using nucleotide
analogs devoid of hydrogen bonding groups. Kool’s laboratory tested a series of nonnatural nucleotides that mimic thymine but are devoid of the canonical hydrogen bonding
groups (Figure 1.11) (56). These analogs were specifically designed by introducing
halogen groups (F, Cl, Br, I) increasing the bond length by an increment of 1 Å across the
library. The overall efficiency for the nucleotide analogs increased till the size of the base

27

pair reached the optimal size. Insertion of larger analogs (than dT:adenine base pair)
decreased the enzyme’s fidelity, consistent with the influence of active site tightness in
nucleotide selection and insertion. Hence, the more rigid the active surface, the higher
would be the enthalpic penalty for the insertion of an incorrect nucleotide. This is
consistent with the tighter active site of a high fidelity replicative DNA polymerase.
Conversely, low fidelity DNA polymerases (Y-family) with larger active sites (Dpo4)
were able to accommodate larger nucleotides as substrates accounting for their lower
fidelity. Again, the larger active site allows the polymerases to accommodate larger
nucleotides due to lower enthalpic penalties (57,58). This is consistent with their ability
to replicate damaged lesions including the large bulky ones. Therefore, these “error
prone” polymerase’s lower fidelity were found to be evolutionarily desirable.
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Figure 1.11 Chemical structures of a series of halogenated thymidine analogs with
variations in subangstrom increments. The figure the halogenated analogs that have
been used as biochemical probes to investigate the role of active site tightness of the
DNA polymerase during DNA replication.
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1.8 DNA damage and its effects on polymerization
Our DNA is under constant assault from several endogenous and exogenous
damaging agents inflicting damage to the DNA by altering its chemical structure. The
chemically altered nucleobases are called DNA lesions. These alterations can often lead
to a change in hydrogen bonding interactions, a prerequisite for replicative DNA
polymerases to form Watson-Crick base pairing during DNA polymerization. Figure 1.12
provides a brief illustration of DNA damaging agents and the lesions they form within the
DNA template.
Since they behave as physical barriers during DNA synthesis, they prevent
efficient replication of DNA by DNA polymerases. Replicative polymerases are the
primary encounters of these lesions, thereby hindering their ability to synthesize DNA
with high processivity, a necessity for the synthesis of our genome. Sometimes, the DNA
polymerases might form mismatches enabling the activation of repair polymerases which
either repair the damaged DNA or cause cell death. Temozolomide, a monofunctional
alkylating agent serves as an excellent example for this phenomenon. It modified guanine
by simple alkylation of the O-6 position of guanine. This modification alters the
hydrogen bonding capability of guanine promulgating the misincorporation of an
incorrect thymine forming mispairs more frequently (59). This activates the mismatch
repair pathway (MMR) causing apoptosis (60). Some chemotherapeutic agents like
doxorubicin, and ionizing radiation form double stranded breaks (DSBs) which lack
templating information, hence directly block the replicative process of the polymerases.
To overcome this issue two repair processes, nonhomologous end-joining (NHEJ) and
homologous recombination (HR) are activated.
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Figure 1.12 DNA damaging agents, and the formed lesions. The figure illustrates the
formation of DNA lesions from various endogenous and exogenous DNA damaging
agents. These lesions often promote misreplication that could initiate oncogenesis.
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Some of the most commonly used chemotherapeutic agents like cisplatin,
chlorambucil and cyclophosphamide form interstrand cross links, and/or bulky adducts
(61,62). Since these lesions stall DNA synthesis by forming single and double stranded
breaks, repair processes like NHEJ and/or HR are activated to promote DNA synthesis
and cell survival. Figure 1.13 provides structural illustrations of some of the DNA lesions
formed by chemotherapeutic agents.
Overall, these discussions make it apparent that DNA polymerases play an
important primary and secondary roles in the therapeutic response to DNA-damaging
agents. The focus of the next section is to discuss how different DNA polymerases
participate in the repair of damaged nucleic acid. Provided here are brief summaries
explaining the major DNA repair pathways including MMR, BER, NER, HR, and NHEJ.
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(A)

(B)

Figure 1.13 DNA lesions formed by chemotherapeutic agents. (A) Structure of O6methylguanine caused by the DNA-damaging agent, temozolomide. This modification
allows it mispair with thymine and cytosine. (B) Structure of an intra-strand crosslink in
DNA caused by cisplatin.
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1.9 Repair mechanisms employed by DNA polymerases
DNA Mismatch Repair. The MMR pathway plays a crucial role in safeguarding the
genome by repairing mispaired DNA formed during DNA replication. Because of its high
functional priority, the proteins involved in this process are considered to be ubiquitous.
In fact, these proteins are conserved amongst prokaryotic to eukaryotic and mammalian
systems. For example, human homologs MutS, MutL, EXO1, single-strand DNA-binding
protein (RPA), proliferating cellular nuclear antigen (PCNA), pol δ, and DNA ligase I are
also found in E.coli MMR proteins (63). The hMSH2 (homolog of MutS in E.coli) forms
a heterodimers with hMSH6 or hMSH3 to form the human homolog of MutS, hMutSα or
hMutSβ. hMutSα via ATP binding and hydrolysis action identifies and repairs small
patches of mismatches (preferentially two or less). hMutSβ, however, using similar
mechanism of action repairs large patches of base-base mismatches. The MutL homologs
are even more diversified in humans. Till date, four human MutL homologs have been
identified, namely hMLH1, hMLH3, hPMS1, and hPMS2 that have been identified (64).
The MutL α forms an assembly with PCNA and RFC to initiate and repair a mismatch.
This is followed by an excision at the 5’-end to the mismatch. EXO1 is a 5′ → 3′
exonuclease that performs 5′ directed mismatch excision in the presence of MutSα or
MutSβ and RPA. Post excision, EXO1 performs 5′ → 3′ excision from the MutLαincision site through and beyond the site of the mismatch. This exonuclease process
creates a single stranded gap which is then repaired by pol δ using the templating strand
as a guide. After the correct nucleotide is inserted, DNA ligase seals the nick in an ATPdependent process.
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Base Excision Repair. BER is an evolutionarily conserved pathway responsible for the
removal or excision of a mismatched base pair or a modified base from the genome (65).
Small

DNA

lesions

like

8-oxo-guanine,

3-methyladenine,

7-methylguanine,

hypoxanthine, and xanthine could be misreplicated as they behave as non-distorting DNA
bases. These types of lesions are abundantly formed under physiological conditions;
hence this pathway is active round the clock repairing about ~20,000 lesion per cell per
day (66). During chemotherapy, alkylative and oxidative modifications increases the
number of lesions formed increases by several orders of magnitude. The primary step
involved is the excision of a modified base from the duplex DNA by a DNA glycosylase.
The glycosylase action, that is cleavage of the N-glycosidic bond results in the formation
of an abasic site (apurinic/apyrimidinic) (67). The formation of an abasic site allows the
AP endonuclease (APE1; humans) to break the phosphodiester bond via hydrolytic action
incojugation with the metal ion, Mg2+. This process enables APE1 to break the DNA
backbone creating a single stranded break with a 5’-deoxyribose phosphate (dRP) (68).
The resulting excised nucleotide/s initiates repair synthesis by DNA polymerases. Pol β
repairs short nucleotide gaps. In the absence of pol β, pol λ takes over (69). Long patches
(~10 nucleotides) are repaired by pol δ and pol ɛ in assembly with the PCNA. The choice
between long and short strand pathways seem to be partly influenced by the
concentration of ATP after the dRP removal step. The final step for any repair pathway is
sealing the nicks between the DNA breaks by generating a phosphodiester bond between
3’-OH and 5’-PO4 by DNA ligase (LIGI or LIGIII) with XRCC (cofactor) seal the nick,
thus completing the BER repair pathway. Several studies have shown that BER plays a
significant role in dictating the cellular response during chemotherapy. Also, activation of
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the BER polymerases has been correlated with the development of cancer and drug
resistance resulting in failure to treat patients with metastatic cancers (70,71). Indeed,
evidence of somatic mutations caused by pol β have been found in ~30% of human
cancers (72). These findings demonstrate that development of inhibitors of BER enzymes
can serve as an efficient treatment strategy to inhibit the growth of cancer cells.
Nucleotide Excision Repair. NER is another type of repair pathway whose primary goal
is to serve in maintaining the genetic integrity of the genome. It primarily focuses on
removing DNA distorting lesions like the pyrimidine dimers, cyclobutane thymine
dimers and cisplatinated DNA formed by UV radiation and chemotherapeutic agents such
as cisplatin respectively. This process involves is carried out by a conglomerate of ~30
protein complex called the nucleotide excision repairosome. The steps involved are as
follows; (1) Recognition of the site of DNA damage; (2) recruiting the necessary proteins
to form a multivariate complex to excise the damaged DNA; (3) gap-filling the patch of
excised DNA and ligating the double strand breaks (73). In eukaryotic systems, XPC and
HR23B proteins help to identify the site of DNA damage distorting the duplex DNA.
Upon recognition, these proteins recruit a 10 protein sub-complex called transcription
factor IIH (TFIIH) to the site of DNA damage. Two helicases (XPD and XPB) within the
TFIIH complex help to unwind the DNA surrounding the lesion, which is considered to
be the first catalytic step in the NER reaction pathway. This allows the endonucleases
XPG and ERC1-XPF to create incisions at 3’ and 5’ ends respectively. Usually, the dual
incision creates an oligomer that is ~25 nucleotides in length. Post excision of the
damaged patch of DNA, replicative polymerases pol δ and/or pol ɛ are recruited to
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complete normal DNA synthesis. The nicks between the newly synthesized DNA are
joined by DNA ligase I.
Repair of DNA Strand Breaks. DSB’s are a common event that occurs in eukaryotic
cells due to DNA lesions formed by endogenous or exogenous DNA damaging agents
(74). There are two major pathways involved; homologous recombination (HR) and nonhomologous recombination (NHEJ). Depending on the phase of cell cycle, respective
pathway is delegated to repair a DSB (75). HR is employed during the late-S and G2
phases (76). NHEJ, on the other hand, is a predominant pathway in all phases of cell
cycle (77).
Homologous Recombination. HR repairs a DSB in three different phases, namely;
presynapsis, synapsis and postsynapsis. During the presynapsis phase, MRN complex
together with CtIP abscise the 5’-end on either side of the DSB creating a 3’overhang of
single stranded DNA. This allows the BLM helicase and Exo1 exonuclease to continue
the unwinding process. Following the abscission and unwinding, replication protein A
(RPA) which has high affinity to ssDNA binds to the overhanging ssDNA tail preventing
and/or removing any of the bound secondary protein structures. This enables the Rad51
recombinase along with other mediatory proteins (Rad52; BRCA 2; and Rad51 paralogs
– Rad51B, Rad51C, Rad51D) to replace the RPA and bind the ssDNA, thus forming a
Rad51 nucleoprotein filament. This nucleoprotein complex executes the DNA sequence
homology search to identify the homologous DNA. Identification of the homologous
DNA promotes strand invasion in the presence of Rad51. This creates a D-loop between
the 3’overhang strand and the homologous chromosome. Post invasion, pol δ and/or pol ɛ
extends the end of the invading 3′ strand to synthesize a new piece of DNA. Following
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the synthesis of a new strand and continuous ligation by DNA ligase I converts the Dloop into a Holliday junction (78).
Nonhomologous End Joining. Though NHEJ is considered as simple joining of any two
ends, it is much more complex than understood. It involves an agglomeration of several
distinct proteins such as Ku 70/80 heterodimer, DNA-dependent protein kinase (DNAPkcs), X-ray-cross-complementing gene 4 (XRCC4), DNA ligase IV, Artemis, and
XRCC4-like factor (XLF) (79). The Ku-heterodimer binds to the broken ends of a DNA
that occur after a break. Post binding, Ku complex employs DNA-Pkcs initiating protein
kinase activity. The kinase activity makes the DNA ends available to the Artemis
endonuclease activity that allows it to open any hairpin loops present. The resultant
ssDNA gaps if any present are filled by the polymerase activity of pol λ or pol µ. The
filled gaps are ligated by XRCC and DNA ligase IV. Sometimes, in the absence of pol λ
or pol µ, Ku complex recruits’ terminal deoxynucleotidyl transferase (TdT) to insert
nucleotides randomly as a desperate maneuver to ensure cell survival (80). This unique
activity demonstrates immunological diversity during V(D)J recombination. However,
this unique activity has its own consequences, as it can also lead to error-prone
replication contributing to genomic instability and loss of genetic information during end
processing (81,82).

1.10 Translesion DNA synthesis
Though repair mechanisms discussed above exist to repair the damaged DNA,
some types of DNA lesions evade repair thereby stalling the replicative process. The
replication machinery when stalled can disintegrate due to their fragile nature, resulting
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in a DSB. This further decreases the genomic stability. Replicative high fidelity DNA
polymerases have meticulous specificity for natural Watson-Crick base pairs during DNA
polymerization. Chemical alteration of natural bases decreases the ability of the high
fidelity DNA polymerases to replicate damaged DNA. In a desperate move to rescue the
cell from replication arrest, our cells employ “specialized” DNA polymerases that help to
bypass the lesion. These polymerases are present in both prokaryotes and eukaryotes
whose primary role is to insert either a correct or incorrect nucleotide to bypass the
lesion. None of these polymerases possess any proofreading capacity.
There are two currently accepted models for how the activities of various DNA
polymerases are coordinated during TLS (Figure 1.14) (83,84). In one model, the
replicative DNA polymerase encounters a DNA lesion and incorporates a nucleotide
opposite it. However, the high-fidelity polymerase is unable to extend beyond the lesion.
The stalling of the replication fork then acts as a signal to recruit a different DNA
polymerase such as pol κ or pol ζ that function to extend beyond the lesion. Once the
lesion is by-passed, the replicative DNA polymerase displaces the extender polymerase to
resume processive DNA synthesis on the remainder of DNA which is presumably
undamaged. This scenario likely occurs during the replication of small miscoding DNA
lesions such as O6-methylguanine and 8-oxo-guanine.
After encountering a DNA lesion, a replicative DNA polymerase incorporates a
nucleotide opposite it but is unable to extend beyond the lesion. A specialized DNA
polymerase extends beyond the lesion. Once the lesion is bypassed, the specialized
polymerase is replaced by the replicative polymerase to resume processive DNA
synthesis. In some cases, the replicative polymerase stalls at the DNA lesion and is
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unable to incorporate a nucleotide opposite the adduct. As a result, a specialized
polymerase is recruited to the DNA lesion to incorporate a nucleotide opposite the lesion.
A different specialized polymerase is then recruited for extension beyond the DNA
lesion.
The second model is slightly different as the replicative polymerase does not
incorporate a nucleotide opposite the lesion. Instead, a specialized polymerase is
recruited to the lesion to incorporate a dNTP and, depending upon the nature of the
lesion, can also extend beyond it. However, an “extender” polymerase such as pol ζ is
needed in many cases to elongate beyond most bulky DNA lesions. Once by-pass occurs,
a replicative DNA polymerase can displace the extender polymerase to resume
processive DNA synthesis on the remainder of the undamaged DNA. This pathway likely
takes place when crosslinked or large bulky DNA lesion such as thymine dimers and
cisplatinated DNA are encountered.
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Figure 1.14 Models illustrating DNA lesion bypass during translesion DNA
synthesis. Upon encountering a lesion, the replicative polymerase (E1) incorporates
opposite the lesion but fails to extend beyond. A specialized DNA polymerase (E2)
enables lesion bypass, then switches back with the replicative DNA polymerase to
promote normal DNA synthesis. Occasionally, the replicative polymerase fails to insert a
nucleotide opposite the lesion, thereby, recruiting the specialized polymerase to promote
incorporation. Following this, a secondary specialized polymerase (E3) is recruited to
enable extension beyond the lesion. Post extension, its switches back with the replicative
polymerase to propagate normal DNA synthesis.
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Lesion bypass by DNA polymerases is a desperate measure to ensure cell survival
despite being assumed to be a promutagenic process. Though, some specialized DNA
polymerases have been found to insert the correct nucleotide opposite the templating
lesion, upregulation of certain polymerases have been associated with the development of
resistance to several types of chemotherapeutic drugs. For example, pol η can extend
beyond cisplatin-DNA lesions, and overexpression of this specialized DNA polymerases
causes resistance to cisplatin in cancer cell lines (85). Another example is the
overexpression of TdT which occurs in certain types of leukemia and causes resistance to
DNA-damaging agents that create DSBs (86). These evidences make DNA polymerases a
key target to inhibit mutagenic replication. In the next section, I discuss the current
strategies to inhibit DNA polymerases involved in cancer progression.

1.11 General strategy to inhibit DNA polymerases
The Trojan Horse strategy is the most widely used approach to DNA polymerases
(Figure 1.15). In this approach, a nucleotide analog bearing similar structural properties
to a natural nucleotide is provided in disguise to the DNA polymerase. This nucleotide
analog bears simple alterations to the deoxyribose moiety which prevents it from being
incorporated and/or elongated. Since the nucleobase is unmodified, the polymerases
readily accept the nucleotide analog, however do not elongate as it lacks a required 3’OH
group. This Trojan horse mechanism stalls the replicative fork, leading to its collapse,
thus triggering apoptosis. This information will help to provide a paradigm to develop a
potent therapeutic nucleotide analog with an ability to terminate mutagenic DNA
synthesis. To achieve this, there are four main features that need to be considered; (1)
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high catalytic efficiency for incorporation; (2) no potential for subsequent elongation; (3)
poor excision after incorporation; and (4) effective metabolism of the parental nucleoside
to form the corresponding nucleoside triphosphate.
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Figure 1.15 Trojan horse strategy to inhibit DNA polymerases. A nucleotide analog
with altered nucleobase and/or ribose group is provided for elongation by the DNA
polymerase. Its ability to mimic a natural nucleotide allows the DNA polymerase to
accept and utilize the modified analog for primer extension. The altered configuration of
the ribose sugar prevents elongation, thereby, inhibiting replication.
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Today, nucleoside analogs are essential treatments against all types of
lymphoproliferative disorders and many types of solid tumors. There are currently eleven
FDA approved nucleoside analogs (Figure 1.16) that account for 20% of all drugs used
in chemotherapy (85). The primary pharmacological effect for nucleoside analogs is
identical as they function as classic chain-terminators of DNA synthesis. These
nucleoside analogs are often subdivided into two distinct classes – one that resemble
purine nucleosides and those resembling pyrimidine nucleosides (Figure 1.16).
This distinction is based on differences in pharmacokinetic behavior rather than
pharmacodynamic properties. For example, the pyrimidine analog, cytarabine, is highly
toxic against actively replicating cells as it is primarily utilized during the S phase of the
cell cycle. In contrast, purine analogs such as fludarabine and cladribine are more
cytotoxic against slowly replicating cells such as indolent lymphoma as they can be
utilized to inhibit the repair of DSBs (86).
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Figure 1.16 Structures of FDA approved purine and pyrimidine nucleosides.
(A) Purine-like nucleosides include cladribine (2-chlorodeoxyadenosine), clofarabine [2chloro-9-(29deoxy- 29-fluoroarabinofuranosyl)adenine], fludarabine (9-β-d-arabinoside2-fluoroadenine), and pentostatin (29-deoxycoformycin). (B) Pyrimidine-like nucleosides
include cytarabine [1-β-d-arabinofuranosylcytosine (Ara-C)], gemcitabine [29,29difluorodeoxycytidine (dFdC)], 5-aza-deoxycytidine, and tezacitabine.
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1.12 Emerging evidence of DNA polymerases in cancer
Mutagenesis by DNA polymerases is a fundamental occurrence for majority of
genomic related diseases, especially cancer. Often characterized as a conglomerate of
diseases involving abnormal cell growth, cancer has the ability to spread and invade other
parts of the body. This unregulated hyper-proliferative nature is synonymous with the
promutagenic replication by DNA polymerases. Hence, many anticancer agents are
designed to slowdown or inhibit the uncontrolled growth of cellular replication resulting
in cell death. For example, cisplatin, a well-known chemotherapeutic drug has been used
in the treatment of various types of human cancers. Its primary mechanism of action is by
initiating the formation of an interstrand cross link between purine nucleobases within the
duplex DNA. This interferes with the ability of DNA polymerases to replicate effectively,
activating the DNA repair mechanism pathways, subsequently leading to DNA damage
and apoptosis (87). Other chemotherapeutic agents that follow a similar mechanism of
action are nitrogen mustards, mitomycin C, and psoralens and its derivatives (88).
Finally, the oldest family of anticancer drugs, and widely used clinically, called
antimetabolites act by inhibiting the biosynthetic DNA replicative pathway. Some of the
drugs categorized under this classification are purine and pyrimidine nucleoside
analogues such as fludarabine, gemcitabine, and mercaptopurine (89).
Decades of cancer research suggests that, though the hallmarks of cancer are
consistent in all patients, the prognosis of cancer depends on several factors ranging from
genetic makeup of a patient to the growth rate of a tumor. Hence, pharmacogenomics
plays a crucial role in diagnosing the most appropriate therapeutic strategy for a cancer
patient. For example, certain types of cancer have elevated protein levels when compared
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to others. These key proteins which are upregulated can be used as biomarkers to
determine the type and stage of cancer progression. With this in mind, efforts in
personalized medicine involves identifying the expression levels of DNA polymerases in
different types of cancer, and the polymerases that are resistant to drugs used during
chemotherapy. Here, I briefly summarize the clinical reports identifying the DNA
polymerases involved in cancer progression.
Pol β is probably the most extensively studied DNA polymerase whose evidence
of expression levels were found to be associated with chemotherapeutic drug resistance
and cancer treatment. Evidence of cell lines with overexpressed pol β demonstrated
enhanced mutations promoting genetic instability, a common hallmark of cancer cell
progression. These studies were confirmed using several independent assays by Canitrot
et al. (90). Also, overexpression of pol β was found to induce genomic defects promoting
tumorigenesis in mice. These reports are supported by the findings of Wilson et al.,
where pol β was found to be overexpressed in all the breast and colon adenocarcinoma
tissue cells lines tested (90). Surprisingly, cell lines with over expressed pol β were found
to be sensitive to chemotherapeutic agents such as cisplatin (91).
These findings accelerated more clinical trials aimed at determining gene
expression of DNA polymerases in cancers. Indeed, the presence of different types of
mutagenic lesions, the varied chemotherapeutic agents and the different DNA
polymerases used to replicate these lesion makes these studies even more difficult.
However, despite these complications, elaborate clinical studies identified key DNA
polymerases that appeared to play a crucial role in regulating patient response to
chemotherapy. Though many types of polymerases’ expression levels have been explored
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in various types of cancers, for the most part no clear trend has emerged. However, there
have been several exceptions. Expression levels of specialized polymerases such as pol η,
pol λ, and pol ι were found to correlate with the developmental stage and therapeutic
outcome for several types of cancers (92,94). For example, the expression of Pol η was
inversely proportional to the chemotherapeutic response in patients with non-small cell
lung cancer (95). Surprisingly, pol η however, was under expressed in lung and stomach
cancer tissue cells in comparison to normal tissues.
Pol ι, a specialized DNA polymerase involved in TLS and BER is overexpressed
in breast cancer patients undergo UV treatment. In fact, cells with upregulated pol ι
demonstrate lower fidelities indicating that it does play a role in breast cancer
development. This is further reflected in the decreased survival times suggesting that the
life of a patient directly correlates to the survival time of a patient (96). Similarly, another
error prone polymerase pol q, was found to be overexpressed in colorectal cancer tumor
cells in comparison to normal cells. In fact, screening of breast cancer patients found that
pol q was the sole DNA polymerase to be overexpressed which was further corroborated
with poor clinical outcome. Though these reports suggest that overexpression of
specialized polymerases correlate with outcome of chemotherapeutic patient response
and cancer developmental stage, several reports suggest otherwise (97). For example, pol
k was found to be expressed inconsistently among different types of tumors. Lu’s group
demonstrated that pol k was significantly elevated in ~70% of the patients with human
gliomas (72 out of 104) (99). Further, patients survival time also decreased
synonymously when compared to pol k-negative glioma patients. In contrast, Alberta
et.al and Pan et.al demonstrated that pol k levels decreased in lung cancer cell lines and
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rat carcinoma cell lines respectively (93,98). Further, pol k was commonly expressed in
many types of breast and lung cancer patients. These differences suggest that DNA
polymerase expression levels in the same tumor samples is not co-regulated. However,
despite these differences, there is demonstrated evidence of at least one or more
specialized DNA polymerases (i,b, and l) as being overexpressed in specific tumors (93).
While this particular report provides evidence for specialized DNA polymerases
participating in cancer, it is clear that more pre-clinical and clinical studies are needed to
better define the exact roles of these enigmatic polymerases in the initiation and
progression of cancer. In contrast, replicative polymerases such as pol d and e did not
display any change in expression levels., possibly due to their ability to their ability to
mitigate mutations because of their proofreading capacities. Remarkably, pol a, lacking a
3’-exonuclease activity for proofreading errors, was found to have a greater tumor:normal
expression ratio in stomach and kidney tumors (93).

1.13 Nucleotide analogs as molecular probes to study translesion DNA synthesis
DNA polymerases misreplicate chemically modified DNA (DNA lesions) which
initiate mutagenic events, that can eventually progress to the development of dreadful
diseases such as cancer. Several DNA lesions have been extensively studied to estimate
their mutagenic potential both in-vitro and in-vivo. Non-natural nucleotides can be used
as chemical tools to identify the molecular forces influencing DNA polymerases while
replicating damaged lesions. The mechanistic information derived can be used to develop
nucleotide analogs with therapeutic and diagnostic capabilities.
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1.13.1 Abasic site as a model to study translesion DNA synthesis
Abasic sites are non-templating lesions formed due to the hydrolysis or the Nglycosidic bond joining the nucleobase to the ribose sugar. This leads to the removal of
the nucleobase, hence are also called as apurinic or apyrimidinic sites (AP). Studies
predict that about 10,000 bases are lost per day per mammalian cell due to the
spontaneous hydrolysis of N-glycosidic bond. Recent studies indicate that healthy liver
cells form about 50,000 AP sites per genome (100). These AP sites are considered to be
cytotoxic to the cell due to their ability to block DNA synthesis (101). As illustrated in
Figure 1.17, nucleobases of damaged DNA bases are susceptible to N-glycosylase action,
resulting in the removal the purine/pyrimidine nucleobase.
Most of the AP sites are repaired by the BER/NER with high fidelity, fostering
cell survival. However, many lesions that evade the repair systems are either
misreplicated initiating mutagenesis, or by acting as a replicative block by stalling the
replicative machinery, resulting in cell death. Both pathways are deleterious for the
survival of the cell. Further, most replicative DNA polymerases were found to
preferentially misinsert adenine opposite a non-coding abasic site, called as the “A-rule
of translesion DNA synthesis” (102). Absence of coding information in an abasic site
makes it an ideal model to study the influence of molecular forces such as hydrogen
bonding interactions, nucleobase hydrophobicity, π-electron density, and shape
complementary/steric fit during the DNA polymerization pathway. Here, I discuss the use
of nucleotide probes by several labs (with primary focus on the works on Berdis and Lee
labs) that helped derive useful insight into the mechanism employed by high fidelity
polymerases involved in replication of mutagenic lesions such as the abasic site.
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Figure 1.17 Origin, repair and biological consequence of abasic sites. Nucleobases of
damaged DNA lesions are excised by glycosylase enzymes, thereby, creating a nontemplating abasic site. These sites are called abasic sites. If not repaired, abasic sites are
often misreplicated with adenine that could prove to be fatal for cell survival.
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1.13.2 Incorporation of natural nucleotides opposite a non-coding lesion, the abasic site
Replicative DNA polymerases such as the bacteriophage T4 DNA polymerase,
DNA polymerase I (E. coli), pol d (mammalian) follow the A-rule of translesion DNA
synthesis, by selectively misinserting an incorrect adenine opposite an abasic site
(103,104). This kinetic phenomenon bewildered researchers due to the longstanding
perception of hydrogen bonding interactions playing a key role in nucleotide selectivity
and base pairing. This preferential selection for the insertion of a specific nucleotide
encouraged scientists to study the promutagenic nature of this lesion more closely.
Kinetic studies from the Goodman’s group using pol a showed than dATP was
preferentially inserted opposite an abasic site with a Km value ~2-fold better and Vmax of
~5-fold faster than dGTP (105). Similar trends were obtained for kinetic studies using pol
I. Though the A-rule seems to be followed by a majority of DNA polymerases, there have
been some exceptions. Pol i was found to insert dGTP and dTTP over dATP opposite an
abasic site (106). A specialized polyemrase, Rev-1 was found to insert a pyrimidine
(dCTP) over dATP opposite an abasic site (107).
Some of the most elaborate studies evaluating the promutagenic replication of the
abasic site were performed by the Berdis laboratories using the bacteriophage T4 DNA
polymerase as a model system (108-111). Kinetic assays were performed under single
turnover conditions (molar excess of enzyme than the DNA) to determine the kinetic
dissociation constant (Kd) and the maximal rate constant of polymerization (kpol).
Preliminary studies measuring the kinetic parameters for the incorporation of natural
nucleotides opposite an abasic site show that dATP is preferred over other dNTPs. This
was predominantly due to the better binding affinity of dATP (35 µM) which is ~4-~35-
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fold lower than other dNTPs (103). Also, the kpol of dATP (0.15 s-1) is at least ~3-fold
faster than the next best nucleotide (dGTP) (103). These studies are consistent with the
finding of previous works of Goodman et.al where high fidelity DNA polymerases utilize
purines over pyrimidines for insertion opposite an abasic site (105). The preferential
selection of larger purines over the relatively smaller pyrimidines have evoked multiple
theories. The shape complementarity model projected by Kool’s lab is consistent with the
favored selection and insertion of larger nucleotide, dATP (112). NMR structures
indicating the presence of adenine stacked in a thermodynamically favored conformation
opposite an abasic site indicates the role of base stacking interactions in nucleotide
selection and insertion. In fact, these observations were found to directly correlate with
the efficiency of nucleotide insertion opposite the lesion.
1.13.3 Indole nucleotides as probes to evaluate translesion replication of an abasic site
Kool’s lab demonstrated that a non-natural analog pyrene triphosphate was
inserted with incredibly high efficiency opposite an abasic site. Kinetic studies
demonstrated that the base stacking interactions appeared to play a predominant role due
to its ability to fill the void of an abasic site (52). Berdis and Lee laboratories further
evaluated the biophysical forces involved in translesion replication of an abasic site using
non-natural indole nucleotides. A unique non-natural nucleotide, 5-nitro-indolyl-2’deoxyribose triphosphate (5-NITP), was inserted with an efficiency of ~1000-fold greater
than the preferred dATP (113). Kinetic studies revealed that this high efficiency was due
to a combination of an incredibly low Kd value of 18 µM) and a remarkably fast kpol
value of 126 s-1 (113). These values reiterate that, hydrogen bonding interactions are not
essential for nucleotide insertion. This is because the kinetic parameters for a 5-NI:abasic
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site mispair is nearly identical to the formation of a natural Watson-Crick base pair
(dA:T). Considering the small size of 5-NITP, its inability to fill the void of an abasic site
contradicts the influence of shape complementarity. Unfortunately, it is impossible to
identify which biophysical feature of 5-NI is responsible for the high kinetic parameters
opposite an abasic site. The unique nature of nitro group due to its varying physical
features such as hydrophobicity, p-electron density, electron withdrawing potential and
zwitter ionic character have further been investigated by strategically replacing the nitro
group with different functional groups differing in the aforementioned biophysical
features. Kinetic characterization of these analogs determined that the catalytic efficiency
for nucleotide insertion opposite an abasic site relies upon the p-electron surface area that
is similar to that of a natural base pair. This is further backed by the kinetic
characterization of three analogs, 5-cyclohexyl (5-CHITP), 5-cyclohexene (5-CEITP) and
5-phenyl (5-PhITP) indole-2’deoxyribose triphosphates similar in size and shape but with
varying p-electron surface area (Figure 1.18) (108). The data revealed that analogs with
greater p-electron density achieved relatively higher catalytic efficiencies, due to a
predominant influence on the kpol value. A crucial observation made was the influence of
nucleobase hydrophobicity in the nucleotide binding step. This was investigated by the
kinetic comparison of non-natural analogs 5-CITP, 5-MeCITP and 5-NITP. 5-CITP
achieves a fast kpol like 5-MeCITP and 5-NITP (109,111). However, the absence of a
hydrophobic functional group dramatically decreases its binding affinity by ~10-fold
when compared to other indole analogs. This demonstrates that nucleobase
hydrophobicity influences the nucleotide binding step.
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Figure 1.18 Chemical structures of non-natural indole analogs. These analogs have
been used as efficient chemical probes to determine the underlying mechanism involved
in translesion replication of an abasic site.
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1.13.4 Using modified purine nucleotides to study the A-rule of translesion DNA
synthesis
Devadoss et al. used modified purine analogs with altered hydrogen bonding
groups to determine if DNA polymerase’s fidelity is synergistically reduced due to the
presence of modified functional groups (110). Their studies resulted in elucidating a
structure activity relationship for the enzyme while performing translesion DNA
synthesis. Simple alkylation of a purine resulted in a synergistic increase in misinsertions,
caused by a decrease in the enzyme’s fidelity. This is consistent with the increases of
secondary cancers in patients when administered with a chemotherapeutic alkylating
agents such as the Temozolomide. Kinetic characterization demonstrates the role of
hydrophobicity and aromaticity in translesion replication of a non-templating lesion.
However, comparative studies with a templating undamaged DNA showed that the
biophysical features influencing a template versus non-templating DNA might differ,
refuting the existence of a universal mechanism of DNA polymerization for a damaged
versus undamaged DNA. Collectively, these studies helped derive a molecular model
demonstrating the different molecular forces facilitating transfer the nucleotide binding
step and the conformational change step preceding phosphoryl during the replication of
an abasic site, a non-instructional lesion (Figure 1.19). Desolvation appears to play a
predominant role during the nucleotide binding step, whereas, the conformational change
step, is influenced both by nucleobase desolvation and p-stacking interactions to promote
the chemistry step to occur. This model is in congruence with the Kd and kpol values
derived for the library of modified analogs used. Modified analogs with hydrophobic
functional groups achieved better binding affinities, and faster rate constants.
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Figure 1.19 Model illustrating the role of different molecular forces during the
translesion replication of an abasic site by a high fidelity DNA polymerase. The
mechanistic model here demonstrates that the nucleotide binding step (Kd) is influenced
by desolvation whereas the conformational change step (kpol) is predominantly influenced
by nucleobase desolvation and pi-stacking interactions.

58

1.14 Statement of purpose
Previous work from Berdis laboratories show that a high fidelity bacteriophage
T4 DNA polymerase efficiently incorporate nucleotide analogs devoid of hydrogen
bonding groups opposite an abasic site. Kinetic studies have shown that the nucleotide
binding step is predominantly influenced by the ability of the incoming nucleotide to be
desolvated. This is evident from the incredibly low Kd values of the hydrophobic nonnatural analogs. The conformational change step preceding the chemistry step is
influenced by the ability of the nucleotide to stack within the void of the abasic site. The
high p-stacking ability of the indole analogs enable them to achieve remarkably fast kpol
values. One of the key questions to be answered is if this mechanism is employed in the
translesion replication of other promutagenic lesions. For this study, I chose 8-oxoguanine a prevalently found lesion in the cell. Its ability to base pair with adenine like the
abasic site allows me to do a comparative analysis for the insertion of our library of
modified and non-natural analogs. In this dissertation work, I investigated the following:
In Chapter II I set out to answer the question, which molecular forces of the modified
nucleotides influence translesion replication of damaged 8-oxo-guanine and undamaged
guanine. In Chapter III, I investigated if physicochemical properties of non-natural indole
analogs that influenced the replication of an abasic site, also influenced the translesion
replication of 8-oxo-guanine. During the kinetic investigations, I observed a unique
modified analog N2-MedGTP that was selectively not incorporated opposite 8-oxoguanine by the high fidelity bacteriophage T4 DNA polymerase, despite achieving high
catalytic efficiencies for insertion opposite pol h. In chapter IV, I set out to investigate
this interesting dichotomy by performing inhibition assays to observe if N2-MedGTP
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inhibits high fidelity bacteriophage T4 DNA polymerase while replicating a
promutagenic lesion such as 8-oxo-guanine.
Collectively, the structure activity relationship information derived from these
chapters will enable me to derive further insight into the understanding of translesion
DNA replication of structurally different lesions. This information can be further used to
design novel nucleotide analogs that can be developed as biochemical tools, and/or
therapeutic agents to inhibit mutagenic replication of DNA lesions involved in
propagation of dreadful diseases such as cancer, age-related and neurological disorders.
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CHAPTER II
EVALUATING THE PROMUTAGENIC REPLICATION OF 8-OXO-GUANINE
CATALYZED BY A HIGH FIDELITY DNA POLYMERASE

2.1 Introduction
High oxidative stress leads to the formation of a wide range of reactive oxygen
species (ROS) and are considered to be a major source of DNA damage. In humans, ROS
are constantly formed as by-products of oxidative respiration (mitochondria), chemical
exposure, environmental exposure, etc. (114). When oxidative metabolism occurs in the
mitochondria, the oxygen (O2) we breathe is converted into water (H2O). During this
process, leakage of electrons might occur leading to the formation of super oxide anions
(•O2-). These anions can be converted to hydrogen peroxide (H2O2) either spontaneously
or enzymatically (superoxide dismutase). H2O2 can be further reduced to form highly
reactive hydroxyl radicals (•OH). Due to its ability to easily diffuse through cell
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membranes, it can often cause damage to nuclear DNA by forming mutagenic adducts
(115-117). This leads to genomic instability, and when misreplicated can lead to the
initiation of a mutagenic event. Though several repair processes and apoptotic events can
occur to prevent further damage, unrepairable damages can progress or contribute to
oncogenesis. There are ~100 different types of oxidative base modifications that ROS can
form (114). Of the four nucleobases, guanine is often subjected to oxidative modification
due to its low redox potential. Its vulnerability to ROS leads to the formation of two main
modifications, 7,8-dihydro-8-oxo-guanine (8-oxo-G) and 2,6-diamino-4-hydroxy-5formamidopyrimidine (faPy-G) (118-120). Adenine is oxidized to form 8-oxo-A and
faPy-A, whereas pyrimidines are oxidized by ROS to form thymine glycol, dihyrouracil,
and 5-hydorxycytosine etc (121).
8-oxo-G is the most prevalently formed type of oxidative DNA lesion, forming
~1000 in a healthy cell and 100000 in a cancer cell/ per day (122). Such high prevalence
allows 8-oxo-G to be used as biomarker to indicate the intensity of oxidative stress (123).
The difference between guanine and 8-oxo-G is a single oxygen atom, formed by at the
C-8 position of guanine by oxygen radicals. This leads to protonation at its N-7 position
to incorporate an extra hydrogen. These modifications allow 8-oxo-G to adopt either the
syn or anti conformations (124). The syn conformation may actually be favored over the
anti as the modified O-8 might hinder/interfere with the phosphate backbone. Structural
analysis (NMR and X-ray) of a replicative DNA polymerase (RB69) has shown that 8oxo-G in anti-position resembles guanine allowing it to pair with cytosine with three (3)
hydrogen bonds. However, in syn-conformation, 8-oxo-G exposes its Hoogsten edge with
two (2) hydrogen bonds to pair with adenine (Figure 2.1) (125-128). This dual coding
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potential of 8-oxo-G during templative DNA synthesis characterizes it as a highly
promutagenic lesion. The miscoding nature of 8-oxo-G often results in the formation of
G–C to A–T transversion mutations, often implicated in cancer development (124). In a
detailed survey by Greenman, et al., of 518 protein kinase genes in 210 diverse human
cancers identified, G–C to A–T transversions were the most prominent ones in lung,
breast, ovarian, and gastric cancers (129).
Replicative DNA polymerases perform genomic replication with incredible high
fidelity. When exposed to xenophobic agents, they damaged DNA forming DNA lesions.
These are usually first confronted by the high fidelity replicative DNA polymerases.
Under normal conditions, these high fidelity DNA polymerases halt, and switch with a
specialized DNA polymerase to help bypass the lesion. However, majority of the
replicative DNA polymerases primarily misinsert the incorrect adenine (A) opposite 8oxo-G (syn). Since 8-oxo-G (syn):A mimics a normal base pair (T:A), the exonuclease
proofreading domain fails to identify the mispair, leading to mutagenic replication that
can eventually progress to oncogenesis. To prevent such adverse effects, cells respond by
initiating a number of repair systems. One of the most common one is the base excision
repair system involving the removal of the damaged base. In humans, when replicative
DNA polymerases insert “A” opposite 8-oxo-G, MUTYH recognizes the mispair and
removes the incorrect A. However, these repair systems are not perfect, and under high
oxidative stress, MUTYH fails to repair the formed mispair (130,131). Further, high
fidelity replicative DNA polymerases such as pol d (human) (132), pol I (E.coli) (133)
were found to insert both A and C opposite 8-oxo-G, in ratios varying from 7:1 to 2000:1.
These polymerases were found to efficiently extend beyond the A:8-oxo-G mispair.
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Figure 2.1 The replication of 8-oxo-guanine (8-oxo-G) can be “error free” (dC
insertion) or “error prone” (dA insertion). In anti-conformation 8-oxo-G resembles
guanine pairs with the correct cytosine. However, in syn conformation, 8-oxo-G mimics
thymine which misleads several DNA polymerases to misinsert the incorrect adenine.
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The ability of 8-oxo-G in reducing the nucleotide selectivity to varying degrees would
have detrimental effects to the fidelity of genomic replication.
Crystal structures of dCTP and dATP opposite damaged and undamaged DNA in
the active site of DNA polymerases have been modelled to identify the difference sin
structural conformations. When compared to canonical base pairs (dC:G, dA:T), dC:8oxo-G (anti) and dA:8-oxo-G(syn) have similar interglycosyl distances (C1’-C1’) of
~10.5 Å. In fact, superimposition of a 8-oxo-G (syn):A base pair over a canonical
Watson-Crick T:A base pair in the active site of a high fidelity RB69 DNA polymerase
showed near identical conformations with C1’-C1’ distance within the normal range for
Watson-Crick base pairs (Figure 2.2). These similarities might have allowed the 8-oxoG:A to fit within the active site of the polymerase. Other structural studies investigated
the geometry of the 8-oxo-G:A base pair suggesting hydrogen interactions between the
bases. However, no study clearly sheds light into understanding the molecular
mechanism employed by the replicative DNA polymerases in replicating 8-oxo-G.
These studies give rise to the question: do hydrogen bonding interactions
influence the misinsertion of adenine opposite 8-oxo-G (syn)? To determine this, a
thorough kinetic analysis was performed using our library of modified purine analogs and
non-natural indole nucleotide analogs. Biophysical forces such as hydrogen bonding
interactions, shape complementarity, nucleobase hydrophobicity, and π-stacking
interactions were evaluated. Collectively, these studies enabled me to derive a structure
activity relationship to determine the biophysical forces involved in the translesion
replication of 8-oxo-G.
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Figure 2.2 Crystal structures of natural nucleotides opposite damaged (8-oxoguanine; 8-oxo-G) and undamaged DNA (dT; thymine) in the active site of RB69
DNA polymerase. Structures were built from the crystal structures obtained from protein
data bank (PDB: 3LDS/3NC1) using Molecular Operating Environment (MOE) and
Chimera softwares.
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I chose the exonuclease deficient bacteriophage T4 DNA polymerase (gp43
family), a high fidelity replicative DNA polymerase functionally analogous to pol delta,
involved in human genomic replication. Since, previous studies in the Berdis lab used the
T4 DNA polymerase as a model system to study the promutagenecity of the abasic site,
using the same polymerase system has enabled me to compare and contrast the molecular
mechanisms employed by a high fidelity DNA polymerase in replicating structurally
distinct lesions, 8-oxo-G and the abasic site.
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2.2 Materials and Methods
2.2.1 Purification of bacteriophage T4 DNA polymerase, and DNA substrates.
Exonuclease deficient bacteriophage T4 DNA polymerase (gp43exo-) was purified and
quantified as previously described (134). Defined duplex DNA substrates with desired
oligonucleotides were synthesized by Operon and purified as previously described.
Single and double stranded duplex DNA used in this study (Figure 2.2) were purified and
quantified as described (135).

13/20mer

5’-TCGCAGCCGTCCA
3’-AGCGTCGGCAGGT-X-ACCAAA

X = G or 8-oxo-G

Figure 2.3 Defined duplex DNA substrates used in this study.

2.2.2 Modified purine nucleotide analogs
The modified nucleotides listed in Figure 2.4 were purchased from Trilink
Biotechnologies (San Diego, CA). All nucleotides are greater than 99% pure.

2.2.3 Radiolabeling duplex DNA substrate.
Duplex DNA substrates used in this study were radiolabeled with {γ-32P}ATP before
using them in polymerization assays. The amount of {γ-32P}ATP depends on the amount
of DNA to be used and the half-life of the radioactive substance. A conventional labelling
reaction for 1 µM duplex DNA consists of 100 pmol 13/20mer, 10 pmol {γ-32P}ATP,
polynucleotide kinase buffer (100 mM Tris-pH 9.5, 10 mM MgCl2, 2.5 mM DTT, 2.5%
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Figure 2.4 Chemical structures of modified nucleotides used in this study.
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glycerol, 1 mM spermidine, and 0.1 mM EDTA), polynucleotide kinase (1 µL), and
ddH2O is added to make up the volume to 100 µL. Both the primer and template strands
were labelled at 5’ end after purification of the DNA substrates. This allows both the
template and substrate (primer) strands to be visualized post electrophoresis and
PhosphorImaging. The labelling reaction mixture is incubated at 370 C for 30 minutes,
followed by 10 minutes at 670 C to inactivate the polynucleotide kinase. The reaction
mixture is slow cooled to room temperature (250 C) before using for polymerization
assays.

2.2.4 Polymerization assays to determine the kinetic dissociation and rate constants for
dNTP incorporation opposite guanine and 8-oxo-guanine.
All kinetic assays were performed at 250 C under single turnover conditions. The
buffers used in all the assays consisted of 25 mM Tris-OAc (pH 7.5), 150 mM KOAc,
and 10 mM 2-mercaptoethanol. The amount of product formed in the polymerization
assays were monitored through analysis on 20% sequencing gels. Gel images were
obtained using a Packard PhosphorImager and Optiquant software supplied by the
manufacturer. The amount of product formed was quantified by measuring the ratio of
32

P-labelled extended to non-extended primer. Obtained ratios were corrected for

substrate in the absence of the polymerase (zero point). Corrected ratios of product
formation were multiplied by the concentration of primer/template used in each assay to
yield total amount of product.
Unless otherwise noted, all reaction assays were carried out on the benchtop
manually at time intervals ranging from 5 to 300 seconds. The volume of each reaction is
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50 µL. In a typical enzymatic assay, DNA substrate (100 nM) is preincubated with dNTP
(10-500 µM), and the reaction was initiated by the addition of the DNA polymerase (200
nM). After quenching with EDTA, the sample buffer was mixed with sequencing gel
loading buffer in 1:1 ratio. The products were analyzed for product formation by 20%
denaturing gel electrophoresis. The gel was transferred onto a plastic film sheet, which is
then covered with a plastic wrap. The location of radioactive bands of DNA was verified
using a Geiger counter. The phosphor screen plates were placed with the phosphor screen
(blue) facing the region with the radioactive DNA. The time of exposure ranges from 2
hours to overnight, depending on the intensity of band required. The plates were scanned
to produce digital images of the labelled oligonucleotides on the gel. The intensities of
the products formed from the substrates were quantified using Optiquant software. The
obtained values were corrected for substrate in the absence of the polymerase (zero
point). The corrected ratio of product formed is multiplied by the concentration of
13/20mer for each assay to yield the total product formed.
The rate constant (kobs) of each reaction was obtained by fitting the data to
equation 2.1
y = A(1 - e-kt) + C

(2.1)

where A is the amplitude of product formation, k is the observed rate constant in product
formation, t is time, C is a defined constant and y is the amount of product formed. The
data for the dependency of kobs on dNTP concentration was fit to the Michaelis-Menten
equation (equation 2.2):
kobs = kpol [dNTP]/(Kd + [dNTP])

(2.2)
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where kobs is the observed rate constant, kpol is the maximal polymerization rate constant,
Kd is the dissociation constant for dNTP, and [dNTP] is the concentration of the modified
or non-natural nucleotide substrate (Figure 2.5). Using the Michaelis-Menten equation
(2.2), the kinetic parameters Kd, kpol and kpol/Kd were deduced.

kpol

Kd
E:DNA + dNTP

E:DNA:dNTP

PPi
E*:DNA:dNTP

E* + DNAn+1

Figure 2.5 A simplified polymerization pathway. Kinetic dissociation constant is
represented as (Kd), and maximal polymerization rate constant as kpol for the nucleotide
(dNTP). E denotes enzyme, whereas E* denotes enzyme post conformational change. PPi
represents pyrophosphate.

2.2.5 Calculation of physicochemical parameters of modified analogs
Solvation energies (kcal/mol), surface areas (Å2), volume (Å3) and logP values
from calculated using Hartree-Fock molecular mechanics in the Spartan software (Table
2.1).

2.2.6 Calculation of change in Gibb’s free energies for nucleotide analogs
The overall change in Gibb’s free energy was calculated using the equation, DDG0 = RT
In K, where K = ratio of the respective kinetic parameters (Kd, kpol and/or kpol/Kd) for the
nucleotide analogs, R = 1.9872 cal mol-1K-1, T (temperature) = 298 K.
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Table 2.1 Physicochemical parameters of natural and modified purine analogs. The
energy minimization calculations and geometric optimizations were performed with
Hartree-Fock molecular mechanics Spartan’14.
Surface
area ( Å2)

Volume
( Å3 )

Solvation
energy
(kcal/mol)

logP

dATP

142.98

121.65

-19.36

-1.45

dGTP

152.50

129.03

-23.91

-1.74

N6-methyldATP

164.95

142.08

-16.15

-0.930

O6-methyldGTP

174.49

148.89

-19.71

-0.600

N2-methyldGTP

174.34

149.94

-20.81

-1.21

6-ChlorodATP

145.22

125.13

-15.84

-0.240

6-Chloro-2APTP

158.70

135.13

-18.86

-0.290

2,6-APTP

156.44

131.65

-22.79

-1.50

dITP

138.96

119.00

-21.30

-1.69

dNTP

Nucleobase
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2.2.7 Extension beyond 8-oxo-guanine
Assays were performed using single turnover reaction conditions in order to
maximize signal-to-noise ratios in product formation. Under these conditions, an excess
concentration of gp43exo- (200 nM) was incubated with 100 nM 13/208-oxo-G in assay
buffer containing 10 mM magnesium acetate and then mixed with a fixed concentration
of nucleotide (dNTP) and 5 mM Mg2+ to initiate insertion opposite the lesion. After 4
half-lives, an aliquot of dTTP and dGTP (200 µM final concentration) was added to
initiate the elongation reaction (Figure 2.5). Aliquots of the reactions were quenched with
EDTA at variable times (0-600 seconds) and analyzed by denaturing gel electrophoresis
to assess elongation.
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2.3 Results and Discussion
2.3.1 Kinetic evaluation for the insertion of natural nucleotides opposite undamaged
guanine and damaged 8-oxo-guanine
Initial experiments compared the efficiency for incorporating dCTP and dATP
opposite guanine or 8-oxo-G by gp43exo-. Figure 2.3 provides the sequences of the DNA
substrates used in this study containing either guanine or 8-oxo-G at the 14th position of
the template strand. Representative gel electrophoresis images provided in Figure 2.6
show that gp43exo- efficiently incorporates dCTP opposite G while poorly incorporating
dATP opposite an unmodified G. Gp43exo- also misinserts dCTP opposite 8-oxo-G,
albeit with a lower overall efficiency. Surprisingly, this high-fidelity polymerase
misinserts dATP opposite the oxidized lesion with an efficiency that is comparable to
dCTP.
To further quantify the replication of 8-oxo-G, the kinetic parameters kpol, Kd, and
kpol/Kd were measured for the insertion of dCTP and dATP opposite the undamaged G
and damaged 8-oxo-G (Table 2.2). During normal DNA synthesis, gp43exo- efficiently
incorporates dCTP opposite an undamaged G with a low Kd value of 6 µM and fast kpol
value of 118 s-1.40 When replicating 8-oxo-G, however, the catalytic efficiency for
inserting dCTP is ~1400 fold lower (compare 1.97Í107 M-1sec-1 versus 1.40 Í104 M1

sec-1, respectively). This reduction reflects a ~8-fold increase in Kd value (49 µM)

combined with a ~170-fold reduction in kpol (0.707 s-1). I next determined the kinetic
parameters for the misinsertion of adenine opposite 8-oxo-G.
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Figure 2.6 Representative gel electrophoresis images for the incorporation of dCTP
and dATP opposite guanine (13/20G) and 8-oxo-guanine (13/208-oxo-G). Assays were
performed used a fixed concentration of 100 µM nucleotide substrate. Reactions were
quenched at 120 seconds.
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The observed rate constants for each nucleotide concentration are plotted as a function of
time yields a hyperbolic curve (Figure 2.7). The derived rate constants were plotted as a
function of nucleotide concentration, yielding another hyperbolic curve. Using the
Michaelis-Menten equation (2.2), the kinetic parameters Kd, kpol and kpol/Kd were
deduced. Surprisingly, the efficiency for inserting dATP opposite 8-oxo-G is only ~15fold lower than dCTP (compare 1.40 Í 104 M-1sec-1 versus 9.50 Í 102 M-1sec-1,
respectively) (Figure 2.8). The reduced efficiency for utilizing dATP is not caused by an
effect on the conformational change step since the kpol value for dATP is nearly identical
to that measured for dCTP (compare 0.535 s-1 versus 0.707 s-1, respectively). Instead, the
reduced efficiency is caused almost exclusively by a ~10-fold decrease in binding affinity
(compare Kd values of 566 µM versus 49 µM, respectively). As expected, the high
fidelity DNA polymerase does not incorporate dATP opposite an unmodified G. Thus,
the ability of gp43exo- to misincorporate dATP opposite 8-oxo-G highlights the promutagenic properties of the oxidized lesion. These values are summarized in Table 2.2
and provide the basis for our analyses comparing correct versus translesion DNA
synthesis catalyzed by gp43exo-.
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Figure 2.7 Dependency of dATP concentration on the observed rate constant in
misinsertion opposite a miscoding lesion, 8-oxo-G. Radiolabeled 13/208-oxo-G (100 nM)
was preincubated with variable concentrations of N6-MedATP [50 µM (l); 100 µM, (n);
250 µM, (n); 350 µM, (l); and 1000 µM, ()], Mg(OAc)2 and reaction buffer. The
reactions were initiated with gp43exo- (200 nM) and quenched with 200 mM EDTA at
variable times (0-180 seconds). The solid lines represent the data fit to a single
exponential.
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Figure 2.8 Michaelis-Menten plot comparing the insertion of dCTP (■) versus dATP
(●) opposite 8-oxo-guanine by gp43exo-.

Table 2.2 Summary of kinetic parameters for the insertion of dCTP and dATP
opposite guanine (13/20G)and 8-oxo-guanine (13/208-oxo-G). a Values taken from (136).
NA = not applicable

DNA

dNTP
a

13/20G

13/208-oxo-G

dCTP

Kd (µM)

kpol (s-1)

kpol/Kd (M-1s-1)

6±1

118 ± 7

1.97 Í 107

dATP

NA

dCTP

49 ± 8

0.707 ± 0.055

1.40 Í 104

dATP

566 ± 24

0.535 ± 0.015

9.50 Í 102
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2.3.2 Modified analogs as mechanistic probes to evaluate the promutagenecity of 8-oxoGuanine
Preliminary gel survey analysis demonstrated that none of the modified analogues were
inserted opposite the undamaged guanine (Figure 2.9). To further investigate the
molecular forces associated with the pro-mutagenic replication of 8-oxo-G, I measured
the kinetic parameters for modified purine analogs containing alterations in hydrogen
bonding groups (Table 2.3).
Kinetic evaluation of alkylated purine analogs on insertion opposite guanine and 8oxo-guanine. The primary focus is to understand the molecular forces influencing
translesion replication of 8-oxo-G by a high fidelity DNA polymerase. Structural studies
have shown that hydrogen bonding interactions between the incoming dATP and the
templating 8-oxo-G (syn) are critical for base pairing (135). To evaluate if hydrogen
bonding interactions are the primary driving force for dATP insertion, I performed primer
extension assays for insertion and extension beyond the mispair with a series of alkylated
purine analogs by gp43exo- under single turnover conditions where an excess of enzyme
concentration was used against the substrate (DNA). These studies enabled me to
kinetically evaluate the nucleotide binding step, and the maximal rate constant for
polymerization.
First, I investigated if subtle modifications to the hydrogen bonding groups of
dATP and dGTP influence the kinetics of incorporation opposite 8-oxo-G. N6-MedATP,
formed by simple alkylation to hydrogen bonding N-6 position of adenine was first tested
to evaluate the influence of alkylation on the dynamics of misinsertion opposite a
miscoding lesion, 8-oxo-G. The observed rate constants for each nucleotide concentration
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Figure 2.9 Gel survey images comparing the insertion of modified analogs opposite
guanine and 8-oxo-guanine by the high fidelity gp43exo-. Denaturing gel
electrophoresis images comparing the incorporation of non-natural nucleotide analogs
opposite G (13/20G) versus 8-oxo-guanine (13/208-oxo-G) by gp43exo-. Survey assay was
performed under single turnover conditions as represented in the text, with 100 µM dNTP
quenched at 120 seconds.
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was derived from the plot representing a single exponential process where the amount of
product formed is plotted as a function of time (Figure 2.10A). This yields a hyperbolic
curve derived from the Michaelis-Menten equation deriving the kpol and the Kd values
(Figure 2.10B). The ratio of kpol/Kd yielded the catalytic efficiency for the incorporation
of N6-MedATP opposite 8-oxo-G by gp43exo-. Interestingly, the catalytic efficiency for
the insertion of N6-MedATP opposite 8-oxo-G decreased by ~2.5-fold when compared to
dATP (Table 2.3). This decrease in catalytic efficiency arises not due to an effect on the
binding affinity, but from a drastic decline in the rate of kpol (0.056 s-1) for N6-MedATP.
In fact, the binding affinity (Kd) is ~4-fold better when compared to dATP (compare 135
µM vs 566 µM respectively). This enhancement in binding affinity could be attributed to
the hydrophobic nature of the alkylated nucleotide. At face value, this effect is in
congruence with the lower solvation energy of N6-MedATP when compared to dATP.
However, free energy calculations (∆∆G0) using Kd values showed that the energetic
contribution of desolvation is only 0.8 kcal/mol at the nucleotide binding step. It is
significantly less when compared to the ~3.2 kcal/mol difference between the modified
and the unmodified analogs. This further indicates that other biophysical factors such as
shape complementarity/steric fit along with hydrophobicity influence the ground state
binding of the nucleotide. The dramatic decline in kpol however, could be due to the
absence of the required hydrogen bonding interactions between the N6-MedATP and the
templating 8-oxo-G, an expected perquisite for the conformational change step preceding
the phosphoryl transfer.
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(A)

(B)

Figure 2.10 N6-MedATP concentration dependence on the apparent burst rate
under single turnover conditions. (A) Radiolabeled 13/20 8-oxo-G (100 nM) was
preincubated with variable concentrations of N6-MedATP [50 µM (l); 100 µM, (n); 250
µM, (n); 350 µM, (l); 500 µM, (); 1000 µM, (l)], Mg(OAc)2 and reaction buffer.
The reactions were initiated with gp43exo- (200 nM) and quenched with 200 mM EDTA
at variable times (0-300 seconds). (B) The observed rate constant for the incorporation of
N6-MedATP (l) is derived by plotting against N6-MedATP incorporation and fit to the
Michaelis-Menten equation to determine the values corresponding to Kd and kpol.
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One complication with the N6-MedATP is the rotational freedom of -CH3 group.
Computational modelling studies have shown that N6-MedATP achieves two (2) stable
conformations, “a” and “b” respectively (Figure 2.11A). When in “b” conformation, N6MedATP can base pair with two hydrogen bonds to 8-oxo-G. This should reflect with a
similar kpol when compared to dATP. However, the ~10-fold decline in kpol when
compared to dATP suggests that the incoming N6-MedATP pairs with 8-oxo-G with only
one available hydrogen bond in “a” conformation. One plausible hypothesis for the “a”
conformation is the Van der Waals interactions between the non-polar Leucine (L561)
and hydrophobic methyl group of N6-MedATP (Figure 2.11B).
I next evaluated the incorporation of dGTP opposite 8-oxo-G. The amount of
dGTP incorporated opposite 8-oxo-G was too low to measure the kinetic parameters. To
observe if alkylating the natural nucleotide dGTP increased the promutagenic nature of 8oxo-G, I evaluated the kinetic parameters for the insertion of O6-MedGTP and N2MedGTP. Both analogs are similar in size, volume and solvation energies. The catalytic
efficiency for the insertion of O6-MedGTP opposite 8-oxo-G is 270 M-1s-1. Though
alkylation of dGTP has increased the promutagenic potential of 8-oxo-G when compared
to dGTP, its catalytic efficiency is ~3.5-fold lower than dATP. This decrease is due to a
slower kpol value (0.023 s-1) despite achieving better Kd value (82 µM). This is consistent
with the trend observed in N6-MedATP, where modifying the hydrogen groups decreased
the kpol values, whereas increased hydrophobicity helped them achieve better Kd values.
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(A)

(B)

Figure 2.11 Structural conformations of N6-MedATP. (A) Chemical structures of N6MedATP representing possible rotatory conformations of –CH3 group and its base
pairing with 8-oxo-guanine (8-oxo-G). (B) Molecular models for 8-oxo-G paired
opposite N6-MedATP in the active site of RB69 DNA polymerase (PDB ID: 3NCI).
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Surprisingly, N2-MedGTP was not utilized by gp43exo- during replication with 8oxo-G. This negative result is particularly interesting since previous studies in the Berdis
lab demonstrated that the specialized DNA polymerase, pol η utilizes N2-MedGTP 10fold more efficiently than dATP when replicating the oxidized DNA lesion (138). In the
case of pol η the increased efficiency was caused by a very low Km for N2-MedGTP (0.64
µM) rather than an effect on kcat. Regardless, the dichotomy between the two DNA
polymerases in utilizing N2-MedGTP prompted me to investigate if N2-MedGTP acts as
an inhibitor against the high-fidelity T4 DNA polymerase. This is discussed in detail in
Chapter IV.

Investigating the role of hydrogen bonding interactions using halogenated purine
analogs. The decreased kpol values for the insertion of alkylated analogs contributed to
their decreased catalytic efficiencies opposite 8-oxo-G. Since these results suggest that
modifications to hydrogen bonding groups might have influenced the drastic decrease in
kpol values, I next evaluated the kinetic parameters for the insertion of halogenated purine
analogs, 6-Cl-dATP and 6-Cl-2-APTP. Here, the hydrogen bonding groups are replaced
by a non-hydrogen bonding halogen group. Therefore, these analogs will enable me to
evaluate the contributions of hydrogen bonding interactions along with shape
complementarity and nucleobase hydrophobicity. Gp43exo- inserts 6-Cl-dATP with a
catalytic efficiency of 2.30 Í 102 M-1s-1, ~4-fold lower than dATP. This decrease is due
to a diminished kpol value (0.012 s-1), consistent with the assumption that hydrogen
bonding interactions play a more significant role in conformational change step preceding
phosphoryl transfer. Presence of a hydrogen bonding –NH2 group in 6-Cl-2-APTP allows
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it to achieve a slightly higher catalytic efficiency when compared to 6-Cl-dATP (compare
3.30 Í 102 M-1s-1 versus 2.30 Í 102 M-1s-1, respectively) due to a ~4-fold increase in kpol
value (0.049 s-1). This difference can be observed in the Michaelis-Menten plot
represented in Figure 2.12. When comparing the binding affinities of 6-Cl-dATP and 6Cl-2-APTP, absence of -NH2 group in the former relatively increases its Kd value. This is
reflected in the ~3 kcal/mol lower solvation energy of 6-Cl-dATP compared to 6-Cl2APTP. This data further indicates that hydrophobicity of the incoming nucleotide does
influence nucleotide incorporation.
To further evaluate the role of hydrogen bonding on catalytic efficiency, I tested
the kinetic parameters for the insertion of 2,6-dATP and dITP. Introduction of a hydrogen
bonding group as in 2,6-dATP produced a slight increase in kpol (compare 0.787 s-1
versus 0.535 s-1, respectively) coupled with 2.4-fold increase in Kd value (compare 1,370
µM vs 566 µM, respectively) when compared to dATP. The negative effect on the
binding affinity can be attributed to the relatively high solvation energy of 2,6-APTP
when compared to other analogs. This is best explained when compared with 6-Cl2APTP. Both analogs are similar in size, shape and volume. However, the solvation
energy of 6-Cl-2APTP is ~4 kcal/mol lower than 2,6-APTP, largely due to the presence
of a hydrophobic –Cl group at C-6 position of guanine. This is consistent with the
mechanism in which ground state binding of the incoming nucleotide is influenced by the
hydrophobicity of the incoming nucleotide while the conformational change step is
controlled by hydrogen-bonding interactions with the oxidized lesion.
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Figure 2.12 Michaelis-Menten plots comparing the kobs for the incorporation of 6-CldATP (l) and 6-Cl-2-dATP (n) opposite 8-oxo-guanine by gp43exo-.
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However, dITP appears to be an exception to this mechanism. Despite having a
natural hydrogen bonding group, it displays a low kpol value (0.008 s-1) coupled with a
high binding affinity (28 µM). The relatively low binding affinity is contrary to the
proposed mechanism where an increase in hydrophobicity influences the ground state
binding of a nucleotide. In fact, lower solvation energy of modified analogs is in
congruence with their relatively lower Kd values. dITP, however, achieves the lowest Kd
value despite a higher desolvation energy. One plausible reason could be smaller size of
dITP allowing it to snugly fit into the active site of gp43exo-. Further, its resemblance to
the tautomeric form of dGTP might have prevented it from forming hydrogen bonds with
the templating 8-oxo-G, hence the low kpol value. This suggests that the N-6 hydrogen
bonding –NH2 group in dATP is required for efficient hydrogen bonding opposite 8-oxoG. Overall, kinetic characterization using our library of modified purine analogs has
demonstrated that the binding affinity is predominantly influenced by hydrophobicity of
the incoming nucleotide. This is best illustrated in figure 2.13 where increasing solvation
energies correlates with decrease in binding affinity for dATP and analogs.
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Figure 2.13 Plot representing correlation between solvation energies and binding
affinities of adenine and its analogs. The figure above demonstrates that solvation
energies of the modified analog are directly correlated with their respective Kd values.
This indicates that nucleobase desolvation plays a predominant role in the nucleotide
binding step during the translesion replication of 8-oxo-guanine by the high fidelity gp43
DNA polymerase.
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Table 2.3 Summary of kinetic parameters for the incorporation of modified analogs opposite 8-oxo-guanine.
Solvation energies and surface areas for each nucleobase are calculated using Spartan’14 software. NA = not applicable

dNTP

Surface area (Å2)

Solvation
Energy (kcal/mol)

Kd (µM)

kpol (s-1)

dATP

142.98

-19.36

566 ± 24

0.535 ± 0.015

9.50 Í 102

2,6-APTP

156.44

-22.79

1,370 ± 410

0.787 ± 0.156

5.10 Í 102

N6-MedATP

164.95

-16.15

135 ± 41

0.056 ± 0.005

4.10 Í 102

6-Cl-PTP

145.22

-15.84

51 ± 17

0.012 ± 0.001

2.30 Í 102

6-Cl-2-APTP

158.80

-18.86

145 ± 33

0.049 ± 0.003

3.30 Í 102

dGTP

152.50

-23.91

O6-MedGTP

174.79

-19.71

N2-MedGTP

174.34

-20.81

dITP

138.96

-21.30

kpol/Kd (M-1s-1)

NA
82 ± 11

0.023 ± 0.001

2.70 Í 102

NA
28 ± 8
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0.008 ± 0.005

2.90 Í 102

2.3.3 Extension studies beyond 8-oxo-Guanine
I next examined the ability of gp43exo- to extend beyond various nucleotides
paired opposite 8-oxo-G. Assays were performed using single turnover conditions in
which gp43exo- (200 nM) and 13/208-oxo-G (100 nM) were pre-incubated in assay buffer
and then mixed with a fixed concentration of nucleotide (dNTP) and 5 mM Mg2+ to
initiate insertion opposite the lesion. After 4 half-lives, an aliquot of dTTP and dGTP
(200 µM final concentration) was added to initiate the elongation reaction (Figure
2.14A). Representative gel electrophoresis data provided in Figure 2.14B demonstrates
that gp43exo- easily extends beyond both dCMP and dAMP when paired opposite 8-oxoG. This ability of a high fidelity DNA polymerase to extend beyond a mispair such as
A:8-oxo-G can be detrimental. To further observe if this promutagenecity extends to our
library of modified purine analogs, I test the incorporation of selected modified analogs
with altered hydrogen bonding groups.
Surprisingly, the high fidelity polymerase can extend beyond alkylated
nucleotides such as N6-MedATP and O6-MedGTP. Both the analogs have hydrophobic
modifications to their hydrogen bonding groups, albeit they can form hydrogen bonds
with 8-oxo-G. To determine if hydrophobicity of the nucleotide is influencing extension
beyond 8-oxo-G, I tested the insertion of 6-Cl-dATP. Remarkably, gp43exo- has
difficulty in extending beyond 6-Cl-PTP. This difference in extension suggests that the
absence of a hydrogen bonding group has a detrimental effect on the ability of the high
fidelity polymerase to elongate DNA.
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(A)

(B)

Figure 2.14 Extension studies beyond 8-oxo-guanine. (A) Assay protocol used to
measure extension beyond modified and non-natural nucleotides when inserted opposite
8-oxo-G. (B) Denaturing gel electrophoresis image comparing the incorporation and
extension of nucleotide analogs beyond 8-oxo-G by gp43exo-.
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2.3.4 Incorporation of modified purine analogs opposite undamaged DNA by gp43exoI next evaluated if modification of hydrogen bonding groups to natural purine
analogs would cause misinsertion opposite the undamaged guanine. A preliminary survey
demonstrated that none of the modified analogues were inserted opposite the undamaged
guanine (Figure 2.13). Further evaluation of their kinetic parameters Kd, kpol and kpol/Kd
revealed further insight into the understanding of the molecular forces influencing
replication of an undamaged DNA by a high fidelity DNA polymerase. As expected,
adenine a non-cognate partner of guanine was not incorporated by the high fidelity
gp43exo-. In fact, the rate of incorporations (kpol) for all the modified analogues opposite
guanine is either not determinable or less than ~0.03 s-1 even at higher dNTP
concentrations (250 µM). This was expected, since guanine, a purine is not a stable
partner for another modified purine analogue due to steric constraints. This is supported
by the enhanced efficiencies for the insertion of modified analogs opposite thymine and
cytosine, the predicted “correct” pairing partner for a modified purine analogue (110).
The incorporation of majority of modified analogs opposite guanine is too low for the
catalytic efficiencies to be accurately determined. In this regard, it is surprising that
dGTP was inserted with an efficiency of 2.3 Í 101 M-1s-1. Remarkably, dITP, a tautomer
of dGTP, was inserted with an efficiency of 4.80 Í 102 M-1s-1. Though, the kpol of dITP
is only ~2-fold greater than dGTP, it achieves a ~10-fold better binding affinity. This is
interesting since dITP is a tautomeric form of dGTP, with a slightly lower desolvation
energy.
A critical comparison would be the insertion of modified analogs opposite
thymine and its supposed “look-alike” 8-oxo-G. Assuming 8-oxo-G mimics thymine,
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gp43exo- should insert the modified analogs with similar efficiencies opposite the
damaged (8-oxo-G) and undamaged DNA (T). However, the kinetic parameters
demonstrate otherwise, indicating that the underlying mechanisms used by the high
fidelity gp43exo- DNA polymerase to replicate damaged and undamaged DNA are
different (Table 2.4). This is evident from the ~10,000-fold decrease in efficiency of
insertion of adenine opposite 8-oxo-G when compared to thymine. In fact, gp43exoinserts modified analogues with comparatively higher efficiencies opposite thymine than
8-oxo-G. Modifications to N-6 or its comparable O-6 position enabled them to achieve
better catalytic efficiencies opposite thymine than 8-oxo-G. Modification at the N-2
position, however, decreased the efficiency for insertion opposite thymine by several fold
when compared to other alkylated analogues. This was due to a significant decrease in
kpol value by a greater than ~1000-fold when compared to other analogues. This is
interesting since, a similar observation was made for insertion opposite 8-oxo-G,
suggesting the influence of specific hydrogen bonding groups in nucleotide binding and
insertion.
Collectively, these differences in mechanisms employed by DNA polymerases to
replicate damaged versus undamaged DNA makes it impossible to unequivocally
compare and identify the common mechanistic forces influencing DNA replication.
Further, previous studies have determined that when replicating undamaged DNA, high
fidelity DNA polymerases like gp43exo- use hydrogen bonding interactions between the
incoming nucleotide and the templating nucleotide to form a stable base pair. This is
evident from the incredibly high catalytic efficiencies for the insertion of natural
nucleotide opposite their cognate templating partners (A-T, T-A, G-C, C-G). In fact,
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gp43exo- inserts natural nucleotides with an efficiency of 1.0 Í 107 M-1s-1 opposite their
complimentary partners. Such high catalytic efficiencies can only be achieved with
incredibly fast kpol (~100 s-1) and high binding affinities (~10 µM) (103). This is possible
because, unlike replication of damaged DNA, normal DNA synthesis primarily relies on
hydrogen bonding interactions rather than other molecular forces such as hydrophobicity,
π-stacking interactions and steric fit. In fact, of all the parameters, desolvation is crucial
for the efficient and insertion of an incoming nucleotide into the hydrophobic duplex
structure of DNA. However, the enthalpic penalties associated with desolvation are offset
due to hydrogen bonding interactions between the incoming correct nucleotide to its
complimentary templating base.
Overall, comparative analysis of the kinetic parameters for the insertion of
modified analogues opposite 8-oxo-G, guanine and thymine reveals that gp43exoemploys different mechanisms while replicating damaged and undamaged DNA. This is
critical, since the mechanistic information derived from here has two important
ramifications. First, it will enable me to evaluate the mutagenic potential of a miscoding
lesion abundantly formed inside the cell. Second, it will provide more insight into
developing novel nucleotide analogs with therapeutic and diagnostic applications to
either block or monitor translesion replication of 8-oxo-G in-vivo.
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Table 2.4: Catalytic efficiencies for the insertion of modified nucleotide analogues
opposite guanine, thymine and 8-oxo-guanine (8-oxo-G). aValues taken from (110).
NA = not applicable
Guanine

a

Thymine

8-oxo-G

dNTP

kpol/Kd (M-1s-1)

kpol/Kd (M-1s-1)

kpol/Kd (M-1s-1)

dATP

NA

1.00 Í 107

1.00 Í 103

2,6-APTP

NA

NA

5.00 Í 102

N6-MedATP

NA

4.00 Í106

4.10 Í 102

6-Cl-PTP

NA

5.20 Í105

2.30 Í 102

6-Cl-2dATP

NA

NA

3.30 Í 102

dGTP

2.30 Í 101

7.50 Í 101

NA

O6-MedGTP

NA

2.47 Í 105

2.70 Í 102

N2-MedGTP

NA

1.50 Í 102

NA

dITP

4.80 Í 102

1.14 Í 103

2.90 Í 102
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2.4 Comparative analysis of translesion replication of 8-oxo-Guanine and abasic site
using modified purine analogs
DNA is constantly damaged under the influence of various DNA damaging
agents, forming DNA lesions. There are ~100 different types of lesions constantly
formed, each structurally unique in its own way. For survival, cells developed an intricate
biological process to replicate damaged DNA, called translesion DNA synthesis (45).
This process allows living organisms to cope with the DNA lesions that evaded the repair
processes. Though the role of TLS in cell viability is known to be a crucial process
ensuring cell survival, the underlying mechanisms used by DNA polymerases to replicate
different types of DNA lesions still remains elusive, bewildering researchers. To address
this questions, I chose to quantitatively compare the ability of a high fidelity DNA
polymerase to replicate a miscoding DNA lesion versus a non-instructional DNA lesion.
Using this approach, I attempted to identify the common biophysical forces employed by
high fidelity DNA polymerases like gp43exo- to replicate structurally distinct lesions.
Gp43exo- inserts dATP opposite both an abasic site and 8-oxo-G, and extends
beyond the mispair initiating a potential genomic error (103). This is remarkable since
two structurally distinct lesions specifically form a mispair with the same natural
nucleotide. Evaluation of their kinetic parameters demonstrated that dATP is inserted
with only ~4-fold greater efficiency opposite an abasic site than 8-oxo-G (compare 4.30
Í 103 M-1s-1 versus 9.5 Í 102 M-1s-1 respectively). This difference is due to a ~16-fold
reduction in binding affinity opposite 8-oxo-G when compared to an abasic site. The
relatively high Kd value of dATP opposite 8-oxo-G has been attributed to the lack of
hydrophobic functional groups resulting in high desolvation energy. However, absence of
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a coding information on an abasic site allows dATP to stack opposite the non-templating
lesion. A key difference between the kinetic parameters is the enhanced kpol of dATP
opposite 8-oxo-G. The high hydrogen bonding potential of 8-oxo-G allows dATP to form
a stable mispair. But, absence of coding nucleobase slows the rate of incorporation
opposite an abasic site. This is an important observation as it indicates that the
conformational change step preceding phosphoryl transfer is dependent on the physical
and chemical natural of the templating lesion.
Comparison of kinetic parameters for the insertion of modified purine analogs
yielded further insight into the understanding of the molecular mechanisms of translesion
DNA replication of structurally different lesions (Table 2.5). Gp43exo- inserted alkylated
analogs (N6-MedATP and O6-MedGTP) opposite the abasic site with efficiencies higher
than dATP. These enhanced efficiencies have been achieved due to a ~40-fold increase in
their kpol values when compared to their parent analogs (108). This has been attributed to
the hydrophobic and aromatic nature of the incoming nucleotide due to their ability to
influence the enzymatic conformational change step preceding phosphoryl transfer. Since
hydrogen bonding interactions do not exist in the non-templating abasic site, removal of
water molecules becomes a prerequisite for efficient base pairing. The solvation energies
of the alkylated analogs are relatively lower when compared to their unmodified parent
analog, consistent with the enhanced kpol values (110). In a miscoding lesion like 8-oxoG, presence of hydrogen bonding interactions allows it to deceive the polymerase
depicting itself as thymine. Due to the presence of a templating nucleobase, hydrogen
bonding interactions take precedence over desolvation at the conformational change step
preceding phosphoryl transfer. Hence, the lower kpol values for the alkylated analogs.
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Halogenated analogs (6-Cl-dATP and 6-Cl-2-APTP) showed only a slight increase in
their rate constants when compared to their parent analogs dATP and dGTP (Table 2.5).
Though the tautomeric form of 6-Cl-2APTP to resemble dATP is a critical factor in
achieving a fast kpol, its enhanced hydrophobicity is consistent with the mechanism
previously discussed where hydrophobicity plays a more prominent role in the
conformational change preceding phosphoryl transfer step. Absence of templating
information on an abasic site, negates the role of hydrogen bonding interactions to occur.
Since water molecules occupy the void of the absentee nucleobase, it is essential for the
enzyme to eliminate them while inserting the incoming nucleotide. Therefore, our library
of analogs that are relatively more hydrophobic than dATP are inserted with a faster kpol
due to their ability to bypass the enthalpic penalty of desolvation during the
conformational change preceding phosphoryl transfer. This is best illustrated in Figure
2.15. Overall, the kinetic comparison of modified analogs provides a strong correlation
between different biophysical forces influencing conformational change preceding
phosphoryl transfer step. Though, the low binding affinities for modified analogs
opposite 8-oxo-G could be credited to their enhanced hydrophobicity, the same cannot be
attributed to insertion opposite an abasic site. This is further explored in Chapter III.
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Figure 2.15 Molecular model comparing the influence of molecular forces on the
conformational change preceding phosphoryl transfer step of abasic site and 8-oxoguanine. Kinetic characterization of 8-oxo-guanine using modified analogs and their
comparison with the abasic site demonstrated that the conformational change step is
influenced by the nature of the templating lesion.
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Table 2.5 Summary of kinetic parameters for the incorporation of modified analogs opposite 8-oxo-G and an abasic
site. aValues taken from ref (108). NA = not applicable

a

8-oxo-guanine

Abasic site

dNTP

Kd (µM)

kpol (s-1)

kpol/Kd (M-1s-1)

Kd (µM)

kpol (s-1)

dATP

566 ± 24

0.535 ± 0.015

9.50 Í 102

35 ± 5

0.150 ± 0.001

2,6-APTP

1,370 ± 410

0.787 ± 0.156

5.10 Í 102

N6-MedATP

135 ± 41

0.056 ± 0.005

4.10 Í 102

190 ± 45

5.6 ± 0.6

2.90 Í 104

6-Cl-PTP

51 ± 17

0.012 ± 0.001

2.30 Í 102

83 ± 16

0.28 ± 0.02

3.30 Í 103

6-Cl-2dATP

145 ± 33

0.049 ± 0.003

3.30 Í 102

71 ± 20

0.12 ± 0.12

1.70 Í 103

130 ± 5

0.023 ± 0.005

1.80 Í 102

181 ± 35

0.980 ± 0.008

5.40 Í 103

245 ± 68

0.12 ± 0.02

4.90 Í 102

103 ± 14

0.044 ± 0.003

4.30 Í 102

dGTP
O6-MedGTP

NA
82 ± 11

N2-MedGTP
dITP

0.023 ± 0.001

2.70 Í 102

NA
28 ± 8

0.008 ± 0.005

2.90 Í 102
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kpol/Kd (M-1s-1)
4.30 Í 103

NA

2.5 Conclusion
In this work, I have demonstrated that modified purine analogues are inserted
with catalytic efficiencies lower than dATP. Further evaluation of their kinetic data
yielded crucial insight into the molecular mechanism employed by a high fidelity DNA
polymerase replicating a miscoding lesion like 8-oxo-G. While replicating a mutagenic
lesion with hydrogen bonding potential, the conformational change preceding phosphoryl
transfer (kpol) is influenced by the hydrogen bonding ability of the incoming nucleotide.
This is consistent with the decreasing kpol values for our library of modified purine
analogs with altered hydrogen bonding groups. The low Kd values indicate that
hydrophobicity plays a crucial role in the nucleotide binding step. This is consistent with
the notion that, removal of water molecules on the incoming nucleotide is essential to
form a stable base pair within the hydrophobic environment of a duplex DNA.
Finally, comparison of molecular mechanisms of 8-oxo-G and an abasic site
reveal that the nature of templating lesion influences the rates of incorporation for
modified purine analogs by a high fidelity DNA polymerase. The hydrophobic and
aromatic nature of an incoming nucleotide enable modified analogs to be inserted with
high catalytic efficiencies opposite a non-coding lesion. However, replication of a coding
lesion leads to a more complex scenario, where the hydrogen bonding nature of the
templating base precede the influence of hydrophobicity and shape complimentary on
nucleotide insertion. Though it is impossible to make an unambiguous conclusion on the
influence of which biophysical features takes precedence, the data presented here does
indicate that presence or absence of templating information dictates the dominance of one
biophysical forces over another. This difference shows why hydrophobic analogs are
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inserted with greater efficiency opposite a non-templating lesion like an abasic site.
Absence of a coding nucleobase voids the complexity of a templating base, making it
simpler to unambiguously identify and analyze the molecular forces aiding in nucleotide
insertion. This is evident from the novel nucleotide analogs that were designed to be
efficiently inserted opposite an abasic site than opposite a templating base. It is clear that
a universal mechanism of polymerization during replication of damaged versus
undamaged DNA does not exist, and any comparisons between their mechanisms might
be invalid. I, here attempted to compare the mechanisms of polymerization for replication
of DNA lesions with striking structural differences. Despite the complexity involved, I
was able to identify that the nature of templating lesion dictates which biophysical force
to take precedence on the conformational change step preceding phosphoryl transfer. This
is further explored in detail in Chapter III.
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CHAPTER III
USING NON-NATURAL INDOLE NUCLEOTIDE ANALOGS AS CHEMICAL
PROBES TO STUDY THE TRANSLESION REPLICATION OF 8-OXO-GUANINE

3.1 Introduction
Mutagenic lesions play crucial biological roles due to their ability to disrupt
critical cellular processes like DNA replication, which is essential for our survival.
Blocking the replication of these lesions is pertinent to prevent the initiation of a
mutagenic event that can progress to diseases like cancer. Prior to the development of
therapeutic strategies to disrupt the misreplication of these lesions, it is essential to have
complete understanding of the underlying mechanisms, employed by DNA polymerases
to misreplicate these lesions. An emerging strategy is the use of nucleotide analogs as
chemical probes to elucidate the mechanistic details regarding how these DNA lesions
biophysically interact with and affect genomic replication inside the cell (139). Over the
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past few years, much attention has been paid to non-natural nucleotide analogs that
behaved as excellent probes for misreplication of an abasic site (140,54). Presence of
coding information on 8-oxo-G makes it more complicated to design a non-natural analog
that can efficiently pair with it. Here, I used a series of non-natural indole analogs as
molecular probes to identify the biophysical interactions with templating 8-oxo-G,
polymerase and the nucleobase adduct.
Previous experiments in Chapter II have demonstrated that, while replicating a
miscoding lesion like 8-oxo-G, nucleobase hydrophobicity influences the nucleotide
binding step (Kd), whereas the conformational change preceding phosphoryl transfer
(kpol) is predominantly influenced by the hydrogen bonding abilities of the incoming
nucleotide with the templating 8-oxo-G. Further comparison with a non-templating lesion
like 8-oxo-G revealed that nucleobase hydrophobicity is a common influencing factor for
the nucleotide binding step, while the conformational change preceding phosphoryl
transfer is dependent on the nature of the templating lesion. To further evaluate this
phenomenon, I have used a series of non-natural nucleotide analogs with different
substituent functional groups. A critical trait of these non-natural analogs is their core
structure, the indole group. It consists of a six (6) cyclic benzene ring fused to a five (5)
membered nitrogen containing pyrrole ring. This bicyclic fused ring structure is similar in
shape and size to the core structure of adenine, the purine (Figure 3.1). Previous studies
in the Berdis lab have demonstrated that high fidelity DNA polymerases like gp43exoefficiently insert our library of non-natural analogs opposite an abasic site. In fact,
analogs such as 5-PhITP and 5-NITP were inserted with high catalytic efficiencies
greater than 106 M-1s-1, comparable to the efficiency of insertion of a natural nucleotide
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Solvation energy
(kcal/mol)
Area (Å2)
Volume (Å3)
Log P

-5.20

-16.10

146.0
131.0
0.140

129.0
111.0
-1.08

Figure 3.1 Chemical structures of indole and purine and their physicochemical
properties. The electrostatic potential maps have been generated using Hartree-Fock
calculations. The physicochemical properties have been calculated using molecular
modelling software, Spartan 14.
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(like, T) opposite its complimentary templating base partner (A). Such high efficiencies
were attributed to favorable pi-stacking interactions, and its ability to fill the void created
by the removal of the nucleobase.
In this Chapter, I have evaluated the kinetic parameters for the insertion of nonnatural nucleotide to observe if similar biophysical forces influence replication of a
miscoding lesion like 8-oxo-G. This report outlines the structure activity relationship
deduced from the insertion of indolyl nucleotide analogs. Kinetic evidence revealed that
low desolvation energies enabled our library indolyl analog to achieve high binding
affinities. The conformational change step, however, relied on hydrogen bonding
interactions between 8-oxo-G and the incoming indolyl analog. The collective data set
derived enabled me to develop a comprehensive model illustrating similarities and
dissimilarities in the translesion replication of a non-coding versus miscoding lesion by a
high fidelity DNA polymerase, like gp43exo-.
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3.2 Materials and Methods
3.2.1 Purification of bacteriophage T4 DNA polymerase, and DNA substrates.
Exonuclease deficient bacteriophage T4 DNA polymerase (gp43exo-) was purified and
quantified as previously described (134). Defined duplex DNA substrates with desired
oligonucleotides were synthesized by Operon and purified as previously described.
Single and double stranded duplex DNA used in this study (Figure 2.2) were purified and
quantified as described (135).

13/20mer

5’-TCGCAGCCGTCCA
3’-AGCGTCGGCAGGT-X-ACCAAA

X = G or 8-oxo-G

Figure 3.2 Defined duplex DNA substrates used in this study.

3.2.2 Non-natural indole nucleotide analogs
The indolyl nucleotides listed in Figure 3.3 are synthesized and purified as described
previously (53,54,108,113).
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Figure 3.3 Chemical structures of non-natural nucleotide analogs used in this study.
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3.2.3 Radiolabeling duplex DNA substrate.
Duplex DNA substrates used in this study were radiolabeled with {γ-32P}ATP
before using them in polymerization assays. The amount of {γ-32P}ATP depends on the
amount of DNA to be used and the half-life of the radioactive substance. A conventional
labelling reaction for 1 µM duplex DNA consists of 100 pmol 13/20mer, 10 pmol {γ32

P}ATP, polynucleotide kinase buffer (100 mM Tris-pH 9.5, 10 mM MgCl2, 2.5 mM

DTT, 2.5% glycerol, 1 mM spermidine, and 0.1 mM EDTA), polynucleotide kinase (1
µL), and ddH2O is added to make up the volume to 100 µL. Both the primer and
template strands were labelled at 5’ end after purification of the DNA substrates. This
allows both the template and substrate (primer) strands to be visualized post
electrophoresis and PhosphorImaging. The labelling reaction mixture is incubated at 370
C for 30 minutes, followed by 10 minutes at 670 C to inactivate the polynucleotide
kinase. The reaction mixture is slow cooled to room temperature (250 C) before using it
for polymerization assays.

3.2.4 Polymerization assays to determine the kinetic dissociation and rate constants for
dNTP incorporation opposite guanine and 8-oxo-guanine.
All kinetic assays were performed at 250 C under single turnover conditions. The
buffers used in all the assays consisted of 25 mM Tris-OAc (pH 7.5), 150 mM KOAc,
and 10 mM 2-mercaptoethanol. The amount of product formed in the polymerization
assays were monitored through analysis on 20% sequencing gels. Gel images were
obtained using a Packard PhosphorImager and Optiquant software supplied by the
manufacturer. The amount of product formed was quantified by measuring the ratio of
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32

P-labelled extended to non-extended primer. Obtained ratios were corrected for

substrate in the absence of the polymerase (zero point). Corrected ratios of product
formation were multiplied by the concentration of primer/template used in each assay to
yield total amount of product.
Unless otherwise noted, all reaction assays were carried out on the benchtop
manually at time intervals ranging from 5 to 300 seconds. The volume of each reaction is
50 µL. In a typical enzymatic assay, DNA substrate (100 nM) is preincubated with dNTP
(10-500 µM), and the reaction was initiated by the addition of the DNA polymerase (200
nM). After quenching with EDTA, the sample buffer was mixed with sequencing gel
loading buffer in 1:1 ratio. The products were analyzed for product formation by 20%
denaturing gel electrophoresis. The gel was transferred onto a plastic film sheet, which is
then covered with a plastic wrap. The location of radioactive bands of DNA was verified
using a Geiger counter. The phosphor screen plates were placed with the phosphor screen
(blue side) facing the region with the radioactive DNA. The time of exposure ranges from
2 hours to overnight, depending on the intensity of band required. The plates were
scanned to produce digital images of the labelled oligonucleotides on the gel. The
intensities of the products formed from the substrates were quantified using Optiquant
software. The obtained values were corrected for substrate in the absence of the
polymerase (zero point). The corrected ratio of product formed is multiplied by the
concentration of 13/20mer for each assay to yield the total product formed.
The rate constant (kobs) of each reaction was obtained by fitting the data to
equation 2.1
y = A(1 - e-kt) + C

(3.1)
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where A is the amplitude of product formation, k is the observed rate constant in product
formation, t is time, and C is a defined constant. The data for the dependency of kobs on
dNTP concentration was fit to the Michaelis-Menten equation (equation 2.2):
kobs = kpol [dNTP]/(Kd + [dNTP])

(3.2)

where kobs is the observed rate constant, kpol is the maximal polymerization rate constant,
Kd is the dissociation constant for dNTP, and dNTP is the concentration of the modified
or non-natural nucleotide substrate.

3.2.5 Calculation of physicochemical parameters of non-natural indole nucleotide
analogs
Solvation energies (kcal/mol), surface areas (Å2), Volume (Å3) and logP values
were calculated using Hartree-Fock molecular mechanics (Table 3.1).

3.2.6 Extension beyond 8-oxo-guanine
Assays were performed using single turnover reaction conditions in order to
maximize signal-to-noise ratios in product formation. Under these conditions, an excess
concentration of gp43exo- (200 nM) was incubated with 100 nM 13/208-oxo-G in assay
buffer containing 10 mM magnesium acetate and then mixed with a fixed concentration
of nucleotide (dNTP) and 5 mM Mg2+ to initiate insertion opposite the lesion. After 4
half-lives, an aliquot of dTTP and dGTP (200 µM final concentration) was added to
initiate the elongation reaction (Figure 2.5). Aliquots of the reactions were quenched with
EDTA at variable times (0-600 seconds) and analyzed by denaturing gel electrophoresis
to assess elongation.
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Table 3.1 Physicochemical parameters of non-natural nucleotide analogs.
The energy minimization calculations and geometric optimizations were performed with
Hartree-Fock molecular mechanics Spartan’14.
Solvation
energy
(kcal/mol)

logP

131.05

-5.20

0.140

166.08

149.34

-5.10

0.320

5-EtITP

186.00

167.68

-4.71

0.740

5-EyITP

180.03

163.28

-4.48

0.470

5-MeCITP

198.82

179.08

-6.68

-0.350

5-CITP

173.49

156.74

-71.6

NA

4-NITP

173.41

154.51

-6.90

1.67

5-NITP

174.32

154.52

-6.91

1.67

6-NITP

173.99

154.44

-6.89

1.67

Surface
area (Å2)

Volume
(Å3)

IndTP

146.17

5-MeITP

dNTP

Nucleobase

114

3.3 Results and Discussion
3.3.1 Kinetic evaluation for the incorporation of non-natural indole nucleotide analogs
opposite 8-oxo-G by gp43exo-.
The non-natural indolyl analogs are used as chemical probes to further evaluate the
biophysical forces influencing translesion replication of 8-oxo-G by the high fidelity
gp43exo- DNA polymerase. Preliminary screening comparing the incorporation of
dNTPs opposite guanine and 8-oxo-G is shown in Figure 3.4. Gel electrophoresis data
has shown significant differences in the insertion of non-natural nucleotide opposite
damaged and undamaged DNA. In fact, the majority of the non-natural nucleotide
analogs show preferential incorporation opposite guanine rather than the oxidized DNA
lesion. To further evaluate the underlying mechanism adopted by gp43exo-, I evaluated
the kinetic parameters Kd, kpol, and kpol/Kd to evaluate the influence of different molecular
forces during replication by gp43exo- (Table 3.2).
Non-natural indole nucleotide analogs as chemical probes. I evaluated the kinetic
parameters for 5’-substituted indolyl-2’-deoxynucleotide analogs to evaluate the role of
hydrogen bonding, shape complementarity and hydrophobicity on misincorporation
opposite 8-oxo-G by gp43exo-. First, I tested the kinetic parameters for the insertion of
three novel analogs, 5-MeITP, 5-EtITP, and 5-EyITP (Table 3.2). A common feature for
the three analogs is their enhanced binding affinities when compared to dATP. However,
their efficiencies for insertion vary significantly. Gp43exo- inserts 5-EyITP with an
efficiency of 7.14Í102 M-1s-1, ~2 to 5-fold higher than 5-EtITP and 5-MeITP. This high
efficiency is largely due to the enhanced binding affinity despite a lower kpol value.
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Figure 3.4 Gel survey comparing the insertion of dNTPs opposite guanine and 8oxo-guanine by gp43exo-. Denaturing gel electrophoresis images comparing the
incorporation of non-natural nucleotide analogs opposite G (13/20G) versus 8-oxo-G
(13/208-oxo-G) by gp43exo-. Survey assay was performed under single turnover conditions
as represented in the text, with 100 µM dNTP quenched at 120 seconds.
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This is surprising, since both 5-EtITP and 5-EyITP are roughly the same size, however,
achieve different binding affinities (compare 184 µM versus 41.3 µM, respectively). In
fact, the increase in binding affinities is consistent with the decreasing solvation energies
(compare 5-MeITP; 5.1 kcal/mol, 5-EtITP; 4.7 kcal/mol and 5-EyITP; 4.4 kcal/mol,
respectively). The correlation between solvation energies and binding affinities is best
illustrated in figure 3.5. Indeed, the low Kd value of 5-EyITP is likely attributed to its low
desolvation energy and enhanced pi-electron density at the ethynyl moiety.
Consistent with this argument is the observation that 5-MeCITP, a hydrophobic
analog possessing significant pi-electron density, displays a relatively low Kd value of 57
µM. Furthermore, the hydrophilic analog, 5-CITP, is poorly incorporated opposite 8-oxoG and this is likely caused by poor binding affinity induced by the presence of the
carboxyl moiety. This is supported by the enormous difference of ~64 kcal/mol in their
solvation energies (compare 5-CITP; -71.46 kcal/mol versus 5-MeCITP; -6.66 kcal/mol).
Collectively, this data reiterates the importance of hydrophobicity as a guiding and
influencing factor in nucleotide binding and insertion. Though 5-CITP has hydrogen
bonding potential, the enthalpic penalty in removing the water molecules off 5-CITP
would be too high resulting in unfavorable binding to the replicating gp43exo-. This is
reflected in the incredibly low rate of incorporation opposite 8-oxo-G when compared to
5-MeCITP (Figure 3.6). This indicates that absence of proper nucleotide binding prevents
the enzyme to undergo a conformational change to incorporate the nucleotide opposite
the templating base.
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Figure 3.5 Non-natural indole analogs represented in their order of increasing
solvation energies. The increasing binding affinities of these analogs appear to be
influenced by their decreasing desolvation energies.

118

Figure 3.6 Time course comparing the incorporation of 5-MeCITP (n)and 5-CITP
(n) opposite 8-oxo-guanine by gp43exo-. Assays were performed under single turnover
conditions (100 nM 13/208-oxo-G is preincubated with Mg(OAc)2 and 200 µM dNTP). The
reactions were initiated with 200 nM gp43exo- and quenched with EDTA.
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A crucial observation made was the similarity in the orientation of –CH3 group on
5-MeCITP and N6-MedATP. Like N6-MedATP, 5-MeCITP also consists of a
hydrophobic methyl group on a hydrogen bonding functional group. Modeling studies
performed using Spartan demonstrated that the minimal energy conformation for the
orientation of –CH3 group lies in both “a” and “b” conformations as represented in
Figure 3.7. In “a” conformation, 5-MeCITP has the ability to bond with 8-oxo-G using
two hydrogen bonds. However, the conformational rate for the insertion of 5-MeCITP is
only ~2.5-fold lower than dATP. This suggests that 5-MeCITP pairs with 8-oxo-G in “b”
conformation, with one hydrogen bond (Figure 3.7A). Also, structural analysis in the
active site indicates that, as in the case of N6-MedATP, Van der Waals interactions
between the methyl group of Leucine 561 and 5-MeCITP could have favored the “b”
orientation. This is clearly depicted in Figure 3.7B.
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(A)

(B)

Figure 3.7 Structural conformations of 5-MeCITP opposite 8-oxo-guanine. (A)
Chemical structures of 5-MeCITP representing possible rotatory conformations of –CH3
group and its base pairing with 8-oxo-G. (B) Molecular models for 8-oxo-G paired
opposite 5-MeCITP in the active site of RB69 DNA polymerase.
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Position of nitro group influencing nucleotide incorporation opposite 8-oxo-G by
gp43exo-. To further evaluate the role of nucleobase hydrophobicity, pi-stacking
interactions and shape complementarity, I evaluated the kinetic parameters for the
insertion of nitro indole analogs positioned at various strategic positioned on the indole
nucleobase (4-NITP, 5-NITP and 6-NITP, respectively) (Figure 3.8 A). Kinetic
characterization has revealed that both 4-NITP and 6-NITP were inserted with near equal
catalytic efficiencies (compare 1.84Í103 M-1s-1 versus 1.82Í103 M-1s-1, respectively)
opposite 8-oxo-G, slightly better than dATP) (Figure 3.8B). Surprisingly, 5-NITP was
inserted with a relatively low efficiency of 1.34Í102 M-1s-1 (Figure 3.8 B). This low
efficiency is due to a drastic decrease in binding affinity, reflected by a high Kd value of
264 µM. These differences are interesting since, all the three analogs bear similar size,
shape, hydrophobicity and pi-electron density. Therefore, the negative influence of the
nitro group at 5’-position suggests that nucleotide insertion by gp43exo- can be swayed
by the permutational alterations in the position of the nitro moiety.
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(A)

(B)

Figure 3.8 Incorporation of non-natural nitro indole analogs opposite 8-oxoguanine. (A) Electrostatic potential maps of nitro indole nucleotide analogs. (The heat
maps were generated using Spartan’14’s Hartree-Fock calculations). (B) Michaelis
Menten plots comparing the incorporation of nitro-indole analogs, 4-NITP (l), 5-NITP
(n), and 6-NITP (n) opposite 8-oxo-guanine by gp43exo-. The position of nitro group
significantly influences its efficiency of incorporation opposite 8-oxo-G by gp43exoDNA polymerase.
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3.3.2 Primer extension beyond 8-oxo-G
I previously demonstrated that gp43exo- extends beyond dAMP or dCMP when
paired opposite 8-oxo-G. Further analysis with modified analogs demonstrated that the
extension beyond a mispair opposite 8-oxo-G was dependent on the presence or absence
of hydrogen bonding interactions on the misincorporated nucleotide. To observe if this
mechanism holds for non-natural analogs too, I tested the incorporation and extension for
our library of indole analogs beyond 8-oxo-G. Briefly, for these experiments single
turnover experiments were employed as indicated in the experimental section. Assays
were performed using single turnover conditions in which gp43exo- (200 nM) and 13/208oxo-G

(100 nM) were pre-incubated in assay buffer and then mixed with a fixed

concentration of nucleotide (dNTP) and 5 mM Mg2+ to initiate insertion opposite the
lesion. After 4 half-lives, an aliquot of dTTP and dGTP (200 µM final concentration)
were added to initiate the elongation reaction (Figure 3.9A).
Representative data depicted in Figure 3.9B shows that bacteriophage gp43exodoes not extend beyond any of the hydrophobic analogs such as 5-EyITP. This data
indicates that hydrogen bonding interactions play a predominant role in extension beyond
8-oxo-G. However, 5-MeCITP does not extend beyond 8-oxo-G despite bearing the
ability to form one/two hydrogen bonds with 8-oxo-G. This is in contrast to their ability
to extend beyond an abasic site, possibly due to their ability to form important hydrogen
bonds with amino-acids in the enzyme’s active site, necessary for primer elongation.
These results indicate that extension beyond a lesion depends on the nature of the
templating lesion/base. This is further confirmed by the inability of gp43exo- to extend
beyond a templating thymine.
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Collectively, these data suggest that base stacking potential of a non-natural
analog does not primarily influence elongation. In fact, hydrogen bonding interactions
coupled with the conformation of the primer:template plays a predominant role in the
ability of a gp43exo- to extend beyond a templating base. Indeed, this depiction is
coherent with the workings of Romesberg and group, who demonstrated that extension
beyond a base pair consisting of a non-natural analog relies on the ability of the terminal
base pair to hold a proper geometrical conformation (49). The results obtained from this
study supporting the role of hydrogen bonding interactions in primer extension, suggests
that hydrogen bonding groups on an incorporating nucleotide are required to enable the
DNA template form a proper geometric orientation, enabling extension.
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(A)

(B)

Figure 3.9 Extension studies beyond 8-oxo-guanine. (A) Assay protocol used to
measure extension beyond modified and non-natural nucleotides when inserted opposite
8-oxo-G. (B) Denaturing gel electrophoresis image comparing the incorporation and
extension of non-nucleotide analogs (5-EyITP and 5-MeCITP) beyond 8-oxo-G by
gp43exo-.
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Table 3.2 Summary of kinetic parameters for the incorporation of indole nucleotide analogs opposite 8-oxo-guanine.
(Solvation energies and surface areas for each nucleobase are calculated using Spartan’14 software. NA = not applicable)

dNTP

Surface
area (Å2)

Solvation
Energy (kcal/mol)

Kd (µM)

kpol (s-1)

kpol/Kd (M-1s-1)

dATP

142.98

-19.36

566 ± 24

0.535 ± 0.015

9.50 Î 102

IndTP

146.17

-5.220

5-MeITP

166.08

-5.100

260 ± 98

0.042 ± 0.008

1.62 Î 102

5-EtITP

186.00

-4.710

184 ± 36

0.079 ± 0.007

4.30 Î 102

5-EyITP

180.03

-4.480

41.3 ± 9.2

0.029 ± 0.002

7.14 Î 102

5-MeCITP

198.82

-6.680

57 ± 12

0.231 ± 0.021

4.05 Î 103

5-CITP

173.49

-71.64

4-NITP

173.41

-6.900

28 ± 11

0.052 ± 0.004

1.84 Î 103

5-NITP

174.32

-6.910

264 ± 31

0.036 ± 0.002

1.34 Î 102

6-NITP

173.99

-6.890

53 ± 13

0.097 ± 0.008

1.82 Î 103

NA

NA
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3.3.3 Incorporation of non-natural nucleotides opposite undamaged DNA
I, next evaluated the kinetic parameters for the insertion of non-natural indole
nucleotide analogs opposite undamaged guanine (Table 3.3). Kinetic characterization
revealed that, as indicated in preliminary results, all the non-natural analogs were inserted
opposite guanine with better efficiencies than opposite 8-oxo-G. Their enhanced
efficiencies are caused by higher kpol and lower Kd values. This is interesting, since nonnatural analogs display different efficiencies for incorporation opposite two templating
bases with similar hydrogen bonding capabilities. Of all the analogs, 5-MeCITP is
inserted with a high efficiency of 3.80 Í 105 M-1s-1. Though it achieves a high binding
affinity (36 µM), the enhanced efficiency is largely due to its incredibly fast kpol of 1.4 s1

. Moreover, its kpol is ~2-fold higher than the next best 5-EyITP (0.72 s-1). This indicates

that the hydrogen bonding capability of 5-MeCITP appears to aid in increase of the rate
of conformational change preceding phosphoryl transfer step. Collectively, these results
suggest that though hydrogen bonding interactions are important for achieving fast kpol’s,
a combination of nucleobase hydrophobicity and p-electron density also influence the
efficiency for insertion opposite templating guanine when compared to 8-oxo-G.
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Table 3.3: Kinetic parameters for the insertion of non-natural indole analogs
opposite guanine. (NA = Not applicable)

dNTP

Kd (µM)

kpol (s-1)

dATP

kpol/ Kd (M-1s-1)

NA

IndTP

86 ± 27

0.041 ± 0.004

4.80 Î 102

5-MeITP

107 ± 19

0.119 ± 0.009

1.10 Î 103

5-EtITP

158 ± 60

0.30 ± 0.06

1.90 Î 103

5-EyITP

136 ± 27

0.720 ± 0.007

5.30 Î 103

5-MeCITP

36 ± 10

1.4 ± 0.1

3.80 Î 105

5-CITP

125 ± 35

0.074 ± 0.007

5.90 Î 102

5-NITP

64 ± 8

0.045 ± 0.002

7.10 Î 102

4-NITP
6-NITP

NA
20 ± 5

0.244 ± 0.017
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1.20 Î 104

3.4 Comparative analysis of translesion DNA synthesis by a high fidelity DNA
polymerase
Translesion DNA synthesis involves replication of damaged DNA in an effort to
aid in cell survival. This process is a leading cause for mutagenesis which also plays an
important role in progression of mutagenic diseases such as cancer. DNA damage results
in the formation of various DNA lesions, whose mutagenic potential have been evaluated
both in vitro and in-vivo. A key strategy has been the use of non-natural nucleotide
analogs as chemical probes to identify the biophysical forces influencing the replication
of damaged DNA. Of all the lesions, abasic sites are perhaps the most interesting kind of
DNA lesions. As previously discussed in Chapter II, kinetic comparisons have revealed
that the efficiency of misinsertion for modified purine analogs are dependent on the
nature of the templating lesions. Absence of coding information for an abasic site allows
hydrophobicity and aromaticity of a nucleotide to bolster efficiency of incorporation and
extension beyond an abasic site. However, presence of hydrogen bonding groups on 8oxo-G, allows hydrogen bonding interactions to play a predominant role in the
conformational change preceding phosphoryl transfer step.
To further evaluate this mechanism, I compared the kinetic parameters for the
insertion of non-natural analogs opposite an abasic site and 8-oxo-G (Table 3.4).
Opposite an abasic site, non-natural analogs are inserted with efficiencies that are nearly
similar to the insertion of a natural nucleotide opposite its complimentary templating base
partner. These enhanced efficiencies are due to a combination of incredibly fast kpol
coupled with low Kd values. For example, 5-MeCITP and 5-NITP are insertion with an
efficiency of 7.00 Î 106 M-1-s-1 and 6.00 Î 106 M-1s-1, respectively. As indicated above,
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these high efficiencies are due to their ability to reach incredibly fast kpol values (5NITP; 126 s-1, 5-MeCITP; 80s-1, respectively) and low Kd values (5-NITP; 18µM, 5MeCITP; 13.3 µM, respectively). These data suggest that the conformational change
preceding phosphoryl transfer step, represented by kpol is influenced by the p-electron
density and hydrophobicity of the incoming nucleotide. The nucleotide binding step is
predominantly dictated by the ability of the incoming nucleotide to be desolvated. This is
further supported by the low binding affinity for 5-CITP (172 µM), despite achieving a
relatively fast kpol of 67 s-1. Due to its similar shape, size and p-electron density to 5NITP, any change in catalytic efficiencies could be directly attributed to the enthalpic
requirements for desolvation. In fact, previous works by Motea et al. have measured that
desolvation contributes ~1.71 kcal/mol to the overall efficiency for the incorporation
opposite an abasic site. This was further broken down to each kinetic step, namely the Kd
and kpol, where the energetic contributions for desolvation were 1.34 kcal/mol and 0.370
kcal/mol respectively. These analysis indicate that desolvation plays a more critical role
while nucleotide binding, while the conformational change step is influenced by both
desolvation and p-electron density. The question is, does this model, hold for replication
of other lesions.
This question was addressed through kinetic characterization and comparison for
the misinsertion of non-natural analogs opposite a miscoding lesion like 8-oxo-G. All the
analogs tested, were inserted with efficiencies lower than dATP. This decrease in
efficiency, was due to their incredibly low kpol values. This data is consistent with the
mechanism derived from previous studies with modified purine analogs in Chapter II.
Any alterations to the hydrogen bonding groups drastically decreased the rates for the
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conformational change step preceding phosphoryl transfer. However, their hydrophobic
nature, enabled them to achieve better binding affinities, which is consistent with the idea
of desolvation as a prerequisite for nucleotide binding.
These findings are crucial, since current mechanistic models explaining
nucleotide selectivity and incorporation rely on the steric constraints and shape
complementarity and structural differences that exist between different classes of
polymerases. All DNA polymerases possess a similar global architecture resembling a
right hand, with fingers, palm and thumb domain. However, structural analysis of their
active sites reveals that high fidelity DNA polymerases possess a smaller and tighter
active site while specialized DNA polymerases have a significantly larger active site.
This explains why specialized DNA polymerases are employed to help bypass bulky
lesions such as pyrimidine dimers. Their large active sites help to accommodate the bulky
lesions, allowing them to bind with the incoming nucleotide and undergo a
conformational change to misinsert them opposite the lesion. The smaller active site of
high fidelity DNA polymerases cannot accommodate these bulky lesions, preventing
them from replicating damaged DNA efficiently.
The results presented here using modified analogs (Chapter II) and non-natural
analogs (Chapter III) provide another level of sophistication to this model as it invokes
the contributions of nucleotide desolvation as a mechanism for nucleotide discrimination.
I argue that while replicating damaged DNA, stripping the water molecules bound to the
incoming nucleotide’s hydrogen bonding groups is a necessity. This is reflected in the
high binding affinities for our library of hydrophobic analogs. The enthalpic penalties
associated with nucleotide binding are lowered due to the presence of the hydrophobic
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functional groups on our library of novel nucleotide analogs. The inference here is that,
the water molecules bound around a nucleotide create a solvation sphere, whose size and
shape influences nucleotide binding in the active site of a DNA polymerase. If an
incoming nucleotide consists of hydrophilic functional groups, the water molecules
bound to them create a larger solvation sphere. This in turn hinders binding efficiency in
the smaller and tighter active site of a high fidelity DNA polymerase. However, when the
binding nucleotide is relatively hydrophobic, the size of the solvation sphere will be
relatively smaller, which further can be easily accommodated in the enzyme’s smaller
active site. Reduction in the size of solvation sphere, coupled with optimization in steric
fit lowers the enthalpic penalty required for complete desolvation of the incoming
nucleotide.
Collectively, the wealth of kinetic information obtained from the studies of 8-oxoG and abasic site has enabled me to deduce a molecular model illustrating role of
different biophysical forces influencing their misreplication by a high fidelity DNA
polymerase (Figure 3.11). While desolvation appears to play a universal role in
nucleotide binding during TLS, the molecular forces regulating the conformational
change step that precedes phosphoryl transfer are more divergent as they depend upon the
physical nature of the DNA lesion. For instance, pi-stacking interactions play a
significant role in facilitating the conformational change step during the replication of
non-instructional lesions such as abasic sites, evident from the high kpol values of indole
analogs such as 5-MeCITP, 5NITP, and 5-CITP (111). In contrast, the same analogs
achieve incredibly low kpol values, suggesting that hydrogen bonding interactions play a
more prevalent role while replicating a miscoding lesion such as 8-oxo-G.
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Table 3.4 Summary of kinetic parameters for the incorporation of modified analogs opposite 8-oxo-guanine (13/208-oxoa
b
c
d
G) and an abasic site (13/20sp). Values taken from 109. Values taken from 54,141. Values taken from 109. Values taken
from 142. NA = not applicable

8-oxo-guanine

Abasic site

dNTP

Kd (µM)

kpol (s-1)

kpol/Kd (M-1s-1)

dATP

566 ± 24

0.535 ± 0.015

9.50 Î 102

IndTP

a
b

NA

kpol (s-1)

Kd (µM)
35 ± 5

145 ± 10

a

kpol/Kd (M-1s-1)

0.150 ± 0.001

a

4.30 Î 103

b

0.28 ± 0.07

b

1.90 Î 103

5-MeITP

260 ± 98

0.042 ± 0.008

1.62 Î 102

b

58 ± 10

b

60.1 ± 3.6

b

7.60 Î 105

5-EtITP

184 ± 36

0.079 ± 0.007

4.30 Î 102

b

86 ± 12

b

88.5 ± 4.5

b

1.00 Î 106

5-EyITP

41.3 ± 9.2

0.029 ± 0.002

7.14 Î 102

94 ± 5

b

1.90 Î 106

5-MeCITP

57 ± 12

0.231 ± 0.021

4.05 Î 103

79.8 ± 1.2

c

6.00 Î 106

67 ± 5

c

3.90 Î 105

0.06 ± 0.01

d

2.60 Î 103

126 ± 7

d

7.00 Î 106

d

d

1.80 Î 107

5-CITP

b
c

13.3 ± 0.9

c

NA

c

c

172 ± 31

4-NITP

28 ± 11

0.052± 0.004

1.84 Î 103

d

23 ± 2

5-NITP

264 ± 31

0.036 ± 0.002

1.34 Î 102

d

18 ± 3

6-NITP

53 ± 13

0.097 ± 0.008

1.82 Î 103
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b

50 ± 8

d

4.3 ± 0.4

d

d

81 ± 8

Figure 3.10 Model comparing the molecular forces used during the replication of
non-instructional (abasic site) versus miscoding (8-oxo-guanine) DNA lesions. The
nucleotide binding step is dependent on the hydrophobicity of the incoming nucleotide
for both, abasic site and 8-oxo-G. The conformational change step, however, is
predominantly controlled by the nature of the templating lesion.
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3.5 Conclusion
Methylating and oxidizing agents modify guanine to form mutagenic lesions like
the abasic site and 8-oxo-G. Despite being structurally distinct, high fidelity DNA
polymerases selectively insert adenine opposite them. Further, the catalytic efficiencies
for misinsertion of dATP opposite an abasic site and 8-oxo-G are only 4-fold different
(compare 4.30 Í 103 M-1s-1, and 9.5 Í 102 M-1s-1 respectively). A crucial observation is
the rate of conformational change for misinsertion of dATP is ~3.5 fold greater opposite
8-oxo-G when compared to an abasic site. However, the binding affinity dATP was ~16fold lower than the abasic site. These differences indicate that though gp43exoselectively misinserts dATP, the underlying mechanisms involved in their misreplication
might be different. In continuation to the studies performed in Chapter II using modified
purine analogs, I used non-natural indole analogs as chemical probes to further
understand the underlying mechanisms employed by high fidelity DNA polymerases such
as gp43exo-, while replicating structurally different lesions.
In this chapter, I demonstrated that non-natural indole analogs follow a similar
trend as seen with modified purine analogs while replicating 8-oxo-G. Further evaluation
of their kinetic parameters yielded more insight into the underlying mechanisms
employed by high fidelity DNA polymerases such as gp43exo- while replicating
structurally distinct lesions like 8-oxo-G and abasic site. These data confirm that any
modifications to the hydrogen bonding groups decreases the rate of conformational
change preceding phosphoryl step. Their hydrophobic nature however allows them to
achieve better binding affinities due to the low enthalpic penalty required for desolvation.
This is best illustrated through relationship between the hydrophobicity of the nucleotide
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to the size of the solvation sphere. This correlation explains why our library of
hydrophobic analogs achieve better binding affinities with gp43exo- when compared to
other hydrophilic analogs.
Further comparison with the mechanism of an abasic site reveals that desolvation
is an influential biophysical force on the nucleotide binding step for high fidelity DNA
polymerases like gp43exo-. Though both lesions are structurally different, removal of
water molecules appears to be a prerequisite for gp43exo- to incorporate the incoming
nucleotide within the hydrophobic environment of the duplex DNA. If the incoming
nucleotide is hydrophilic, the enthalpic compensation will be too large to enable efficient
binding. In case of normal DNA replication, these energetic penalties are offset since the
polymerase recognizes the incoming natural nucleotide’s hydrogen bonding interactions,
allowing favorable enthalpic contributions between its complimentary templating base.
The conformational change preceding phosphoryl transfer represented by kpol, is a little
more complex. Absence of coding information allows water molecules to inhabit the void
of an abasic site. This negates the possibility of an enthalpic compensation through
hydrogen bonding interactions with the incoming nucleotide. Therefore, desolvation
appears to play a more prominent role in removing the present water molecules for
efficient incorporation. While replicating 8-oxo-G, presence of coding information with
hydrogen bonding capability, allows hydrogen bonding interactions to play a more
predominant role. This is reflected in the decreased kpol values for our library of
nucleotide analogs with altered hydrogen bonding groups, as in the case of 5-MecITP, 5EyITP, etc.
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CHAPTER IV
INVESTIGATING THE UNIQUE SELECTIVITY OF A MODIFIED PURINE
ANALOG TOWARDS THE DEVELOPMENT OF A BIOPHYSICAL PROBE TO
MONITOR TRANSLESION DNA SYNTHESIS

4.1 Introduction
Maintaining the integrity of genome is crucial for the faithful transfer of genetic
information from parent to daughter cells. However, our DNA is subjected to various
forms of exogenous and endogenous DNA damaging agents like environmental mutagens
and reactive metabolites. Though several repair pathways exist to repair the damaged
DNA, some DNA lesions may evade detection and repair leaking into the S-phase (143).
Replicative polymerases involved in the replication of our genome have an exonuclease
proofreading domain, thus enabling them to stall at the site of DNA damage (144). This
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causes the replicative fork to halt, eventually leading to its collapse at the DNA lesion
and formation of double stranded DNA breaks leading to chromosomal rearrangement,
cell-cycle arrest and death (145). In such an event, cells postpone repair of the blocking
lesion to ensure the maintenance of cell cycle and its survival by a process known as
translesion DNA synthesis (TLS). This mechanism appears to be conserved from E. coli
to humans (45). Eukaryotic DNA polymerases like pol h, pol k, pol i, Dpo4 and Rev 1
replicate normal DNA with lower efficiencies than the replicative DNA polymerases
(146). Structural studies have revealed that these specialized polymerases have a more
open architecture when compared to the high fidelity replicative DNA polymerases, thus
providing ample space for water to compete with nucleobases in forming H-bonds. This
diminishes the ability of the error prone polymerases to discriminate between the correct
and incorrect incoming nucleotide to form complementary Watson-Crick H-bonds with
the templating base. The efficiencies for replicating damaged DNA are reversed when
replicating damaged DNA. In fact, specialized DNA polymerases like pol h have evolved
to perform a more efficient job while replicating covalently linked bulky DNA lesions
like pyrimidine dimers (147). This is best illustrated in Figure 4.1 where a specialized
DNA polymerase (Pol h) accommodates a pyrimidine dimer (purple) with the correct
dATP in comparison with the high fidelity DNA RB69 DNA polymerases pairing dCTP
opposite guanine (yellow). Some lesions like 8-oxo-G are replicated and bypassed by
both replicative and specialized DNA polymerases. Misreplication of this lesion by
mispairing with an incorrect adenine initiates mutagenesis, leading to A:T to G:C
transversion. These somatic mutations promote tumorigenesis and are a hallmark of lung
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Figure 4.1 Molecular models comparing the structures of a specialized DNA
polymerase, h (PDB 3SI8) versus a high fidelity RB69 DNA polymerase (PDB
3LDS). Molecular modeling software Chimera was used to illustrate the structures of
polymerases using their PDB ID’s from the protein structure data base (www.rcsb.org).
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cancer. Such high pro mutagenicity makes it imperative to study the underlying
mechanisms involved in the misreplication of this miscoding lesion. Like the high fidelity
gp43exo-, pol h incorporates both dATP and dCTP opposite 8-oxo-G. Further kinetic
characterization with our library of modified purine and non-natural nucleotide analogs
invoked a model where hydrogen bonding interactions play a more prominent role while
replicating 8-oxo-G. This is reflected in the catalytic efficiencies for the misinsertion of
our library of modified purine and indole analogs with altered hydrogen bonding groups.
Nearly all the analogs achieve a catalytic efficiency that is nearly equal or lower than
dATP. One major exception is a modified purine analog, N2-MedGTP. It is inserted with
an efficiency of ~7 fold greater than dATP (Table 4.1). Despite a ~10-fold decrease in kcat
(comparable to kpol), it achieves an incredibly high binding affinity that is ~73-fold better
than dATP. Remarkably, the same analog is not inserted opposite 8-oxo-G by gp43exo-.
This dichotomy of positive versus negative utilization by a low and high fidelity DNA
polymerase while replicating a mutagenic miscoding lesion is intriguing. In this Chapter,
I investigated the dynamics involved in the preferential utilization of N2-by DNA
polymerases with biologically distinct functions.
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Table 4.1 Kinetic parameters for insertion of N2-MedGTP opposite 8-oxo-guanine
by gp43exo- and pol h. aValues taken from reference 138. (ND = Not determined)

DNA
polymerase
Gp43exoa

Pol h

Kd (µM)

kpol (s-1)

kpol/Kd (M-1s-1)

Km (µM)
0.64 ± 0.05

ND
kcat (s )
0.11 ± 0.02

kcat/Km ) (M-1s-1)
1.70 Í 105

-1
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4.2 Materials and Methods
4.2.1 Purification of bacteriophage T4 DNA polymerase, and DNA substrates.
Exonuclease deficient bacteriophage T4 DNA polymerase (gp43exo-) was purified and
quantified as previously described (133). Defined duplex DNA substrates with desired
oligonucleotides were synthesized by Operon and purified as previously described.
Single and double stranded duplex DNA used in this study (Figure 2.2) were purified and
quantified as described (134).

13/20mer

5’-TCGCAGCCGTCCA
3’-AGCGTCGGCAGGT-X-ACCAAA

X = G or 8-oxo-G

Figure 4.2 Defined duplex DNA substrates used in this study

4.2.2 Radiolabeling duplex DNA substrate.
Duplex DNA substrates used in this study were radiolabeled with {γ-32P}ATP
before using them in polymerization assays. The amount of {γ-32P}ATP depends on the
amount of DNA to be used and the half-life of the radioactive substance. A conventional
labelling reaction for 1 µM duplex DNA consists of 100 pmol 13/20mer, 10 pmol {γ32

P}ATP, polynucleotide kinase buffer (100 mM Tris-pH 9.5, 10 mM MgCl2, 2.5 mM

DTT, 2.5% glycerol, 1 mM spermidine, and 0.1 mM EDTA), polynucleotide kinase (1
µL), and ddH2O is added to make up the volume to 100 µL. Both the primer and
template strands were labelled at 5’ end after purification of the DNA substrates. This
allows both the template and substrate (primer) strands to be visualized post
electrophoresis and PhosphorImaging. The labelling reaction mixture is incubated at 370
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C for 30 minutes, followed by 10 minutes at 670 C to inactivate the polynucleotide
kinase. The reaction mixture is slow cooled to room temperature (250 C) before using for
polymerization assays.

4.2.3 Polymerization assays to determine the kinetic dissociation and rate constants for
dNTP incorporation opposite 8-oxo-guanine.
All kinetic assays were performed at 250 C under single turnover conditions. The
buffers used in all the assays consisted of 25 mM Tris-OAc (pH 7.5), 150 mM KOAc,
and 10 mM 2-mercaptoethanol. The amount of product formed in the polymerization
assays were monitored through analysis on 20% sequencing gels. Gel images were
obtained using a Packard PhosphorImager and Optiquant software supplied by the
manufacturer. The amount of product formed was quantified by measuring the ratio of
32

P-labelled extended to non-extended primer. Obtained ratios were corrected for

substrate in the absence of the polymerase (zero point). Corrected ratios of product
formation were multiplied by the concentration of primer/template used in each assay to
yield total amount of product.
Unless otherwise noted, all reaction assays were carried out on the benchtop
manually at time intervals ranging from 5 to 300 seconds. The volume of each reaction is
50 µL. In a typical enzymatic assay, DNA substrate (100 nM) is preincubated with dNTP
(10-500 µM), and the reaction was initiated by the addition of the DNA polymerase (200
nM). After quenching with EDTA, the sample buffer was mixed with sequencing gel
loading buffer in 1:1 ratio. The products were analyzed for product formation by 20%
denaturing gel electrophoresis. The gel was transferred onto a plastic film sheet, which is
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then covered with a plastic wrap. The location of radioactive bands of DNA was verified
using a Geiger counter. The phosphor screen plates were placed with the phosphor screen
(blue) facing the region with the radioactive DNA. The time of exposure ranges from 2
hours to overnight, depending on the intensity of band required. The plates were scanned
to produce digital images of the labelled oligonucleotides on the gel. The intensities of
the products formed from the substrates were quantified using Optiquant software. The
obtained values were corrected for substrate in the absence of the polymerase (zero
point). The corrected ratio of product formed is multiplied by the concentration of
13/20mer for each assay to yield the total product formed.
The rate constant (kobs) of each reaction was obtained by fitting the data to
equation 2.1
y = A(1 - e-kt) + C

(4.1)

where A is the amplitude of product formation, k is the observed rate constant in product
formation, t is time, and C is a defined constant. The data for the dependency of kobs on
dNTP concentration was fit to the Michaelis-Menten equation (equation 2.2):
kobs = kpol [dNTP]/(Kd + [dNTP])

(4.2)

where kobs is the observed rate constant, kpol is the maximal polymerization rate constant,
Kd is the dissociation constant for dNTP, and dNTP is the concentration of the modified
or non-natural nucleotide substrate.
4.2.4 Inhibition studies
100 nM 13/208-oxo-G was incubated with 10 mM Mg(OAc)2, 50 µM dATP, and
variable concentrations of N2-Me-dGTP (0-200 µM). Polymerization reactions were
initiated through the addition of 200 nM gp43exo-. Reactions were quenched through the
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addition of 200 mM EDTA at variable times (3-180 seconds) and analyzed as described
above. Data were fit to equation 1 which defines a single-exponential process.
Reciprocal rate constants, 1/kobs, were plotted versus the concentration of N2-Me-dGTP,
and extrapolation to the x-axis yielded an apparent Ki value. A true Ki value was obtained
using equation 3:
Ki = appKi / (1+(S/Km)

(4.3)

where Ki is the true inhibition constant, appKi is the apparent inhibition constant, S is the
concentration of dATP, and Km is the Michaelis constant for dATP.
4.2.5 Pulse Chase Experiments
100 nM 13/208-oxo-G was pre-incubated with 10 mM Mg(OAc)2 and 220 µM N2Me-dGTP. 200 nM gp43exo- was added followed by the addition of 50 µM dATP at
variable time points (0.5 – 30 min). The reaction mixture was quenched with 200 mM
EDTA at time intervals ranging from 5 to 180 seconds and the amount of product formed
by the incorporation of dATP was analyzed as described above. The amplitudes in
product formation at these differential time points were plotted vs time of dATP addition.
The resulting plot was linear and fit to the equation for a straight line (equation 4.4),
y = mx + b

(4.4)

where m is the slope of the line, b is the y-intercept, and t is time.
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4.2.6 Molecular modelling studies
Since no complete x-ray or NMR structures are available for the bacteriophage
T4 DNA polymerase, structural models of the RB69 DNA polymerase were used as a
surrogate for the T4 DNA polymerase. The RB69 DNA polymerase is structurally and
functionally homologous to T4 DNA polymerase with a 99% similarity in their protein
sequences. Models of the polymerase in complex with DNA containing 8-oxo-G were
obtained from the Research Collaboratory for Structural Bioinformatics Protein Data
Bank (www.rcsb.org). The structural models of RB69 and pol h containing DNA8-oxo-GdNTP complex were made from the co-crystal structure of RB 69-DNA8-oxo-G-dATP
(PDB ID: 3LDS) and pol h-DNA8-oxo-G-dATP (PDB ID: 403R).
Using the molecular modelling program, Molecular Operating Environment,
structures containing the analog N2-Me-dGMP were generated by modifying dAMP in
the crystal structure PDB ID: 3LDS, and 4O3R. Following the modifications, the active
site of RB69 and pol h was minimized using the MOE modeling software (MOE 2014).
Hydrophobicity surface models were generated for the polymerase containing DNAdNTP complex using Kyle Doolittle hydrophobicity scale. The scale of hydrophobicity is
represented in decreasing order as red > white > blue.
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4.3 Results and Discussion
Gel survey analysis demonstrates that gp43exo- DNA polymerase did not incorporate N2MedGTP opposite 8-oxo-G even at concentrations of 200 µM (Figure 4.3). This negative
selection is unique since, N2-MedGTP like other purine analogs (N6-MedATP, O6MedGTP) with relatively similar hydrophobicity is not utilized by the high fidelity
gp43exo- DNA polymerase. To investigate if this negative selection could be mean
inhibition of gp43exo-, I set out to investigate if N2-MedGTP behave as a potent inhibitor
of the high fidelity DNA polymerase. Inhibition assays were performed in the presence of
50 µM dATP and varying concentrations of N2-MedGTP (0-200 µM). The data depicted
in Figure 4.4A shows that the rate constant of dATP incorporation decreases as the
concentration of N2-MedGTP is increased (Table 4.2). The reciprocal of the rate
constants derived are used to plot a rate constant (1/kobs) versus N2-MedGTP
concentration was used to measure an apparent Ki value of 240 +/- 35 µM (Figure 4.5).
This analysis demonstrates that the modified analog does indeed bind to the Pol:DNA
complex albeit with rather weak binding affinity.
To determine if N2-Me-dGTP undergoes a conformational change post binding, I
performed a series of modified pulse-chase experiments as outlined in Figure 4.6A. In
these assays, DNA substrate and gp43exo- were incubated with 220 µM of N2-Me-dGTP
(Ki concentration) for variable periods of time (∆t = 0 to 30 minutes) and then chased
with 50 µM dATP. During this incubation period, the formed Pol:DNA:N2-Me-dGTP
complex is given sufficient time to undergo the conformational change step to form the
Pol*:DNA:N2-Me-dGTP complex. In this scenario, N2-MedGTP bound to the
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Figure 4.3 Gel image depicting the lack of incorporation of N2-MedGTP opposite 8oxo-guanine by gp43exo-. Assay was performed under single turnover conditions at 100
nM 13/208-oxo-G, 200 nM gp43exo- and 200 mM N2-MedGTP. The reactions were
quenched with EDTA at various time intervals (0 – 300 seconds).
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Figure 4.4 N2-MedGTP acts as a competitive inhibitor for the incorporation of
dATP opposite 8-oxo-guanine. gp43exo- (200 nM) and 5’-labelled 13/208-oxo-G (100
nM) were preincubated with 10mM Mg(OAc)2. Reactions were initiated with a
mixture of 50 µM dATP (●) and N2-MedGTP in variable concentrations of 50 µM (■),
100 µM (●), and 200 µM (♦). Reactions were quenched with 200 mM EDTA at variable
time points.

Table 4.2 Rate constants derived from competitive inhibition assays performed in
the presence of dATP and varied N2-MedGTP concentrations.
N2-MedGTP (µM)
0
50
100
200

kobs (s-1)
0.037
0.032
0.027
0.019
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Figure 4.5 Dixon plot analysis used to measure the apparent Ki value for N2MedGTP. Data analysis yielded an apparent Ki value of 240 µM for N2-MedGTP.
Correcting for the concentration of substrate, dATP, used in these experiments by
applying the Cheng-Prusoff relationship yields a true Ki value of 220 µM.
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gp43:DNA complex will sequester the DNA polymerase into a dead-end complex and
prevent the binding of dATP. The formation of this dead-end complex should this
produce a concomitant reduction in product formed by dATP incorporation opposite 8oxo-G. However, the data provided in Figure 4.7A shows that N2-MedGTP has minimal
effect on dATP incorporation opposite 8-oxo-G. This is clearly illustrated in Figure 4.7B
where the amplitude in product formation is consistent when correlated to a function of
“chase” time for the addition of dATP. The minimal effect on dATP incorporation
suggests that N2-Me-dGTP is unable to induce the conformational change step that is
required for subsequent incorporation of N2-Me-dGTP opposite 8-oxo-G.
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Figure 4.6 Experimental protocol used in pulse chase experiments to monitor the
conformational change step preceding phosphoryl transfer. Gp43exo- and 13/208-oxo-G
were incubated with a Ki concentration of N2-Me-dGTP for variable periods of time (∆t=
0 to 30 minutes) and then chased with 50 µM dATP. During the incubation period, the
formed Pol:DNA:N2-Me-dGTP complex should undergo the conformational change step
to form the Pol*:DNA:N2-MedGTP complex. The formation of this dead-end complex
should prevent dATP binding and thus reduce the amount of dATP incorporation
opposite 8-oxo-G.
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(A)

(B)

Figure 4.7 Pulse chase assays. (A) Gp43exo- and 13/208-oxo-G were incubated with a Ki
concentration of N2-Me-dGTP for variable periods of time {∆t = 0 (●), 5 (■), 10 (■), 20
(●)and 30 (p) minutes} and then chased with 50 µM dATP. (B) Plot of percent amplitude
in dATP incorporation versus “pulse” time of N2-MedGTP pre-incubation with gp43exoand 13/208-oxo-G. The minimal effect on the burst amplitude in product formation as a
function of incubation time suggests that N2-MedGTP does not induce a conformational
change in the gp43exo-.
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Does active site architecture of DNA polymerases influence the positive/negative
selection of N2-Me-dGTP? In general, both high fidelity and specialized DNA
polymerases possess a similar global architecture resembling a right-hand that contains
elements corresponding to fingers, palm, and thumb domains (4,5). However, a more
detailed analysis reveals that the active sites of most specialized DNA polymerases are
significantly larger than those of high fidelity DNA polymerases. The expanded active
site explains why specialized DNA polymerases can accommodate large, bulky lesions
whereas, the more constrained active site of high fidelity polymerases prevents them
from efficiently replicating damaged DNA. The results presented in Chapter II using
modified nucleotide analogs invoke a model where nucleobase desolvation plays a more
predominant role in nucleotide binding. The smaller active site of high fidelity DNA
polymerases appear to use desolvation as an efficient mechanism for nucleotide
discrimination. This is evident from the weaker binding affinity of dATP. Contrastingly,
the large active site of error prone DNA polymerases provides a certain degree of
freedom to accommodate nucleotides with a larger solvation sphere. In fact, dATP binds
pol h with a ~12-fold better binding affinity than gp43exo- (138). Here, the water
molecules bound to the binding nucleotide act as “grease to wheels” providing greater
degree of mobility and flexibility in the active site of pol h. This promotes the
polymerase to optimize steric fit and shape complementarity to insert opposite the
templating lesion. Further, the enlarged solvation sphere allows important hydrogen
bonding interactions to occur that is required for the enthalpic stabilization of the
incoming nucleotide with the DNA lesion. This model when applied to N2-Me-dGTP
provides additional insight into the preferential utilization by a low fidelity DNA
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polymerase like pol h. Though N2-Me-dGTP has a surface area of 174 Å2, presence of
water molecules surrounding it increases its size by more than ~10% to 198 Å2 (Figure
4.8). Further, there are no direct hydrogen bonding interactions between N2-Me-dGMP
and 8-oxo-G, an expected perquisite for efficient insertion opposite the miscoding lesion.
Also, the interglycosyl distance between the alkylated nucleotide and the miscoding
lesion is slightly greater when compared to dAMP opposite 8-oxo-G (compare 9.3 Å2
versus 8.9 Å2 respectively). These properties of N2-MedGMP indicate it to be a poor
substrate for pol h for insertion opposite 8-oxo-G. However, the kinetic data shows that
N2-MedGMP is inserted with a catalytic efficiency greater by a magnitude than dATP.
This enhanced efficiency indicates that the hydrophobic methyl group appears to play a
predominant role by favoring enthalpic contributions between the N-2 CH3 group and
hydrophobic amino acids in the active site of pol h. Indeed, Choi et al. reported that a
non-polar isoleucine residue (ILE 114) in close proximity to the N-2 methyl group could
have influenced it enhanced binding (138). Closer inspection of pol h’s active site
revealed that a triad of three hydrophobic residues create a perfect hydrophobic pocket to
harbor the –CH3 group (Leucine 89, Isoleucine 114 and Phenylalanine 18). Their close
proximity of 4–5 Å allows Van der Waals interactions to favor the orientation of the
methyl group downwards (Figure 4.8A). These strong interactions could have contributed
to the incredibly low Km of 0.64 µM for N2-MedGTP by pol h opposite 8-oxo-G. Similar
structural inspection of the RB69 DNA polymerase showed that similar hydrophobic
residues at strategic positions are absent. Further, this could also have influenced the
methyl group to orient towards the templating 8-oxo-G (Figure 4.8B). Absence of these
Van der Waals interactions further explain the weak binding of N2-MedGMP.
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Figure 4.8 Structural illustration of N2-MedGTP with surrounding water molecules.
Water molecules surrounding the incoming nucleotide enhance the solvation sphere
which further affects nucleotide binding and incorporation.
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(A)

(B)

Figure 4.8 Structural models of N2-MedGMP paired opposite 8-oxo-guanine in the
active site of, (A) pol h (PDB ID: 403R) and (B) RB69 DNA polymerase (PDB ID:
3LDS). The structures were generated using molecular modeling softwares Molecular
Operating Environment (MOE) and Chimera.
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4.4 Summary and Conclusion
When DNA lesions evade repair, error prone polymerases are employed to bypass
the damaged DNA by TLS. Understanding the mechanisms employed by the various
DNA polymerases with different biological roles is difficult due to the absence of
specific chemical probes to quantify the biological processes. Therefore, developing a
molecular probe to monitor TLS in-vivo is imperative due to its biological implications
like cancer, neurological and age-related disorders. In this Chapter, I investigated the
underlying mechanisms employed by high and low fidelity DNA polymerases using a
modified purine analog. Here, I discuss the possibility of a modified purine analog that
could be developed as a biophysical probe to monitor translesion DNA synthesis in-vivo.
Previous studies in the Berdis lab demonstrated that the underlying mechanisms
involved in misreplication of the miscoding lesion are indeed different. In fact, Berdis
laboratory has identified a unique modified analog N2-MedGMP that displayed high
selectivity for the specialized DNA polymerase, h. Remarkably, the same analog was not
utilized by the high fidelity DNA polymerase, gp43exo-. First, I investigated if N2MedGTP behaved as a potent inhibitor to the high fidelity gp43exo-. Kinetic data derived
from inhibition assays revealed that, N2-MedGMP does inhibit dATP insertion opposite
8-oxo-G, but binds with lower binding affinity. Further investigation with pulse chase
experiments revealed that though the modified analog binds to the Pol:DNA complex, it
is unable to undergo a conformational change preceding phosphoryl transfer step for
complete insertion opposite 8-oxo-G. To further investigate this unique positive/negative
selection, I inspected the active sites of pol h and RB69 (surrogate for gp43exo-). Active
site analysis of pol h revealed a unique hydrophobic pocket that formed favorable Van
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der Waal interactions with the alkyl group of N2-MedGMP, which could have influence
its incredibly strong binding affinity. Absence of a similar region in the active site of
RB69 could have prevented efficient binding thus blocking incorporation opposite 8-oxoG. This interesting dichotomy of nucleotide utilization demonstrates that active site
differential architecture of high and low fidelity DNA polymerases plays a predominant
role in the replication of damaged DNA. Further, utilization of N2-MedGMP selectively
by a low fidelity DNA polymerase provides a unique opportunity to develop a chemical
probe to monitor translesion DNA synthesis in-vivo.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Conclusions
The primary objective of my thesis is to evaluate the molecular forces influencing
the translesion replication of a mutagenic miscoding lesion, 8-oxo-G by a high fidelity
DNA polymerase involved in the processing of genomic DNA. Hydrogen bonding
interactions along with base stacking interactions are primary influencers in efficient
nucleotide incorporation (148). Though this is true in the case of normal DNA
replication, the influence of biophysical forces on damaged DNA replication is much
more complex. Understanding how these forces influence and contribute to DNA
polymerases replicating damaged DNA will help to extract invaluable information that
could further be applied to develop strategies with therapeutic and diagnostic
applications. From a biotechnology perspective, our structure activity relationship (SAR)
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studies provide a strong foundation in developing non-natural nucleotide analogs can be
applied from develop chemotherapeutic agents to expanding the genetic alphabet for the
human genetic code. The studies performed here and the data presented extend our
understanding of how DNA polymerases misreplicate miscoding lesions such as 8-oxoG. Further, these studies also helped to explore the similarities and dissimilarities that
exist between replication of structurally different lesions by high fidelity DNA
polymerases.
As demonstrated in Chapter II, I have used gp43exo- as a model for high fidelity
DNA polymerases to understand the biophysical forces influencing misreplication of
miscoding lesions like 8-oxo-G. I have evaluated the kinetic parameters for the
misincorporation of modified purine nucleotides with altered hydrogen bonding groups.
From the results obtained, I was able to deduce that modifications to hydrogen bonding
groups decreased the efficiency of insertion opposite 8-oxo-G when compared to dATP.
In this regard, the rate of conformational change preceding phosphoryl transfer step
declined, which further lowered the misincorporation efficiency opposite 8-oxo-G.
Further, nucleotide analogs with hydrophobic functional groups were able to achieve
better binding affinities than the relatively hydrophilic ones. These studies demonstrated
that desolvation appears to play an important role in nucleotide binding while the
conformational change step was influenced by the ability of the bound nucleotide to form
hydrogen bonds with the templating 8-oxo-G. Further, the hydrogen bonding interactions
also influenced the ability of gp43exo- to extend beyond the miscoding, 8-oxo-G.
In Chapter III, I have used non-natural nucleotide analogs as chemical probes to
further evaluate the role of p-electron density, nucleobase hydrophobicity and hydrogen
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bonding interactions on translesion replication of 8-oxo-G. Kinetic characterization
showed that gp43exo- utilizes non-natural analogs as it did with modified analogs.
Absence of hydrogen bonding groups on our library of non-natural analogs, resulted in
lower kpol values, however, their enhanced hydrophobicity allowed them to achieve better
Kd values.
Previous studies performed in the Berdis laboratory using the same novel
nucleotide analogs, and the wealth of information derived from Chapter II and III allowed
me to compare the underlying mechanisms employed by gp43exo- in translesion
replication of 8-oxo-G and abasic site. Comparison of their kinetic parameters showed
distinct differences in their Kd and kpol values, indicating some similarities and
differences in the mechanism employed for their misreplication. Desolvation appeared to
be a common influencing force for the efficient binding of the modified and non-natural
nucleotides while replicating both the abasic site and 8-oxo-G. The conformational
change step however, is influenced by the nature of the templating lesion. Absence of
coding information allows p-electron density, and desolvation to play a more
predominant role. However, presence of coding information in 8-oxo-G with hydrogen
bonding capability enables hydrogen bonding interactions to influence the rate of
conformational change preceding phosphoryl transfer step. This is best illustrated in
Figure 3.10, Chapter III.
Kinetic characterization using modified purine analogs helped identify a unique
modified purine analog N2-MedGTP, that was not incorporated opposite 8-oxo-G by the
high fidelity gp43exo- DNA polymerase. Surprisingly, the analog was inserted with an
incredibly high efficiency opposite 8-oxo-G by a specialized DNA polymerase, Pol h.
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This negative versus positive selection to DNA polymerases with different biological
roles is intriguing. In Chapter IV, I have performed extensive kinetic studies to
investigate if N2-MeGTP acts as an inhibitor against the high fidelity gp43exo- DNA
polymerase. Results obtained showed that the modified analog N2-MedGTP does indeed
bind to the gp43exo-:13/208-oxo-G complex, but with weaker binding affinity. To further
observe if this weak binding promotes the conformational change step, I have performed
a series of modified pulse-chase experiments, where a Ki concentration of N2-MedGTP
incubated with DNA and polymerase are incubated for varied time periods, and then
chased with appropriate concentration of dATP. The minimal effect on dATP
misinsertion suggests that, N2-MedGTP is unable to undergo the conformational change
step required for complete incorporation opposite 8-oxo-G.

5.2 Future directions
5.2.1 Exploring the role of key amino acid residues in nucleotide incorporation
Hypothesis: The active site residues of DNA polymerases have been found to be highly
conserved within the palm domain (149-153). Sometimes, the non-conserved amino acid
residues within the active site also play a critical role in influencing the efficiency of
enzyme catalysis. For example, substitution of valine for aspartate 276 in the active site
of pol b, enhances the binding affinity for the incoming nucleotide. The negative charge
of aspartate 276 has weakened the ground state binding for the nucleotide (154).
Similarly, key residues within the active site of pol µ (His329, Asp330, Trp436, Gln440,
Glu443, and Arg444) played the role of a “gate keeper” by discriminating the formation
of non-cognate nucleotide base pairs (155). These examples demonstrate that key amino
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acid residues within the active site of the DNA polymerase could influence the efficiency
of a processing DNA polymerase.
Structural analysis of the active site of gp43 DNA polymerase enabled me to
identify a non-polar amino acid, leucine 561. It is strategically juxtaposed in between the
incoming nucleotide and the templating base. As described in Chapter II, kinetic data
derived from N6-MedATP insertion suggested that leucine 561 could have influenced the
orientation of the –CH3 group on the hydrogen bonding N-6 position. This is reflected by
the ~10-fold decrease in its rate of conformational change, represented by kpol. One
plausible hypothesis is the presence of strong Van der Waal interactions between the
methyl groups of the incoming nucleotide and the active site leucine which could have
influenced the orientation of the methyl group on N6-MedATP as represented in Figure
5.1A. Similar observation was also made with the non-natural indole analog, 5-MeCITP.
To confirm this hypothesis, I propose to mutate the non-polar leucine with a polar
asparagine. Asparagine (N) is similar to size in leucine (L), but bears a polar carboxamide
group. It would be crucial to observe if L561N substitution would influence the
orientation of the methyl group on N6-MedATP. Further, it would be interesting to see if
the polar nature of the carboxamide group in asparagine would influence the binding
affinities of the modified nucleotide analogs.
Predicted outcome: Modification of the non-polar leucine with a polar asparagine could
have two crucial ramifications. Firstly, I predict that asparagine could enable N6MedATP to adapt a “b” conformation, facilitating the formation of two hydrogen bonds
with 8-oxo-G (Figure 5.1B). During the nucleotide binding step of N6-MedATP,
asparagine’s polar side chain carboxamide, would not influence the rotation of the alkyl
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analog’s –CH3 group, due to the absence of strong Van der Waal interactions. This would
facilitate the formation of a strong hydrogen bond between the highly electronegative
“O” group at the C-6 position of 8-oxo-G and the amine group of N6-MedATP. Overall,
it would allow the formation of two hydrogen bonds between 8-oxo-G and N6-MedATP
as illustrated in Figure 5.1B. Therefore, an increase in the rate of the conformational
change preceding phosphoryl transfer step would be observed, reflected through a high
kpol value. Similar observations are expected with 5-MeCITP as well. Secondly, L561N
substitution however, could also have an unwarranted effect on the binding affinity of
other nucleotide analogs. I have previously proposed that non-polar amino acid residues
within the active site of the polymerase could cause an overall net attraction for the
hydrophobic nucleotide analogs within the DNA helix’s hydrophobic interior (156). The
same effect might not be observed if a polar asparagine is present in such close proximity
to the binding pocket of the duplex DNA. Its affection for water molecules would create
an unfavorable environment for the binding of the non-polar nucleotide analogs. This
would further increase the enthalpic penalty, associated with stripping off the water
molecules from the active site for the DNA polymerase. The increase in energetic cost of
desolvation due to the absence of a non-polar residue would further increase the Kd
values for the non-polar analogs. These observations, if made, would be in congruence
with my previous analysis where, non-polar active site residues (L561 and F282) have
influenced the positive and negative selection of 5-MeCITP and N2-MedGTP
respectively (156). Overall, these studies would further ascertain the role of non-polar
amino acid residues in facilitating the repulsion of water molecules, thus contributing to
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desolvation, a prerequisite for nucleotide binding step during translesion replication of 8oxo-G.
Potential pitfall: A common pitfall that often arises from site directed mutagenesis
would be the misfolding of the protein post expression. The difference in active site
conformation could shift the asparagine from the expected site where leucine 561 was
previously positioned. This complication would make it difficult to unambiguously
evaluate the role of the non-polar leucine residue during the incorporation of the
nucleotide analogs opposite 8-oxo-G.
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(A)

(B)

Figure 5.1 Crystal structure of active site of RB69 DNA polymerase with L561N
substitution. (A) Crystal structure of the wild type RB69 DNA polymerase illustrating
the pairing of N6-MedATP in “a” conformation opposite 8-oxo-guanine. (PDB ID:
3LDS) (B) Crystal structure of the L561N RB69 DNA polymerase illustrating the pairing
of N6-MedATP in “b” conformation opposite 8-oxo-G.
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5.2.2 Extending 8-oxo-G mutagenic studies to human repair DNA polymerases
Hypothesis: The integrity of DNA replication is under constant threat from not only
exogenous agents but also from various endogenous sources such as metabolic reactions
that generate reactive oxygen species (ROS) (157). Due to their high reactivity nature,
they often damage DNA, forming mutagenic lesions such as 8-oxo-G. Its miscoding
nature and high prevalence (~103–104 per cell per day) has fatal implications to the cell
and the human body (158). In fact, 8-oxo-G is present in different types of tumor, and
neurodegenerative disorders (e.g., Parkinson’s and Alzheimer’s diseases) (156). Several
replicative DNA polymerases such as pol a, pol d, and pol e replicate 8-oxo-G in an error
prone manner by misinserting the incorrect adenine instead of the correct cytosine (157).
To correct these misinsertions, cells recruit the BER repair system, a conglomerate of
proteins involved in OGG1 dependent repair pathway and MUTYH dependent repair
pathway (157,159). When the MUTYH identifies the damaged 8-oxo-G:A mispair, it
removes the incorrect adenine. The PCNA with the help of RPA recruits pol l to
incorporate the correct cytosine opposite 8-oxo-G on the templating strand. The
templating strand containing the 8-oxo-G:C base pair is processed via OGG1 pathway via
short patch BER (160). The central role of pol l in the DNA damage tolerance makes it a
prime chemotherapeutic target to specifically inhibit 8-oxo-G replication. Few studies
have been reported with respect to the inhibition of pol l. Of these, ~10 rhodanine
derivatives were found to specifically target pol l (161). Unfortunately, of the few
inhibitors identified, only a small part of them are selective and active at the non-toxic
level. These inadequacies make it evident that the underlying mechanism involved in
translesion replication of 8-oxo-G by pol l still remain elusive.
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I propose using kinetic characterization techniques to determine and evaluate the
molecular forces involved in the translesion replication of 8-oxo-G by pol l. Pyrimidine
like non-natural analogues (Figure 5.2) can be used as mechanistic probes to perform
kinetic characterization of 8-oxo-G as shown in Chapter II and Chapter III. In fact, Berdis
laboratory has previously used these non-natural analogs as chemical probes to evaluate
the translesion replication of O6-methyl guanine by the high fidelity gp43exo- DNA
polymerase (136).
Predicted outcome: Structural analysis has revealed that pol l utilizes Watson-Crick
interactions to pair 8-oxo-G (anti) opposite dCTP (162). Also, the interglycosyl distance
between the C1’-C1’ distances of the formed base pair was found to be ~10.6 Å, which is
similar to other canonical base pairs (10.5 Å–dA:dTTP; 10.6 Å–dC:dGTP) (163). These
observations indicate that pol l utilizes hydrogen bonding interactions to form stable base
pairs involving 8-oxo-G. Overall, the ability of pol l to utilize Watson-Crick base
pairing interactions to form stable base pairs with 8-oxo-G prompted me to predict that
predict that non-natural analogs with modification to their hydrogen bonding groups
might not behave as good substrates for pol l while replicating 8-oxo-G. For example,
zebularine, a non-natural analog devoid of sufficient hydrogen bonding groups might be
incorporated with lower catalytic efficiencies opposite 8-oxo-G. On the other hand, Pnucleotide, with the same hydrogen bonding functional groups of cytosine might be
inserted with higher catalytic efficiency than zebularine. However, for both zebularine
and P-nucleotide, a key missing feature is the presence of a hydrophobic functional
group. Previous studies with the replicative gp43 DNA polymerase have shown that
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Figure 5.2 Non-natural nucleotide analogs as chemical probes to study translesion
replication of 8-oxo-guanine by pol l. Chemical Structures of the four non-natural
nucleotide analogs, azebularine, aP-nucleotide, a4-methyl pyrimidone, and 2,4-difluoro
toluene. The structures and their electrostatic potential maps have been generated using
Spartan’ 14. (a denotes reference 136).
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hydrophobicity of the incoming nucleotide is a major contributor to nucleobase
desolvation during the nucleotide binding step. If, pol l does follow a similar mechanism,
these “hydrophilic” non-natural analogs could be poorly incorporated opposite 8-oxo-G.
This can be further clarified by performing kinetic studies with 4-methyl pyrimidone
triphosphate. Presence of a hydrophobic methyl group could make it a good substrate if
nucleobase hydrophobicity influences selection of the incoming nucleotide by pol l.
Preliminary structural comparison of the active site of pol l and gp43exo- DNA
polymerase has revealed two crucial details. Firstly, the active site of the former appears
to be slightly larger than the latter (Figure 5.3). In fact, the active site of gp43exo- DNA
polyemrase appears to have a tighter grip on the binding nucleotide whereas, pol l’s
active site is more relaxed, providing a greater degree of freedom for the movement of
the binding nucleotide. Secondly, the active site of gp43exo- appears to be more
hydrophobic than pol l. These differences in their active site architecture could have
critical implications on the ability of pol l to replicate past 8-oxo-G. The larger active
site of pol l provides a greater degree of freedom to accommodate the fully solvated
nucleotide analogs. Also, the water molecules within the solvation sphere of the incoming
nucleotide could provide enthalpic stabilization by providing crucial hydrogen bonding
interactions required between the binding nucleotide and the templating lesion, 8-oxo-G.
Therefore, the binding affinities for the nucleotide analogs might remain invariant
irrespective of their hydrophobic or hydrophilic nature. These observations are consistent
with the previous data obtained during translesion replication of 8-oxo-G by pol h, a
specialized DNA polymerase with an expanded active site (138). Perhaps, these
differences could further validate the influence of hydrophobic amino acid residues
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within the constricted active site of gp43exo- DNA polymerase. Their non-polar nature
could assist in repelling the water molecules from the deep pockets of the high fidelity
DNA polymerase, thereby, decreasing the overall entropy of the system. This is
consistent with my findings in Chapter II and Chapter III where the binding affinities for
hydrophobic nucleotide analogs are several fold better when compared to dATP (156).
The relatively low number of non-polar residues within the expanded active site of pol l
might not have a significant effect on the overall binding affinity of the incoming
nucleotide analogs while insertion opposite 8-oxo-G. However, hydrogen bonding
interactions might take precedence at the conformational change step to form a stable
base pair with the templating 8-oxo-G.
I also made another interesting observation within active site of pol l. A nonpolar amino acid residue alanine (A510) was found in close proximity to the binding
nucleotide within the nucleotide binding pocket of pol l. It is strategically positioned
only ~3.5 Å from the binding nucleotide, similar to leucine (L561) in gp43exo-. Hence,
strong Van der Waal forces might favor better binding for hydrophobic analogs such as
4-methyl pyrimidone triphosphate during the nucleotide binding step (Figure 5.4). If pol
l incorporates 4-MeoPTP with enhanced efficiency opposite 8-oxo-G, it would further
validate the influence of key active site residues such as alanine 510 in nucleotide binding
and insertion.
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(A)

(B)

Figure 5.3 Molecular models comparing the active sites of replicative versus repair
DNA polymerases. (A) Molecular model of 8-oxo-G paired opposite dATP in the active
site of RB69 DNA polymerase (PDB ID: 3LDS). (B) Molecular models of 8-oxo-G
paired opposite dCTP in the active site of pol l, a repair DNA polymerase (PDB ID:
5III). Amino acid residues within 10 Å range from dCTP have been surface capped
according to Kyle Doolittle hydrophobicity scale for better demarcation of the active site.
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Figure 5.4 Molecular model of 8-oxo-guanine paired opposite 4-methyl pyrimidone
triphosphate (4-MePoTP) in the active site of pol l. Presence of a non-polar alanine
(A510) could provide strong Van der Waal interactions for the efficient binding of
hydrophobic 4-MePoTP. The models have been generated using molecular modelling
program, Chimera. 4-MePoTP has been built by modifying dCTP (PDB ID: 5III).
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Potential pitfalls: One complication with this approach could be the flexible active of pol
l as reported by Burak et al. (164). Its malleable active site can tolerate both syn and
anti-conformations of 8-oxo-G without significant distortions to the DNA template within
its active site. Moreover, pol l was also found to favorably accommodate 8-oxo-G in syn
conformation, likely due to the steric clash of C8-carbonyl group with the 5’-phosphate.
This promiscuity makes it difficult to evaluate the promutagenecity of the miscoding 8oxo-G (syn) using the four non-natural nucleotide analogs illustrated above. This
complication could be overcome by utilizing our library of modified purine and nonnatural indole analogs that mimic the core structure of adenine. Kinetic characterization
using these analogs would enable a complete derivatization of the underlying mechanism
involved in the translesion replication of 8-oxo-G in both syn and anti-conformation by
the repair DNA polymerase, pol l. Collectively, these studies can help to identify and/or
design and develop chemical probes to inhibit or monitor translesion replication of 8-oxoG by pol l. Another pitfall could be the influence of accessory proteins such as RPA and
PCNA during translesion replication of 8-oxo-G. These secondary proteins are involved
in the recruitment of pol l during translesion synthesis of damaged DNA, hence, might
also influence its ability to replicate 8-oxo-G (165). Since our kinetic studies are
performed only in the presence of pol l, the underlying mechanism employed in-vivo
might not be identical to the one determined in-vitro.
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5.2.3 Beyond 8-oxo-guanine
Hypothesis: 8-oxo-G has garnered a lot of attention due to its sinister nature. Its ability to
mimic thymine and mispair with adenine has labelled it as a miscoding lesion. However,
several other oxidized DNA lesions have been identified with similar or higher mutagenic
potential. Further oxidation of 8-oxo-G leads to the formation of hydantoin lesions such
as spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh) (Figure 5.5) (166,167). They
have been demonstrated to be highly mutagenic in nature due to their ability to promote
G:C to T:A and G:C to C:G transversions (166). Single nucleotide and primer extension
assays by Burrows et al. demonstrated that Klenow fragment DNA polymerase (KF exo-)
misinserts dAMP and dGMP opposite Sp and Gh, albeit with low efficiencies. Structural
studies have shown that this base pairing is due to their ability to form Watson-Crick
hydrogen bonding like 8-oxo-G (168).
Particularly, Gh is more mutagenic than 8-oxo-G due to its inability to base pair
with dCTP (155). 8-oxo-G forms a Hoogsten base pair with dATP only when in syn
conformation. Gh, on the other hand preferentially adopts a syn conformation mimicking
thymine (167). This results in exposing the hydrogen bond donor/acceptor as represented
for thymine, hence stably pairing with adenine (Figure 5.6A). Its anti-conformation is not
favored as it forms a steric clash with active site residue Ser 565 and Pro361 (168).
However, Gh is poorly bypassed by the high fidelity DNA polymerase RB69. This is
because, Gh is extra-helical and no longer in the templating position to promote primer
extension. However, when bypass does occur it can be lethal due to its ability to pair with
either purine (dATP/dGTP) with a slight preference for dATP opposite Gh.
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Figure 5.5 Chemical structures of guanine’s oxidation products, 8-oxo-guanine,
spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh).
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This would result in a G:C to T:A and G:C to C:G transversion initiating mutagenesis
(168). These similarities with 8-oxo-G, and being more mutagenic makes it imperative to
study and evaluate the underlying mechanism involved in its translesion replication by
the high fidelity gp43 DNA polymerase. Kinetic characterization with our library of
modified purine and non-natural indole analogs will help to determine if the high fidelity
gp43exo- DNA polymerase processes Gh like 8-oxo-G, where the nucleotide binding step
would be influenced by desolvation and the conformational change step by hydrogen
bonding interactions.
Predicted outcome: Similarities in structural conformations could promote the high
fidelity gp43 DNA polymerase to process the hydantoin lesion, Gh like 8-oxo-G. This
assumption is further strengthened by the kinetic data obtained for the misinsertion of
dATP by the RB69 gp43exo- DNA polymerase with an efficiency of 2 Í 103 M-1s-1
opposite Gh (169). The two-fold enhancement when compared to incorporation opposite
8-oxo-G could be due to the lack of ambiguity in Gh’s structural conformation. This is
supported by the crystal structure, illustrating the pairing of dATP opposite Gh in synconformation only, similar to thymine opposite dATP (Figure 5.6B) (169). Further
kinetic characterization with modified purine analogs would yield more mechanistic
insight into the underlying mechanism employed during translesion replication of Gh by
gp43exo-. Like 8-oxo-G, gp43exo- could utilize nucleobase desolvation as an influencing
force during the nucleotide binding step while replicating Gh. This would reflect in the
increased binding affinities for our library of modified purine analogs with non-polar
functional groups. For example, alkylated analogs such as N6-MedATP and O6-MedGTP
could achieve binding affinities similar to those determined while misinsertion opposite

179

8-oxo-G. Similar observations could also be made with the hydrophobic non-natural
indole analogs. With respect to the conformational change step, modifications to their
hydrogen bonding groups could have a negative effect on their kpol values. My predicted
outcome could confirm that the high fidelity gp43exo- processes the miscoding lesions
Gh and 8-oxo-G using similar mechanisms, where the nucleotide binding step is
influenced by desolvation and conformational change step is governed by hydrogen
bonding interactions of the incoming nucleotide. Further, comparative analysis of Gh
with the abasic site could help to confirm that nucleobase desolvation does play a
predominant role during translesion synthesis of damaged DNA.
As previously discussed, the relatively hydrophobic and constricted active site of
the high fidelity gp43exo- DNA polymerase might be playing a critical role in stripping
the water molecules of the incoming nucleotide to achieve better binding affinities. This
is reflected in the higher binding affinities of the hydrophobic purine analogs when
compared to dATP opposite 8-oxo-G (156). It would be wise to predict that similar
observations could also be made with Gh. Also, active analysis has revealed that leucine
561 flanks behind the nucleotide binding pocket of gp43exo-. Therefore, modified
analogs with hydrophobic functional groups, such as N6-MedATP and 5-MeCITP might
be inserted with better binding affinities opposite Gh, as observed with 8-oxo-G. Overall,
these assumptions are in congruence with our previous analysis where, the decrease in
energetic penalty associated with desolvation is dependent on the biophysical feature of
the incoming nucleotide. Since the enthalpic penalty for stripping the water molecules off
the hydrophobic modified analogs would be substantially lower, they would be able to
achieve better binding affinities opposite Gh within the tighter active site of the gp43
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DNA polymerase. Hence, the presence of water could be used to achieve negative
selection against nucleotide binding. Collectively, these studies would provide unique
mechanistic insight into the underlying mechanisms employed by gp43exo- DNA
polymerase while replicating a secondary miscoding lesion, such as Gh. Further, the data
derived here would allow comparative analysis of Gh with other mutagenic DNA lesions
with structural similarities (8-oxo-G) and dissimilarities (abasic site).
Potential pitfalls: The studies derived from here would only be early evidence towards
the role of nucleobase desolvation during DNA replication. Indeed, Motea at al. has
previously reported the influence of desolvation on three different DNA polymerases
(gp43exo-, Klenow fragment and HIV-1 RT) by comparing their ability for the
misinsertion of a non-natural hydrophobic analog, 5-NITP opposite the non-templating
abasic site (113,170,171). These studies have suggested that gp43exo- utilizes
desolvation better, when compared to Klenow fragment and HIV-1 RT due to its
relatively tighter active site. Studies performed with Gh might provide further insight into
the role of desolvation and its varying influence with respect to the templating lesion
residing within the active site of gp43exo-. However, these evidences would only provide
initial evidence towards defining the role of nucleobase desolvation during replication by
the high fidelity DNA polymerase. For further confirmation, additional experiments
involving molecular crowding agents and solvent isotope effects are required.
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(A)

(B)

Figure 5.6 Structural conformations depicting guanidinohydantoin (Gh) as a
miscoding lesion. (A) Chemical structures of adenine (A) paired opposite thymine (T)
and guanidinohydantoin (Gh) in syn conformation. (B) Crystal snapshot of dATP paired
opposite Gh in the active site of RB69 DNA polymerase (PDB:1IG9). The close
proximity of non-polar leucine (L561) is expected to enhance the binding affinity for
hydrophobic nucleotide analogs such as N6-MedATP and 5-MeCITP.
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5.2.4 An LC-MS/MS approach to identify novel nucleotide analogs that behave as best
substrates for the DNA polymerase
Hypothesis: The applications of non-natural nucleotides are manifold. They can be used
for different applications, varying from therapeutic and diagnostic to expanding the
genetic code. For example, single nucleotide analogs are extensively used as chemical
probes to elucidate the different molecular mechanisms employed by DNA polymerases
(52,53,54,80,109,140). Also, a lot of research has lately been focused on the quest for
non-natural base pairs that can function seamlessly in the DNA (172,173,174). These
applications open the doors for greater purposes such as using DNA to as data storage
tools and molecular computers. Their monumental biological significance makes it
imperative to identify faster screening methods to identify the best nucleotide analogs,
because it is difficult to directly predict which nucleotide analog will behave as the best
substrate for a specific DNA polymerase. Current mono-nucleotide approach, where each
nucleotide is tested individually, is time taking, cumbersome and loss of effort since a
number of these modified nucleotides might not be suitable as a good substrate for the
polymerase. Since a number of these novel modified nucleotides have been found to have
therapeutic application (e.g. antiviral agents), and some as useful tools (e.g. molecular
probes) in biochemical and biological studies there is an urgent need to design a method
that can identify the viable nucleotides for the polymerase at a faster pace.
One approach is to tackle this issue by performing LC-MS/MS analysis of DNA
substrates with the incorporated nucleotide analogs. This idea has been inspired from the
works of Kuchta and group who have developed a mass spectrometry based approach to
screen and identify the analogs that behaved as potent substrates for a DNA polymerase
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(175). Though their method was performed on a small scale, their approach has opened
the possibilities for further improving the method development and easing the
experimental processes involved in this approach.
Predicted outcome: Figure 5.7 illustrates a schematic representation of the processes
involved in developing a LC-MS/MS based method to identify the nucleotide analogs
that serve as best substrates for a specific DNA polymerase. By incubating a library of
analogs with a steady concentration of substrate (DNA) and DNA polymerase, different
analogs will be inserted at different efficiencies opposite the templating DNA. Once the
nucleotide analogs have been incorporated, the incorporated analogs can be removed by
filtering the sample using spin column filters. By choosing an optimum filter pore size
(e.g. <2000 Daltons) the unreacted analogs can be separated from the product containing
mixture to avoid interference. Then, the DNA product with the nucleotide analog can be
subject to enzyme digestion to further breakdown to individual oligonucleotides. The
final sample containing the free oligos can be separated through liquid chromatography
and detected via mass spectrometry. Considering dATP as a standard threshold,
nucleotides binding the polymerase better than dATP can be selected as viable ones for
further kinetic analysis. This method once developed successfully can effectively
eliminate the ineffective nucleotides thereby decreasing the work time by ~90%.
Potential pitfalls: One complication with the process is the peak overlap of the substrate
with other interfering compounds. If the m/z (mass–to–charge ratio) of the protonated
substrate nucleoside is identical to that of a

13

C isotope of another nucleoside, it could

lead to slight skewing of the mass peak of interest. This phenomenon is called as matrix
interference. Therefore, it is essential to develop a robust separation method with liquid
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chromatography. Another limitation could be the size of the libraries that can be
screened. Mass spectrometric analysis for large libraries might require skilled personnel
with better expertise, thus limiting the size of the nucleotide library that can be screened.
However, specific nucleotides can be identified and included in a custom library of
nucleotides, thus allowing for the continual screening of several pools at the same time.
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Figure 5.7 Overview of proposed nucleotide selection scheme. The template
containing lesion (X) is incubated with a library of synthetic analogues (dNTP’s) and a
DNA polymerase. The extended DNA is separated from non-extended DNA, remaining
dNTP’s and polymerase through spin column based on size exclusion chromatography
technique. Extended DNA templates greater than matrix pore size will pass through the
spin column matrix and are enzymatically digested to nucleosides and analyzed by LCMS.
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CHAPTER 7 CHEMOTHERAPEUTIC INTERVENTION

OTHER PURINE NUCLEOSIDE ANALOGS

cffecls againsl cells with low growth fractions such as indolent lymphomas. These effects suggest that
these nucleosides effectively inhibit low levels of ONA synthesis associated with maintenance DNA
repair rather that chromosomal replication. The inhibition of DNA repair predicted that combining the
nucleosidc analogs with DNA-damaging agents should produce a synergistic cytotoxic effect. While
this approach works in preclinical models, the developme nt of appropriate combinations in clinical
applications has mcl wi th significant difficulties. For example, the study described previously by Rai
ct al. initially included a third nnn consisting of fludarabinc (20 mg/1112/day 1) combined with chlorambucil (20 mg/m1/day I) every 28 days 11611. Unfortunately, this nnn of the study was discontinued for
scvcraJ reasons. First, patients receiving fludnrabinc and chlorrunbucil did not show better response
rates compared to fludarabine monothempy. Second, patients receiving combination therapy showed
evidence for excessive hematological 1oxici1y. A similar Mudy in CLL patients using a combimuion of
20 mg/m1 chlorambucil on day I and 14 with escalating doses of fludarabinc slarting at 10 mg/m1on
days I through 5 produced high levels of hematological toxicity (163]. Likewise, a study performed
by Elias ct al. using 15 mg/m2 chlonunbucil on day I with 20 mg/m2 fludarabinc on days I through 5
was closed after -90 patients displayed unacceptable hematological toxicity f 1&11. Nearly identical
complications have been experienced with combining cladribine and chlorambucil [165J. In this case,
a schedule of 30 mg/m2 chlorambocil every 2 weeks with 7-day continuous infusion of cladribine was
used to establish 2 mg/m2/day as the maximum tolcralcd dose. However, hematological toxicity was
again a limiting factor in prolonged treatment Il65J.
Alkylating agenl'i other than chlorambucil have also been tested for effective synergism when combined with fludarabinc. One pa11icular agent is cyclophosphamide, an alkylating agent with a cytotoxic
profile similar chlorambucil I 1661. However, cyclophosphamide generally produces less hematological
side effects and is often used lo treat CLL when chlommbucil is poorly tolerated. A study performed
by O'Brien ct al. tn:atcd 128 CLL patients with fludarabine and cyclophosphamide for 3 days [1671.
Included in this study were na·ive patien1s as well as those previously treated with alkylating agents or
fludarabine. The combination of fludarabine and cyclophosphamidc produced an 80% response rate in
patients that were not refractory lo Oudnrnbinc alone and a response rnte of 38% in patients who were
refractory to fludarabine given previously as monotherapy. In previously treated patients, the complete response rate of 35% was similar to thnt observed earlier in CLL patients treated with fludarnbine
alone. However, residual disease was seen in only 8% in previously treated patients receiving fludarabine and cyclophosphamide that displayed a complete response.
Higher efficacy combining fludnrabine and cyclophosph:unide compared with Oudarabine monotherapy has been confirmed in other phase-Ill trials in the treatment of na'ive patients with advanced
CLL I168J. Results from the Gcnnnn CLL Study Group treated 375 patients with advanced CLL and
who were younger than 66 years old I 168J. Patients were randomly assigned to two treatment arms that
included fludarabinc monothcrapy (25 mg/m1/day for 5 days) or fludarabine (30 mg/m1/day) combined
with cyclophosphamidc (250 mg/m1/day) on days 1-3 every 28 days. The overall response rate was
slightly higher in patients receiving the combination of fludarabine and cyclophosphamide (94%) compared to fludarabine alone (83%). In addition, the median progression-free survivaJ was over 1wice as
long in patients treated with fludarabinc alone compared 10 combining fludarabinc with cyclophosphamide (compare 20 ve~us 48 months, rcspcclively). Despite this, combination therapy caused significantly mon: thrombocytopenia and lcukocytopcnia than ftudarabine monothcrapy although the number
of severe infections did not increase.
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Results from the long-tern, UK LRF CUA trial arc perhaps the most impressive 11691. In this
study, 777 previously untreated CLL patienls were randomly assigned to three arms testing fludarabinc
alone (25 mg/m1 fludarabine for 5 days), chlorambucil alone (10 mg/m2 chlorambucil for 7 days), and
combination of fludarabine and cyclophosphamidc (25 mg/m2 fludnrabinc and 250 mg/nl cyclophosphamide for 3 days). The overall and complete response rates were significantly better when fludarabine was combined with cyclophosphnmide (94% and 38%. respectively) compared 10 fludarabinc
monothcrapy (80% and 15%, respecti vely). In fact, both were better than chlorambucil alone (72%
and 7%, respectively). Progression free survival aflcr 5 years was significantly better with fludarabinc
and cyclophosphnmidc (36%) compared with fludambine (10%) or chlorambucil (10%) alone. Despite
these promising rcsuhs, there was no significant difference in overall survival in patienu given fludambine and cyclophosphamide compared to patients uca1cd with fludarabinc or chlommbucil alone. In
addition, patients treated with fludarabinc alone or fludambinc and cyclophosphnmidc suffered more
neutropcnia than palients undergoing chlorambucil monotbempy.
The combination of fludarnbinc and cisplatin also displays syncrgislic effects. and this most likely
reflects the inhibition of n:pair of the fonned DNA crosslinks 1170.171 ]. Initial evaluations of 100 mg/
2
m cisplntin over 4 days combined with 30 mg/m' fludnrabinc followed with high doses (I g/m' ) of
cytnrabinc on days 3 and 4 generated a response rate of 35% in 17 patients with fludarabute-n:fractory
CLL. However. this regimen was 1oxic due to significant hematological toxici1y and renal impairment (1721.
Combinations of fludarabinc with agents that induce DSBs have also been evaluated. In a ~
finding study of fludarabine plus doxorubicin in CLL patients. the MTD was 30 mglm' fludarabinc
daily for 4 days with 50 mglm' doxorubicin on day I. Although 53% of patients presented with positive
responses. over half of the patients displayed hematological toxicity and one out of every ten patients
displayed infections lhat required hospitaliw tion. Fludarnbine has been combined wi1h mitozantrone
and dexamethasone in a dose-escalation study for the treatment of non-Hodgkin's lymphoma [ 173}.
The doses used in this preliminary study consisted of 25 mg/m 2 fludarabine for 1-3 days, 10 mg/m2
mito1.antrone on day l, and 20 mg dexamethasone for 5 days. Although patients with recurrent or
refractory low-grade non-Hodgkin's lymphoma showed an overall response rate of 94%. immunosupprcssion was described as a significant complication [ 174 J.

OTHER PURINE NUCLEOSIDE ANALOGS
2-Chlorodeoxyadenosinc (2-CdA), a dcoxyadenosine analog resistant to dcamination by adenosinc
deaminasc, is widely used to treat indolent lymphoid malignancies and hniry-<:ell lcukcmia f 175.176].
The pharmncokinetic profile of 2-CdA is very similar to that of ftudnrabine 1177]. the tcy exception
being a requirement for dcphosphorylation in order to gain cellular entry. In rapidly dividing cells, the
triphosphatc of 2-chlorodcoxyadenosine (2-CdATP) inhibits DNA synthesis, and this is the primary
mechanism for its anticancer activity I178,l 79J. 2-CdATP can also be incorporated into DNA during
NER in which its chain tennina1ion capabilitfos cause progressive accumulation of SSBs that initiate
apoptosis (180-1821. ln addition, 2-CdA can inhibit DNA replication indirectly through actions against
RnR 1182] which n:duces dNTPs pool rc:quin:d for DNA synthesis and n:pair. Finally. 2-CdATP can
mimic dATP and activate caspasc-3 to induce apoptosis 11551.
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DNA synthesis directly at the site or its insertion. The nonterminal position or dFdCM P in DNA
is denoted as ;•masked chain termination·· as the extra nucleotide hides the incorporated dFdCTP
from DNA repair enzymes [207J. This plays an important pharmacological role as preventing the
detection and subsequent c;i1:cision by DNA repair pathways serves to increase apoptosis. Furthermore, the 3'-+ 5' cxonuclcasc activity of pole is unable to excise dfdCMP from DNA whereas
nra-CMP is removed from the 3'-terminus, albeit at a - 3-fold slower rate compared to natural
nucleotides [208].
In addition to acting as a chain terminating nuclco1idc, gcmcitabinc may also induce DNA
hyperrnethylation of various gene promoters. In fact. it has been suggested that treating cells with
gemcitabine causes epigenetic silencing of critical ONA repair enzymes such as hMLH l [2091.
Epigenetic silencing, whether it be genome-wide or gene-specific, provides another potentialJy cytotoxic mechanism. Indeed, 5-aza-2'-dcoxycytidinc (Dccitabinc) is another pyrimidine analog that is a
near perfect mimetic of 2-deoxy-cytidine as only the CS carbon is replaced with nitrogen (Fig. 7. IO).
This simple subslitution does 001 hinder incorporation into DNA. However. the introduction of nitrogen prevents the ability of the nucleobase to be modified by DNA methyltransferases. Reductions in
DNA methylation cause hypomethylation of cenain gene promoters which then inHucnccs transcription [2 JO[. This is important as many sporadic colon cancers show hypcrmcthylation of the hMLHI
gene promoter which correlates with lower expression of the gene product, hMLH I, an essential
DNA repair protein [211J. Reduced levels of this repair enzyme play imponant roles in the development of carcinogenesis in addition to drug-resistance to various chemotherapeutic agents such M
temorolomide that damage DNA. Upon treatment with 5-az.a-2' -deoxycytidine, these cells regain
expression of the hMLH I protein which then scnsiti£CS cells to the cy101oxic effects of cenain chemotherapeutic agents. Although 5-aza-2'-dcoxycytidine is sometimes used clinically, it possesses
a relatively narrow therapeutic window as it affects the methylation patterns of normal and cancer
cells [212].

MECHANISM OF ACTION
Gemcitabine and ara-C have multiple intracellular targets. However, their primary cytostatic and cytotoxic activities depend upon their ability to directly inhibit DNA synthesis (202,203]. Similar to purine
analogs such as F-am-ATP, the triphosphate form or gemcitabine, dFdCTP, is a substrate for various
DNA polymerases [204,205). In vitro DNA primer extension assays demonstrated that dFdCTP competes: with dCTP for incorporation opposite II templ11ting G. The IC'° values for dFdCTP are 11 and
14 µM for pol a and pol£, respectively.
There is only one available crystal structure of a human DNA polymerase bound with either araCMP or dFdCMP paired opposite a template dG )206]. These structures for pol).,, a specialized polymerase involved in DNA repair. shows that ara-CMP and dFdCMP bind within the nascent base pair
binding pocket of the polymerase. However. there arc interesting differences in the confonnations or
the ribosc moieties of the nuclcosidc analogs thot impact their pharmacological effects. Specifically.
the conformation of the ribosc moiety of ara-CTP is similar to that of the natural substrate, cterP.
whereas the confonnation of dFdCTP is significantly different [206[. This difference explains why pol
:!. efficiently incorporates ara-CTP but docs not incorporate dFdCTP [206[.
Gcmcitabine and ara-C also differ with respect to the mechanism of chain tennination. Afler
incorporation into DNA. dFdC can be elongated by one additional nucleo1ide before DNA synthesis is completely terminated (Fig. 7 12). This contrasts the action of ara-CTP which terminates
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The efficacy of gemcitabine in inhibiting cancer cell growth has been documented using both hematological and adherent cancer cell lines 1213J. In addition, gemcitabine shows remarkable efficacy
against a variety of human tumor xenogrufts in nude mice models 12141, thereby validating the in
vivo efficacy of this antincoplastic agent. Based on extensive preclinical studies, gemcitabine is currently used as a single agent to treat patients with various leukemiM and lymphomas. Gemcitabine is
also used against metastatic pancreatic cancer 121.SJ and in combination with other therapeutic agents
against malignancies such as non-small-cell lung cancer. bladder cancer, ovarian cancer, and breasl
cancer [216,2 17].
As a single agent, dFdC has been most extensively evaluated using doses ranging from 800 to
1250 mglm' administerro as a 30-min infusion on days I. 8. and 15 of a 28-day cycle [218]. The most
frequently occurring toxicities associated with dFdC with this dosage and dosing schedule are hematological in which neutropenia occurs more frequentl y than thrombocytopcnia. Fortunately, hematological toxicity is cumulative and can be easily mnnagcd by dose elimination, dose reduction, or by delays
in dosing. Other reversible forms of 1oxici1y include trans.Cnt increases in hepatic transaminases, fever,
myalgia, Hu-like symptoms, and extremity edema. Nausea. vomiting, fatigue, and headache are typically mild and not dose-dependent.

Termination of DNA synthesis
leads to apopJosis
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FIGURE 7.12 Differences In Ute Moch•nl,m of Chain Termination by Gemcltablne •111 ar.t-C
Af1er incorporation into DNA. ara-CJ'P tcmunai.es ONA synthesis d1rtctly at the site of incorporation while
gcmcitabine can be elongated by one add11ional nudcohdc. The placemcnc of gcmcitabinc at the penultimate
position is cermed Mmasked chain tcnninatiCN'( since che ccmunal nuclcocidc masks detection and removal of
gcmcicabinc by cxonudcascs or ONA repair enzymes.
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POTENTIAL MECHANISMS FOR SYNERGISTIC ACTIVITY

CLINICAL AND BIOCHEMICAL STUDIES OF GEMCITABINE COMBINED
WITH DNA-DAMAGING AGENTS

Several preclinical studies have been performed to evaluate the ability of gemcitabine to sensiti1.e
the cytotoxic effects of ONA-damaging agents such as cisplatin and oxaliplatin [222,223,233,234] A
study perfonned by Jensen ct al. used the ovarian cancer cell line, A2780, as a model to evaluate the
synergistic activity of combining gemcitabine and cisplatin compared with using either agent alone
[233]. These authors demonstrated that the addition of gemcitabine causes an increase in the retention
of platinum-DNA adducts compared to treatment with cisplatin alone, and that this increase resulted
from decreased DNA repair. The authors argued that inhibition of specific exonucleases such as excision repair cross-complementation group 1 (ERCCI) is instrumental in the ability of gemcitabine to
inhibit the repair of the platinum-adducts. However, other modeJs for the synergistic effects have been
proposed. One intriguing model is based on the ability of gemcitabine to inhibit specialized DNA poly.
merases that bypass platinum.adducts [234]. Cells deri ved from XP. V patients deficient in the specialized polymerase pol Tl, for example, are more sensitive to ara-C, gemcitabine, or cisplatin single-agent
treatments compared to nonnal human fibroblast cells that possess pol fl. More importantly, pol Tl
deficient cells arc - 10-fold more sensitive to the combined treatment of gemcitabine and cisplatin.
The results of cellular and biochemical studies suggest that the higher sensiti vity of the pol 11-deficient
cells results from their inability to complete DNA replication beyond unrepaired cisplatin·adducts. The
fact that pol fl plays an important role in defining sensitivity of a cell to DNA-damaging agents has
important implications for developing new therapeutic and diagnostic agents.

As discussed previously wi th fludarabine, the chain termination capabilities of gcmcitabine coupled
with its effects on deoxy nucleotide metabolism predict that it could also be used in combination
with ONA-damaging agents to produce synergistic cytotoxic effects. Indeed, severa l early studies
combining gcmcitabinc with platinum drugs such as cisplatin and oxaliplatin demonstrated synergistic cell-killing activity against several human cancer cell lines [219-223]. These preclinical data
led to the hypothesis that gcmcitabine could be used as a sensitizing agent to enhance the cell-killing
effects of platinum drugs. An additional benefit of this therapeutic regimen is based on the relative
toxicities of each anticancer agent. In particular, gemcitabine is relatively well tolerated as it produces moderate side effects such as mild myelosuppression, asthenia, and nausea/vomiting {224]
while cisplatin causes more serious complications such as cumulative peripheral neurotoxicity and
potential nephrotoxicity [225}. As such, using gemcitnbine as a chemosensitizer could lower acute
and cumulative doses of platinum-based DNA-damaging agents which could alleviate the risk of
serious side effects.
Indeed, several clinical trials have demonstrated that neoadjuvant gemcitabine combined with platinum drugs is a well-tolerated regimen for patients with pancreatic cancer 1226-230]. Howeve r, two
recently developed therapeutic modalities arc more commonly used today. One particular regimen
is FOLFIRINOX, a combination of five chemotherapy agents, which is used to treat patients with
both metastatic and locally advanced pancreatic cancer as well as in patients undergoing neo-adjuvant
therapy. FOLFIRlNOX therapy consists of a combination of anticancer drugs including 5-fluorouracil,
leucovorin, irinotecan, oxaliplntin, and gemcitabine. A recent phase-III clinical trial compared the efficacy of FOLFIRINOX versus gemcitnbine alone in patients with metastatic pancreatic cancer [231].
Patients in the FOLFIR!NOX arm received oxaliplatin (85 mglm' over 2 h), leucovorin (400 mglm'
over 2 h), irinotecan ( 180 mg/m1 over 90 min), and 5-FU (400 mg/m1 bolus then 2,400 mg/m1 over
46 h) and then repeated every 2 weeks. Patients in the control ann received 1,000 mg/m2 of gemcitabine
weekly for seven of 8 weeks, I week rest, and then weekly for 3 of 4 weeks. Results indicated that
nearly 50% of patients on FOLFIRlNOX were alive I-year post-treatment whereas only 20% were
alive after receiving gemcitabine alone. A median overall survival of 11.1 months was obtained on the
FOLFIRINOX ann.
In 2013, the combination of gemcitabine with Abraxane•, paclitaxel protein.bound particles, was
approved for first-line treatment of patients with metastatic pancreatic cancer. Although, Abraxane• has
been previously approved for breast and non-small-cell lung cancer, the use of combining Abraxane•
with gcmcitabine was based on results of a multi-center trial of 861 patients with metastatic pancreatic cancer demonstrating improved an increase in overall survival r232]. In this study, patients were
randomized to receive either the combination of Abraxane• plus gemcitabine (11 = 43 I) or gemcitabine
alone (11 = 430). Results demonstrated significant prolongation of overall survival (OS) for patients
receiving Abraxane• plus gemcitabine (median OS of 8.5 months) compared to receiving gemcitabine
alone (meruan OS of 6.7 months). The most frequent serious adverse reactions in patients who received
the Abraxane• plus gemcitabine include pyrexia, dehydration, pneumonia, and vomiting. The recommended dose and schedule for this combination is 125 mg/m1 of Abraxanc• administered as an intravenous infusion over 30-40 min on days I, 8, and 15 of a 28-day cycle followed by administration of
intravenous gemcitabine.

NUCLEOSIDE ANALOGS AS RADIOSENSITIZERS
Ionizing radiation is used in nearly 50% of all cancer patients as it shows effecti veness against many
malignancies, including brain, cervix, breast, and colon cancers that are in many cases inaccessible to
surgery or refractory to standard chemotherapeutic agents [235]. At the molecular level, ionizing radiation destroys cancer cells by creating radicals that ultimately damage genomic DNA [236]. Although
several forms of DNA damage are produced, DSBs are the most lethal [237]. The inability of a cancer
cell to effectively repair DSBs causes both cytostatic and cytotoxic effects that reduce tumor growth.
Radiosensitiz.ation with nuclcoside analogs such as gemcitabine and Hudarabine has improved clinical
outcome for patients with solid malignancies [238-240J. The rationale for combining nucleoside analogs with ionizing radiation lies in the ability of the corresponding nucleoside triphosphates to inhibit
polymerases involved in DNA synthesis and repair. Since these agents can inhibit DNA repair, they
can increase the amount of residual DNA and chromosome damage after irradiation to induce apoptosis. As inhibitors of DNA synthesis, they specifically target S-phase cell populations to overcome
lumor repopulation that can occur during fractionated irradiation therapies. Finally, nuclcoside analogs
can also inhibit DNA synthesis and DNA repair by depicting nucleotide pools.

CLINICAL COMPLICATIONS ASSOCIATED WITH NUCLEOSIDE ANALOGS
While nuclcosidc analogs arc important for treating cancer, their effectiveness is often limited by doselimiting toxicity that arises due to their nonselective nature. Nonsclectivc killing occurs since a number
of the body's nonnal cells also are rapidly dividing and arc thus killed more frequently by compounds
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